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Abstract 
 
Osteoarthritis (OA) is a whole-joint disease believed to onset after articular cartilage 
damage and accompanied by tissue inflammation, abnormal bone formation and extracellular 
matrix (ECM) mineralization. Gla-rich protein (GRP), the latest discovered vitamin K-
dependent protein (VKDP), was shown to accumulate in mouse and sturgeon cartilage, and 
sites of skin and vascular calcification in human. Therefore, we investigated the possible 
involvement of GRP with OA development. An osteoarthritic and control samples human 
biobank was collected and used for the comparative analysis of GRP patterning at 
transcriptional and translational levels. Two novel GRP alternative spliced transcripts were 
unveiled in human (GRP-F5 and F6), yet GRP-F1, corresponding to the full-length protein, 
was shown to be the predominant variant in articular tissues and upregulated in osteoarthritic 
cartilage. Undercarboxylated GRP was the prevalent protein form found associated with 
osteoarthritic cartilage and synovial membrane tissues, highly accumulated at sites of 
calcification, indicating that the impairment of VKDPs γ-carboxylation may be related with 
OA. Using a chondrocyte and synoviocyte cell system developed within this project, we 
further investigated the association of GRP with OA mineralization and inflammatory 
processes. Upregulation of GRP was found during induced mineralization and inflammation, 
and associated to cell differentiation towards ECM mineralization and inflammatory 
responses, in both cellular types. Moreover, the role of GRP was highlighted through 
functional assays, showing the inhibition of ECM mineralization and decreased inflammatory 
response following GRP supplementation. While γ-carboxylation was required for GRP anti-
mineralization function, its anti-inflammatory effect was independent of protein γ-
carboxylation status. Ultimately, using serum samples from our biobank and a comparative 
proteomic approach, candidate OA biomarkers were identified. Overall, our results 
demonstrated, for the first time, the involvement of GRP in two of the main pathological 
processes occurring in OA, contributing for new knowledge regarding disease progression.  
 
Keywords: Gla-rich protein (GRP), osteoarthritis (OA), ectopic calcification inhibitor, anti-
inflammatory effect, γ-carboxylation status, biomarkers  
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Resumo 
 
A osteoartrite (OA) representa a forma mais comum de doenças degenerativas das 
articulações, sendo a principal causa de incapacidade física crónica na população acima dos 
50 anos de idade. A origem da OA está geralmente associada a danos na cartilagem articular, 
acompanhados por uma remodelação da matriz extracelular (ECM), que numa sucessão de 
eventos acabam por comprometer toda a articulação. A perda de cartilagem articular, 
inflamação tecidular, formação óssea anormal e a mineralização da ECM, são características 
comuns desta patologia. No entanto, o conhecimento sobre mecanismos moleculares da OA 
ainda é limitado, o seu diagnóstico é tardio e não existem atualmente medicamentos eficazes 
para o tratamento da doença. É portanto essencial a descoberta de novos alvos moleculares e 
biomarcadores que beneficiem a patologia. A proteína rica em Glas (GRP), último membro 
descoberto pertencente à família de proteínas dependentes da vitamina K (VKDPs), 
representa um potencial alvo para o estudo de mecanismos da OA. Esta proteína é bastante 
acumulada na cartilagem de ratinho e esturjão, e em zonas calcificadas na pele e sistema 
cardiovascular em humano. Além disso, a GRP é considerada um regulador negativo da 
osteogénse. Partículas de calciproteínas (CPP) presentes em circulação em fluidos biológicos, 
representam igualmente um alvo para o estudo de processos moleculares da OA uma vez que 
estas também são associadas a situações de calcificação patológica e mesmo a processos 
inflamatórios. Neste âmbito, o principal objetivo do presente estudo foi a análise da possível 
associação entre a GRP e o desenvolvimento da osteoartrite. Um objetivo adicional foi a 
procura de biomarcadores para a patologia, com especial interesse na GRP.  
Durante o decorrer deste projeto, foi coletado um biobanco bem caracterizado 
contendo tecidos e fluidos biológicos de pacientes com osteoartrite do joelho e indivíduos 
sem histórico de patologias nas articulações. As amostras deste banco biológico foram 
utilizadas para a realização de análises comparativas de padrões de expressão e acumulação 
da GRP. Haviam sido anteriormente identificadas em ratinho e esturjão quatro variantes por 
splicing alternativo do gene da GRP, nomeadamente a GRP-F1, F2, F3, e F4. Aqui, utilizando 
uma estratégia de RT-PCR, foram identificados em humano dois novos transcritos da GRP, 
denominadas GRP-F5 e F6 e caracterizados pela perda de domínios de γ-carboxilação e 
secreção. No entanto, os nossos resultados evidenciaram a variante GRP-F1, correspondente à 
proteína total, como a maioritariamente expressa em cartilagem e membrana sinovial, 
sugerindo que associações existentes entre a GRP e a OA reflitam sobretudo a contribuição 
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deste transcrito. Além disso, também se verificou que a GRP-F1 era sobrexpressa em 
cartilagem osteoartrítica em comparação com tecidos controlo. O estudo entre a possível 
associação da GRP com a OA prosseguiu utilizando técnicas imunológicas e anticorpos 
conformacionais específicos contra as formas carboxilada (cGRP) e subcarboxilada (ucGRP) 
da GRP. Esta abordagem revelou que embora ambas as entidades sejam acumuladas em 
tecidos articulares e fluidos osteoartríticos, bem como zonas de calcificação ectópica, a 
ucGRP é a forma predominante associada à cartilagem e membrana sinovial osteoartríticas, 
enquanto que a cGRP é preferencialmente acumulada nos mesmos tecidos em condições 
controlo. A forma subcarboxilada da proteína Gla da matriz (ucMGP) foi também a 
predominantemente associada à cartilagem osteoartrítica. A combinação destes resultados 
sugere que deficiências na γ-carboxilação de VKDPs estejam possivelmente relacionadas com 
mecanismos moleculares da OA. Os nossos resultados imunohistológicos também revelaram 
que a acumulação de GRP em membranas sinoviais osteoartríticas não era restrita a zonas de 
calcificação, ocorrendo também nas camadas que revestem estes tecidos e sugerindo 
associações a outros processos. Utilizando um sistema celular de linhas primárias de 
condrócitos e sinoviócitos desenvolvido no âmbito deste projeto, o estudo da associação entre 
a GRP e a mineralização associada à OA foi aprofundado, bem como o seu possível 
envolvimento com processos inflamatórios. A análise comparativas do padrão de expressão 
de GRP entre células osteoartríticas e controlo, revelou que esta era sobrexpressa em células 
osteoartríticas, em concordância com os resultados obtidos in vivo com amostras de 
cartilagem. Também se verificou que a GRP era sobrexpressa mediante a indução de 
mineralização e inflamação do sistema, e associada a processos de diferenciação celular 
inerentes à mineralização da ECM e respostas inflamatórias, em ambos os tipos celulares. 
Notavelmente, foram evidenciadas funções biológicas da GRP na OA através de estudos 
funcionais: a sua capacidade de inibição da mineralização da ECM e a diminuição de 
respostas inflamatórias após suplementação da proteína. Curiosamente, a γ-carboxilação da 
GRP revelou ser essencial para a sua função anti-calcificante enquanto que o efeito anti-
inflamatório observado mediado pela GRP ou GRP-acoplada a cristais de fosfato de cálcio 
básico foi independente do seu estado de γ-carboxilação, evidenciando funções alternativas 
para a ucGRP em particular. Os nossos novos resultados sugerem que na OA ocorra um 
aumento da expressão de VKDPs, como a GRP e MGP, possivelmente associado ao combate 
de processos de calcificação ectópica. No entanto, a sobrecarga do sistema pode resultar numa 
capacidade de γ-carboxilação deficiente, culminando na prevalência de ucGRP e ucMGP. Por 
sua vez, a ucGRP pode estar associada ao controlo de níveis de mediadores de inflamação 
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através de mecanismos ainda desconhecidos. A última parte deste trabalho pretendia 
identificar candidatos a biomarcadores da OA, para fins de diagnóstico da patologia ou de 
monitorização de tratamentos, sendo de particular interesse a análise do potencial da GRP 
como um destes biomarcadores. Contudo, o uso da técnica clássica de electroforese 
bidimensional revelou ser inadequado para o estudo desta proteína. Em alternativa, utilizando 
a mesma abordagem proteómica e amostras de soro do biobanco colecatdo, foi realizada a 
procura de potenciais biomarcadores para a patologia associados a CPP. Esta análise permitiu 
a identificação de 19 proteínas diferencialmente expressas entre condições controlo e 
osteoartríticas, que podem ser consideradas potenciais biomarcadores para a OA. Além disso, 
algumas das proteínas identificadas associadas a estes complexos estão relacionadas com 
processos de calcificação patológica e inflamatórios, o que sugere um possível envolvimento 
entre CPP e osteoartrite.  
Os nossos resultados abrem novas portas no domínio de investigação científica da 
osteoartrite, sobretudo através da associação nunca antes descrita entre a GRP e a patologia. 
Os dados coletados durante o projeto revelaram o envolvimento da GRP, aparentemente com 
efeitos benéficos, em dois dos principais processos patológicos que ocorrem na OA, 
nomeadamente a calcificação patológica e inflamação, o que contribuiu para um melhor 
conhecimento relativo à progressão da patologia.  
 
Palavras-chave: Proteína rica em Glas (GRP), osteoartrite (OA), inibidor de calcificação 
ectópica, efeito anti-inflamatório, estado de γ-carboxilação, biomarcadores  
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1.1 Vitamin K-dependent proteins associated with calcification  
  
 Vitamin K-dependent proteins (VKDPs) comprise a family characterized by the 
presence of γ-carboxyglutamic acid (Gla) residues, which result from the post-translational 
modification of glutamate (Glu) residues [1]. The conversion of Glu to Gla residues is termed 
γ-glutamyl carboxylation and vitamin K is an essential cofactor of this process [1]. Vitamin K 
metabolism was initially considered in the context of haemostasis [2], yet with the discovery 
of VKDPs this vitamin has been associated to multiple biological processes [1]. Vitamin K-
dependent proteins may be categorized into two main groups: hepatic and extrahepatic 
VKDPs [3]. Hepatic VKDPs are mainly involved in balancing blood coagulation, by bridging 
their Gla residues through calcium with negatively charged phospholipids [4,5], whereas 
extrahepatic VKDPs are described to have distinct functions, ranging from roles in bone and 
cardiovascular health [6,7] to the regulation of energy metabolism [8]. Three extrahepatic 
VKDPs have been associated with calcification processes: osteocalcin (OC), matrix Gla 
protein (MGP) and Gla-rich protein (GRP). Osteocalcin was the first identified extrahepatic 
VKDP [9] and has two proposed roles in calcification, the regulation of bone mineralization, 
and osteoblast and osteoclast activity [6,10]. Some years later MGP was discovered [11], 
subsequently related with the inhibition of ectopic calcification [12], and the regulation of 
osteogenesis and chondrocyte maturation [13]. More recently, GRP was identified and 
proposed as a modulator of calcium availability [14,15] and an inhibitor of calcification in the 
cardiovascular system, although its mechanism of action requires further investigation [16].  
 
1.1.1 Vitamin K 
 
Vitamin K is a lipid-soluble vitamin, that in nature may occur in form of 
phylloquinone (K1) or menaquinones (K2) (Fig. 1.1), yet both forms present the cofactor 
activity required for the γ-carboxylation reaction [17]. These vitamin K compounds share a 
common 2-methyl-1,4-naphthoquinone ring structure and an isoprenoid side chain, that 
differs in length and degree of saturation (Fig. 1.1), depending on the organism by which they 
are synthesised [17]. Phylloquinone contains a phytyl side chain, which has only one 
unsaturated bond (Fig. 1.1), and is found in plants and cyanobacteria [18]. Menaquinones are 
composed by a side chain with repeating isoprene residues, each containing an unsaturated 
bond (Fig. 1.1) [17]. Depending on the number of prenyl repeats, menaquinones are 
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subcategorized as MK-n, with n corresponding to the number of isoprenoid units, generally 
ranging from 5 to 13 (Fig. 1.1) [18]. Menaquinones are majorly obtained nutritionally from 
bacterially fermented food and liver, but intestinal bacteria also synthesize these vitamin K 
forms [17]. Although K1 is the major type of vitamin K present on a typical western diet, its 
concentrations in animal tissues are remarkably low compared with those of menaquinones, 
especially MK-4, the major form of vitamin K present in tissues [19]. The origin of tissue 
MK-4 is postulated to be resultant from K1 conversion via integral side-chain removal, with 
subsequent MK-4 accumulation in extrahepatic tissues [19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 – Chemical structures of naturally occurring vitamin K forms. Vitamin K1, also 
termed phylloquinone, contains a phytyl side chain with only one unsaturated bond and 
vitamin K2, known as menaquinones (MK-n), contain a side chain with repeating isoprene 
residues, each containing an unsaturated bond. The respective menaquinone is indicated by 
the number of prenyl units (n) (Adapted from Willems et al., 2014 [3]). 
 
The γ-carboxylation reaction of VKDPs requires the presence of three cofactors: a 
reduced form of vitamin K (vitamin K hydroquinone, KH2), carbon dioxide and oxygen (Fig. 
1.2) [1]
.
 Therefore, the continuous recycling of vitamin K 2,3-epoxide (KO) to its quinone (K) 
and KH2 forms, in successive reactions catalysed by vitamin K reductases, is essential for the 
γ-carboxylation process (Fig. 1.2) [20]. Gamma-glutamyl carboxylase (GGCX) is the enzyme 
responsible for the conversion of Gla to Glu residues, a process concomitant with KH2 
oxidation to KO (Fig. 1.2) [1]. Subsequently, KO is converted back to KH2, through a two-
step reduction, using the enzymes vitamin K epoxide reductase (VKOR) and vitamin K 
reductase (VKR) (Fig. 1.2), in order that each KO molecule may be reused several times [1]. 
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This pathway is known as the vitamin K cycle (Fig. 1.2) [1]. Gamma-glutamyl carboxylase is 
an integral membrane protein localized at the endoplasmic reticulum membrane, where 
luminal VKDPs carboxylation takes place as part of proteins secretion pathway [20]. Specific 
protein binding is accomplished by GGCX interaction with the propeptide region (with the 
exceptions of MGP and periostin [21]), located at the N-terminal part of the VKDPs [1]. The 
carboxylated VKDPs then transit from the endoplasmic reticulum, their propeptide is 
removed in the Golgi apparatus and proteins are secreted [20]. The γ-carboxylation of 
multiple Glu residues is believed to occur through a GGCX processive mechanism, in which 
all Glu residues are carboxylated as a result of one single binding event [20]. The γ-
carboxylation of specific Glu residues within most VKDPs, induces a calcium-dependent 
conformational change in the Gla domain, associated with the binding of calcium ions or 
calcium crystals [20].  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 – Vitamin K cycle. Representation of the enzymes and cofactors required for the 
continuous recycling of vitamin K to its hydroquinone active form (KH2), used as cofactor by 
γ-carboxylase (GGCX), for the conversion of glutamate (Glu) residues into γ-
carboxyglutamic acid (Gla) residues. Coumarins inhibit vitamin K epoxide reductase 
(VKOR). KO, vitamin K 2,3-epoxide; K, quinone form; VKR, vitamin K reductase (Adapted 
from Tie et al., 2015 [1]).  
 
Vitamin K recycling may be inhibited by coumarins, such as warfarin, a drug used to 
treat coagulation-related problems which blocks VKOR activity (Fig. 1.2) [22]. As a 
consequence, depletion of tissue vitamin K reserves occurs, resulting in the 
undercarboxylation of VKDPs [3]. One result of vitamin K antagonists treatment is the 
increased calcification of the vasculature, which was first observed in rats injected with daily 
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doses of warfarin combined with vitamin K1, to prevent lethal haemorrhages [23]. The 
treatment resulted in vitamin K depletion in extrahepatic tissues and consequent aortic 
calcifications, ascribed to the inhibition of MGP γ-carboxylation [23]. 
In the past decade, biological functions of vitamin K other than as a cofactor of GGCX 
have been extensively studied [24]. In concordance, vitamin K has been described to possess 
significant anti-inflammatory and antioxidant actions, among other biological roles [24,25]. 
Vitamin K was shown to be inversely correlated with circulating markers of inflammation and 
suggested to suppress inflammation by decreasing the expression of genes for individual 
cytokines [26,27]. Vitamin K was also described to exert an anti-inflammatory effect by 
suppressing nuclear factor κB (NF-κB) signal transduction [28,29], a proinflammatory 
signalling pathway activated by proinflammatory cytokines [30]. Moreover, vitamin K has 
been shown to have a protective effect against oxidative stress that is independent of 
carboxylation and may be an alternative anti-inflammatory mechanism associated with this 
vitamin [31]. Oxidative stress protection by vitamin K was suggested to function through the 
blocking of reactive oxygen species (ROS) generation [25]. 
 
1.1.2 Physiological cartilage calcification 
 
Calcification is a physiological process required to create mineralized tissue such as 
teeth and bones [3]. The majority of the mammalian skeleton bones originates from cartilage 
templates through a process known as endochondral ossification [32]. The transition from 
cartilage to bone is a multifactorial and complex process tightly coupled with chondrocyte 
and osteoblast differentiation, and vascularization [32].  
Endochondral bone development begins with mesenchymal cells condensation from 
the mesoderm [32]. Bone morphogenetic proteins (BMPs), members of transforming growth 
factor β (TGF-β) superfamily, are essential for chondrogenic mesenchymal condensation 
signalling, and the transcription factor SRY-box 9 (Sox9) plays a fundamental role 
maintaining such condensation [32,33]. Chondrogenic differentiation proceeds stimulated by 
BMPs and Sox9 originating chondrocytes, the exclusive cartilage cell type, which secrete an 
enriched extracellular matrix (ECM) in type II collagen (Col2a1) and proteoglycans such as 
aggrecan [32-34]. After the formation of cartilage primordia chondrocytes undergo a rapid 
proliferation that drives the linear growth of bones and at a certain stage central chondrocytes 
follow progressive maturation [32]. Chondrocytes proliferation and maturation is regulated by 
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extracellular signals such as the Indian Hedgehog (IHH) and parathyroid hormone-related 
(PTHr) proteins, which manage the processes through negative-feedback mechanisms, and 
BMPs [32,35]. Chondrocytes eventually exit the cell cycle and undergo hypertrophy marked 
by a 10-fold increase in cell volume, ECM remodelling and terminal differentiation markers 
expression, including matrix metalloproteínase 13 (MMP13), type X collagen (Col10a1) and 
alkaline phosphatase (ALP) (Fig. 1.3) [36,37]. Hypertrophy is regulated by nuclear factors 
such as runt-related transcription factor 2 (Runx2) and pathways including β-catenin 
activation by canonical Wingless/Int (Wnt) signalling [32,38]. Runx2 drives the expression of 
MMP13 and Col10a1, and secreted MMP13 degrades Col2a1 and aggrecan (Fig. 1.3) [38,39]. 
Col10a1 deposition within the hypertrophic cartilage ECM serves as framework for 
subsequent calcification, which originates from matrix vesicles (MVs) secreted from 
chondrocytes outer plasma membranes (Fig. 1.3) [38,40]. These vesicles contain ALP, 
subsequently anchored to the Col10a1 matrix, and are secreted in response to increased 
calcium levels (Fig. 1.3) [38,40]. In the first step of mineralisation, ALP hydrolyses 
pyrophosphate (PPi) to inorganic phosphate (Pi) inside the MVs forming hydroxyapatite (HA) 
crystals (Ca10(PO4)6(OH)2) in the presence of calcium (Fig. 1.3) [41]. Phospholipids 
hydrolysis and the influx through type-III Na/Pi co-transporter may represent other sources of 
phosphate in the MVs, while calcium influx is believed to be regulated by annexins II, V and 
VI, with annexin V activity directly stimulated by the binding to Col2a1 and Col10a1 fibrils 
[38,42]. The second step of mineralisation is initiated by the infiltration of HA crystals into 
the ECM (Fig. 1.3) [38], a process considered to be regulated by proteins such as OC [43] 
secreted by hypertrophic chondrocytes and osteoblasts [44]. Chondrocyte hypertrophy is 
accompanied by vascular endothelial growth factor (VEGF)-mediated vascular invasion of 
cartilage and differentiation of the inner perichondrium (connective tissue layer that surrounds 
cartilage during bone formation) cells into osteoblasts [32,38]. MMP13 plays a crucial role 
cleaving ECM proteins within hypertrophic cartilage, facilitating vascular invasion [39]. 
Cartilage vascular invasion leads to further degradation of the mineralized matrix by MMP9 
produced by chondroclasts, a resorptive cell type associated with capillary walls [32]. 
Osteoblast differentiation is regulated by extracellular signals and transcription factors such as 
IHH, Runx2, osterix (Osx), Wnt proteins and BMPs [32,38]. Osteoblasts secrete a type I 
collagen (Col1a1)-enriched ECM, in which HA fills the space between Col1a1 fibrils in the 
skeletal matrices, establishing the primary ossification centre to form trabecular bone [32,45]. 
Final stages of endochondral ossification may include chondrocyte apoptosis and generate 
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apoptotic bodies, which exteriorize phosphatidyl serine contributing for calcium binding, that 
in turn may promote more ECM mineralization in the presence of phosphate [46].     
 
 
 
  
 
Fig. 1.3 – Chondrocytes hypertrophic differentiation and mineralization. After chondrocyte 
formation, regulated by Sox9, upon endochondral bone formation, cells proliferate, maturate 
and reach hypertrophy, marked by cell increased volume (red arrows) and extracellular matrix 
(ECM) remodelling. These changes are regulated by transcription factors such as runt-related 
transcription factor 2 (Runx2), which induces the expression of type X collagen (Col10a1) 
and matrix metalloproteínase 13 (MMP13). MMP13 degrades aggrecan and type II collagen 
(Col2a1). Col10a1 facilitates mineralization in association with matrix vesicles (MVs), that 
transport alkaline phosphatase (ALP). ALP dephosphorylates pyrophosphate (PPi) to 
phosphate (PO43-, Pi), leading to hydroxyapatite (HA) formation (Adapted from Studer et al. 
2012 [38]). 
 
1.1.3 Pathological cartilage calcification 
 
Calcification can also be detrimental and tissue ectopic calcification is considered 
pathological [3]. Uncontrolled mineralization, first considered to be a passive process 
occurring as a nonspecific response to tissue injury or necrosis, is now believed to naturally 
occur, thus it must be actively inhibited [47]. Pathological calcification can occur throughout 
the body, yet articular cartilage, the cardiovascular system and kidneys seem to be particularly 
prone to calcify [46]. Unlike physiological mineralization deposits, which only contain HA 
crystals, ectopic mineralization depositions may also include other basic calcium phosphate 
(BCP) crystals, such as octacalcium phosphate (Ca8(HPO4)2(PO4)4.5H2O) and apatite-
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containing magnesium (Ca9Mg(PO4)6(OH)2), calcium pyrophosphate dihydrate 
(Ca2P2O7.2H2O, CPPD) or calcium oxalate (CaC2O4) [46,48,49], the latter more rare [48]. 
Cartilage deposition of BCP and CPPD crystals, is associated with acute pain and decreased 
mobility in destructive arthropathies involving abnormal cartilage homeostasis, such as 
osteoarthritis (OA) [48]. These calcifications modify the biomechanical properties of cartilage 
and ultimately trigger crystal-induced stress, leading to proinflammatory cytokine and MMPs 
production, and eventually chondrocyte apoptosis (Fig. 1.4) [48]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4 – Effects of BCP and CPPD crystals on articular chondrocytes. Basic calcium 
phosphate (BCP) and calcium pyrophosphate dihydrate (CPPD) crystals activate articular 
chondrocytes through crystal-induced stress. Cell activation may lead to significant articular 
chondrocyte phenotype changes including mitogenic, proinflammatory, catabolic and 
apoptotic chondrocytes. Proinflammatory cells may produce cytokines, such as interleukin-1β 
(IL-1β). Catabolic chondrocytes can secrete prodegradative soluble factors, such as nitric 
oxide (NO) and proteases like matrix metalloproteínase 13 (MMP13). Apoptotic cells are able 
to release promineralizing apoptotic bodies prone to enhance crystal-induced stress in the 
vicinity of articular cartilage (Adapted from Ea et al., 2011 [50]).  
 
The triggers for pathological calcification are still not completely understood, 
however, like in physiological calcification, ectopic mineralization is believed to be initiated 
in MVs, where calcium crystals are formed and then propagated into the ECM, inducing their 
further expansion [46]. Chondrocyte apoptosis and their apoptotic bodies are also believed to 
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contribute for cartilage ectopic mineralization (Fig. 1.4) [46]. Articular cartilage is supposed 
to be resistant to ECM mineralization due to the synthesis of calcification inhibitors and the 
maintenance of articular chondrocytes in a mature state, without undergoing hypertrophic 
differentiation [50]. Calcification can proceed when this equilibrium is disrupted by factors of 
multiple origins: genetics, aging, ECM modifications, imbalance between inhibitors and 
promineralizing factors, dysregulation of PPi and Pi metabolism, changes in extracellular 
calcium levels, and chondrocyte phenotype alterations including articular chondrocyte 
hypertrophic differentiation, apoptosis, and altered responses to growth factors, inflammatory 
cytokines, and mediators of inflammation [49,50]. 
Among ECM components, extracellular Pi and PPi concentrations are critical 
determinants of mineralization and the type of calcium-containing crystal accumulating in 
cartilage depends on their levels [49]. High PPi levels promote CPPD crystal formation and 
inhibit BCP crystal nucleation, whereas high Pi concentration and low PPi favour BCP crystal 
formation [49]. 
 
1.1.4 Vitamin K-dependent proteins associated with pathological 
calcification 
 
Several gene and protein alterations have been associated with ectopic calcification 
[51], including impairments in the extrahepatic VKDPs OC, MGP and GRP [12,16,52]. In 
fact, OC and MGP are implicated in the regulation of endochondral calcification, controlling 
HA deposition [43,53], and deficiencies in these VKDPs interfere with endochondral bone 
formation, generating pathological calcification [12,52]. With the discovery of GRP, initially 
identified in cartilaginous tissues and containing an unprecedented high number of Gla 
residues [54], its potential involvement with physiological and pathological calcification was 
hypothesized, and studies have been conducted in the past years to further elucidate this 
question.  
In vertebrates, all extracellular body fluids are supersaturated with calcium and 
phosphate, resulting in a tendency for spontaneous calcium phosphate precipitation [55]. 
Potent inhibitors of calcium salt precipitation and crystallization are therefore essential for 
survival, and indeed, a broad range of inhibitors are found in circulation [56]. Fetuin-A, a 
glycoprotein synthesized in the liver and secreted into circulation, is considered the most 
important systemic inhibitor of soft-tissue calcification [57]. Fetuin-A binds and sequesters 
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mineral nuclei, forming soluble colloidal high molecular weight calciprotein particles (CPP), 
inhibiting crystal growth and aggregation [57,58]. This mechanism is believed to facilitate the 
clearance of calcium crystals from extracellular fluids, that otherwise could seed and possibly 
promote ectopic calcification [58]. Enhanced CPP levels are encountered upon increased bone 
resorption events, where calcium phosphate crystal nuclei are believed to be formed in a 
bone-remodelling compartment (BRC) and released into the circulation, accompanied by the 
complex formation in the BRC [59]. Notably, BRC structures were also identified in the 
vasculature [60], suggesting that calcium crystals and CPP may be formed in other locations, 
such as sites of pathological calcification. Besides fetuin-A, small extrahepatic VKDPs have 
been discovered acting as potent calcification inhibitors, namely OC and MGP [56]. 
Interestingly, a circulating MGP-containing CPP was described and suggested to inhibit 
calcium phosphate crystal precipitation [61], indicating that both fetuin-A and MGP may 
function in association. In contrast to fetuin-A, OC and MGP are local inhibitors of 
calcification, being synthetized in the tissues in which they exert their function [56]. 
Osteocalcin is primarily synthesized by osteoblasts, and OC-deficient mice show increased 
bone mineral content [62]. Matrix Gla protein is majorly synthesized by chondrocytes and 
vascular smooth muscle cells (VSMCs), and MGP-deficient mice show impaired growth, 
resulting from excessive growth plate calcification, and massive calcification of the arterial 
tunica media [12]. In agreement with its local inhibitory activity, and in contrast to MGP, OC 
is not able to inhibit ECM calcification in arteries [63]. An interesting question is why fetuin-
A alone is unable to stop calcification of the former mentioned tissues. A possible answer to 
this issue was provided by studies which demonstrated that fetuin-A is too large to penetrate 
the luminal space within collagen and elastin fibrils while small calcification inhibitors, such 
as OC and MGP, may penetrate the fibrils and prevent mineral growth [43]. This finding 
could explain why elastin fibrils are prone to calcify, especially during vitamin K 
insufficiency, and evidenced the vital importance of vitamin K in the prevention of soft-tissue 
calcification [43].  
The calcification inhibitory effect of MGP is partly based on its direct calcium crystals 
binding ability through the Gla residues [64]. Accordingly, Keutel disease, caused by 
mutations in the human MGP gene resulting in non-functional protein, originates, among 
other features, cartilage calcification similar to that of MGP-deficient mice [65]. Transgenic 
mice with a MGP mutant that could not be carboxylated, also acquired a similar phenotype 
[63]. Moreover, MGP is described to affect osteogenesis, chondrocyte maturation and ECM 
calcification inhibition, by interacting with BMP2, a potent inducer of bone formation in both 
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skeletal and soft tissues [13]. Matrix Gla protein regulates BMP2 activity via binding through 
its Gla residues, emphasizing the need of MGP γ-carboxylation in bone and cartilage 
formation [66]. In concordance, the ectopic calcification of connective tissues observed in 
pseudoxanthoma elasticum (PXE), an autosomal recessive disease [67], is believed to be 
originated, in part, from local tissue deficiency in MGP γ-carboxylation [68]. Also, increased 
circulating levels of undercarboxylated MGP (ucMGP), possibly reflecting local synthesis, 
have been proposed to serve as a predictor for vascular calcifications [69]. A striking 
difference between Keutel syndrome and MGP-deficient animals is that the effects on the 
vasculature are less prominent in human, suggesting that other calcification inhibitors could 
form a backup system for MGP deficiency in humans [56]. Gla-rich protein, the most recently 
discovered VKDP [54], may represent such a calcification inhibitor. Although the function of 
GRP in humans has not yet been completely established, GRP has been associated to sites of 
pathological calcification in human [14-16] and proposed as a modulator of calcium 
availability [14,15] and a calcification inhibitor in the cardiovascular system, depending on its 
γ-carboxylation status [16]. These findings highlight the possibility of GRP association to 
other ectopic calcification-related pathologies, such as OA. 
 
 1.1.4.1 Gla-rich protein 
 
Gla-rich protein was originally identified in Adriatic sturgeon calcified cartilage 
extracts, when analysing OC and MGP protein content [54]. Gla-rich protein revealed to be a 
small secreted protein containing 16 Gla residues in sturgeon (Fig. 1.5), the highest Gla 
percent of any known protein, and it was therefore named Gla-rich protein [54]. This high 
content of Gla residues present in GRP is in clear contrast with the 3 to 5 Gla residues present 
in OC and MGP [70,71]. GRP primary sequence analyses revealed a high content of charge 
density (36 negative and 16 positive with a total of 20 net negative), yet it is insoluble at 
neutral pH [54].  
Gla-rich protein orthologs were identified in all taxonomic groups of vertebrates, and a 
paralog (GRP2) in bony fish [54,72,73]. The protein sequence of this VKDP was shown to be 
highly conserved, with 78% identity between sturgeon and human GRP (Fig. 1.5) and no 
significant sequence homology was identified between GRP and the Gla-containing region of 
any presently known VKDP [54]. Gla-rich protein was verified to contain a transmembrane 
signal peptide of 26-27 amino acids, a propeptide with 38-39 amino acids containing GGCX 
   Chapter 1 – General introduction 
 
13 
 
recognition site, an AXXF motif (first observed in MGP, serving as a proteolytic cleavage 
site), a furin-like cleavage site (for propeptide cleavage at the RXXR polybasic site), and a 
mature protein with dimensions between 67 and 75 amino acids, depending on the species, 
containing 14 highly conserved Glu residues, each of them γ-carboxylated in sturgeon [54] 
(Fig. 1.5). The high level of evolutionary conservation and unprecedented number of Gla 
residues verified for GRP, pointed for a fundamental role of this protein, most likely related 
with the regulation of  calcium in the extracellular environment [54].  
 
  
Fig. 1.5 – Alignment of complete human (HuGRP) and sturgeon (StGRP) GRP deduced 
proteins showing conserved residues in particular positions and highlighting important 
functional domains and motifs. Stars indicate identical residues; the underlined sequences, γ-
glutamyl carboxylase (GGCX) putative recognition site; AXXF motif is evidenced; rectangle, 
furin-like proteolytic site (RXXR); black dots, conserved putative γ-carboxylated Glu 
residues; white dots, non-conserved putative γ-carboxylated Glu residues; Gla domain is 
highlighted with a dashed line; signal peptide is shown in dark grey while propeptide in light 
grey. First residue of mature protein is assigned as number 1 and signal peptide, propeptide 
and mature protein are indicated accordingly (Adapted from Viegas et al., 2008 [54]). 
 
Gla-rich protein mRNA was found in several skeleton-associated tissues and soft 
tissues in sturgeon, although its highest expression was seen in cartilage, with GRP 
expressing cells including chondrocytes, chondroblasts, osteoblasts and osteocytes [54]. In 
rat, GRP was expressed in chondrocytes and bone cells suggesting a widespread role 
throughout skeletal formation [54].  
In the same year that GRP was identified in sturgeon cartilage extracts, it was also 
described by other group as a novel transcript in human fetal growth plate cartilage, which 
was termed unique cartilage matrix associated protein (UCMA) [74]. Using RNA in situ 
hybridization, immunohistochemistry analysis and a mouse model, the same group 
hypothesized that GRP could be a secretory marker for resting chondrocytes and suggested an 
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important function in the early phase of chondrocyte differentiation [74]. Further, GRP was 
suggested as cartilage specific and to be involved in the negative control of osteogenic 
differentiation of osteochondrogenic precursor cells in the peripheral zones of fetal cartilage 
and at the cartilage-bone interface [75]. Accordingly, GRP was shown to be downregulated in 
mice chondrogenic cells by BMP2, associated to chondrocyte maturation towards a 
hypertrophic phenotype, and to downregulate ALP activity and OC expression in mice pre-
osteoblastic cells [75]. Unique cartilage matrix associated protein nomenclature was later 
altered to upper zone of growth plate and cartilage matrix associated protein (National centre 
for biotechnology information, NCBI, database). Gla-rich protein downregulation by BMP2 
was also verified in mice chondrocytes in other study [76], supporting the previous results. 
Yet, recent data showed GRP upregulation in response to Runx2 and Osx, promoting 
osteoblast differentiation and nodule formation in mice pre-osteoblastic cell cultures [77]. 
Gla-rich protein knocked-down studies in zebrafish also supported a role for GRP in cartilage 
development and initial skeletal formation, with reduction of Col2a1 and aggrecan content in 
cartilage, and severe growth retardation and skeletal defects [72]. Interestingly, this phenotype 
could be reproduced by treating zebrafish with warfarin, suggesting that the observed effect 
was ascribed to the inhibition of GRP γ-carboxylation, since VKDPs like MGP and OC are 
only expressed at later time points of zebrafish skeletal development [72]. Surprisingly, GRP-
deficient mice did not display a clear phenotype during normal development, although GRP 
involvement in skeletal homeostasis and association with challenging conditions, such as 
ageing or disease, were not addressed [78]. In human, GRP has been associated to 
pathological situations involving ectopic calcification. The protein was found co-localized 
with mineral deposits in skin of diagnosed patients with dermatomyositis and PXE [14], in the 
vascular system of patients with chronic kidney disease (CKD) [14], in breast carcinomas 
[15], and in aortic valves in patients with calcified aortic valve disease (CAVD) [16]. These 
associations supported GRP role as modulator of calcium availability in the ECM [14,15]. 
Moreover, although both carboxylated (cGRP) and non-carboxylated GRP forms were shown 
to have in vitro BCP crystals binding capacity [15] and both cGRP and undercarboxylated 
GRP (ucGRP) accumulate at sites of pathological calcification in human carcinomas and 
calcified aortic valves [15,16], ucGRP was the prevalent form associated to pathological 
tissues suggesting a role dependent of its γ-carboxylation status. In concordance, cGRP, and 
not ucGRP, was proposed as an inhibitor of calcification in the cardiovascular system, a 
function that might be associated with the prevention of calcium-induced signalling pathways 
and direct mineral binding [16]. This study also shown the presence of GRP in extracellular 
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vesicles (EVs) isolated from cultured aortic segments media, entities whose mineralization 
capacity is highly related with vascular calcification [79], and it was hypothesized that GRP 
could be associated with a fetuin-A-MGP calcification inhibitory system detected in the 
calcified areas [16]. Altogether, the existing data regarding GRP biological roles and 
molecular mechanisms of action reinforce the need for additional characterization of GRP 
regarding human pathological conditions related to ectopic calcification, such as OA.  
The entire GRP protein sequence is originated from an RNA sequence that contains 5 
exons, and four alternatively spliced transcripts of GRP gene were identified in mice - GRP-
F1, F2, F3, and F4 - differing by exon 2, exon 4, or both (Fig. 1.6) [76]. The same variants 
were also detected in zebrafish [72,73], however, no splice variants were yet reported in 
human. In mice, these variants were associated to early stages of chondrogenesis and 
suggested to be possibly implicated in skeletal pathologies in case of an imbalanced 
expression [76]. GRP-F1 and -F3, the first corresponding to the full length protein and the 
second lacking exon 4 (Fig. 1.6), were shown to be secreted, whereas GRP-F2 and -F4, both 
lacking exon 2 and therefore a portion of the signal peptide sequence (Fig. 1.6), were shown 
to accumulate in the cells [76]. In addition, GRP-F4 also lacks exon 4 (Fig. 1.6) [76].  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.6 – Four alternatively spliced variants of GRP described to exist in mouse and 
zebrafish. The RNA structure of the four variants is represented (F1-F4). Exons (E) 2 and 4 
are deleted in GRP-F2 and GRP-F3, respectively, and both in GRP-F4. SP, signal peptide; PP, 
propeptide; MP, mature peptide; GGCX, γ-carboxylase recognition site (Adapted from Le 
Jeune et al., 2009 [76] by Dr. Marta Rafael).  
 
1.1.5. Vitamin K and calcification-related VKDPs involvement with 
osteoarthritis  
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Osteoarthritis is a whole-joint disease characterized by cartilage destruction with 
cartilage mineralization, subchondral bone modifications and mild synovial inflammation 
[80], which will be further addressed in the following section. Currently, there is an urgent 
need for reliable, quantitative and dynamic tests to detect early damage in OA and measure 
the progress of treatments targeted against joint destruction [81]. Vitamin K and the extra-
hepatic VKDPs OC, MGP and GRP represent interesting candidate biomarkers for OA, due to 
their determinant role in skeletal metabolism and associations with ectopic calcification 
[3,56]. 
Several studies have in fact evidenced that subclinical vitamin K levels are associated 
with increased risk of knee OA development [82-84]. Also, vitamin K2 was suggested to 
possibly affect bone turnover when medial condyles, showing advanced knee OA, were 
shown to possess lower menaquinone levels comparing to lateral condyles, showing less 
advanced OA [85]. Interestingly, vitamin K association with OA may not be restricted to 
calcification events since this vitamin has been proposed to exert a protective effect against 
inflammatory events and oxidative stress [24-26,28,29], two features associated with OA 
progression [86-88].  
The absence of functional MGP in animal models has been shown to originate similar 
processes as those occurring in OA. A study attributed the abnormal growth plate 
mineralization observed in chicken hypertrophic chondrocyte cultures to impaired MGP 
synthesis caused by warfarin treatment [89]. The last process can lead to endochondral 
ossification in a similar way as osteophytes are formed (bony outgrowths occurring at the 
joint margins in advanced stages of OA) [89]. Also, chondrocytic abnormalities including 
aberrant chondrocyte proliferation, apoptosis, and defective chondrocyte maturation were 
observed in mice cell cultures underexpressing MGP [90] and in the MGP-deficient mice 
[12]. In addition, the lack of organized chondrocyte columns present in the last model [12] are 
similar to chondrocyte abnormalities occurring in OA [91]. Moreover, osteoarthritic 
chondrocytes have been demonstrated to produce primarily ucMGP while normal 
chondrocytes produce functional γ-carboxylated MGP (cMGP) [92]. Interestingly, the last 
study suggested that MGP lack of function could be associated with pathological cartilage 
mineralization, and MGP calcification inhibition was proposed to occur via a fetuin-A-MGP 
complex present in chondrocyte-released MVs in control conditions [92]. Thus, it is most 
likely that insufficient functional MGP, associated with inadequate concentrations of vitamin 
K, potentially play a role in OA [92,93]. Vitamin K metabolism deficiency may also affect 
OC, and in fact, serum undercarboxylated OC (ucOC) is associated with OA and considered a 
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biomarker for this degenerative disease [94]. Notably, the former association was related with 
inflammatory processes. A significant correlation was observed between serum ucOC and 
serum hyaluronic acid, a marker for synovitis, the clinical term for the synovial membrane 
inflammation occurring in OA [88], suggesting that vitamin K metabolism may be associated 
with synovitis in patients with knee OA [94]. Moreover, the combined assessment of ucMGP 
in serum and synovial fluid was suggested as a potential joint inflammatory marker in arthritis 
patients [95]. Although a precise mechanism of action was not proposed in the last study, it 
was hypothesized that the synovial inflammation might impair the passage of ucMGP 
produced by local chondrocytes into circulation, resulting in higher synovial and lower serum 
ucMGP levels found in inflammatory arthritis [95]. 
Altogether, the existing associations between vitamin K and the extra-hepatic VKDPs 
OC and MGP, not only regarding OA pathological calcification but also inflammatory 
processes, in addition with the notion that other calcification inhibitors may be required to 
backup MGP functions in human [56], highlighted a possible association of GRP with OA.  
  
   
1.2 Osteoarthritis  
 
Osteoarthritis is the prevalent form of arthritis, the general term applied to 
degenerative joint disorders [96]. OA is a chronic health condition and a leading cause of pain 
and disability among adults, with a high impact worldwide [97]. As the population ages, 
along with the increasing prevalence of obesity, it is expected that the burden of OA on the 
population, healthcare system and economy will continue to increase, especially if no major 
improvements in managing the disease are achieved [96]. Osteoarthritis predominantly affects 
weight bearing joints like the knee, hip or ankle [98]. Common OA features are articular 
cartilage degradation and loss, joint space narrowing, subchondral bone changes, osteophytes 
formation, thickening of the joints, synovial membrane inflammation and pathological 
calcification [99,100]. Current diagnosis of OA still relays on routine radiography and clinical 
manifestations, which are unable to evaluate the molecular changes occurring in early stages 
of OA [81]. Therefore, predicting the disease progression is a very challenging task [81]. 
Moreover, there are currently no disease modifying OA drugs (DMOADs) [81] and 
traditional treatments are based on symptom control, trying to post-pone chirurgical 
interventions [96]. In order to improve the management of OA, it is crucial to enrich the 
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knowledge on the pathogenesis of the disease, and the wealth of information relating new OA 
biomarkers with clinical outcomes may permit an earlier diagnosis and better means for 
accessing the effects of new therapeutic interventions [96,101]. 
   
1.2.1 Osteoarthritis epidemiology and burden  
 
Osteoarthritis is a heterogeneous disease characterized by the failure of a synovial 
joint [101]. Multiple risk factors can affect the development and progression of OA including 
age, sex, obesity, family history or trauma [97]. When the origin of OA is idiopathic, 
occurring in the absence of an obvious abnormality, it is termed primary OA, whereas if 
resulting from trauma or diseases OA is considered secondary [102].  
Before the age of 40 the incidence of OA is low and frequently secondary, associated 
with trauma [103]. The prevalence of OA increases between 40 and 60 years old, with a linear 
increase in its incidence in later ages [103]. Global estimates indicate that 9.6% of men and 
18% of women over 60 years old have symptomatic OA [103]. Osteoarthritis is the first cause 
of permanent job incapacity, one of the most frequent motifs of inability in the elderly, and 
one of the most common reasons for primary care visits [104]. USA studies state that OA is 
responsible for 4 million hospitalizations and the loss of 68 million labour days per year 
[105]. Also, a survey performed in England based on a 72% response rate from over 26.000 
adults with more than 50 years old, showed that half of the sample presented OA [106]. In 
Portugal, it is estimated that 6% of the population is affected by this joint disorder [103]. 
Estimates of OA burden need to take into consideration economic, social and/or 
psychological costs or losses to the patient, family and/or society [103]. In USA alone, the 
financial burden of OA has been estimated to be $81 billion in medical costs and $128 billion 
in total cost per year [101]. In Portugal, no published data on specific direct and indirect costs 
was identified to allow any comparisons, however rheumatic diseases are pointed as the first 
cause for early retirement [103]. 
Knee OA is the prevalent form of the disease [97] and the risk of mobility disability 
attributable to it is greater than due to any other medical condition in people aged over 65 
[101]. Recent estimates suggest that the global burden of knee OA affects approximately 250 
million people [101]. In Portugal, studies estimate that the incidence of knee OA corresponds 
to 3.8% of the population and in adults over 40 years old, the prevalence raises to 56.9% in 
men and 57.7% in women [103]. 
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Age is the strongest predictor of OA development with 64% of the affected population 
having more than 60 years old [101]. This outcome is mainly consequence of a degenerative 
process occurring in stable articular cartilage phenotype around the age of 40 in humans, 
where chondrocytes reach terminal differentiation [107]. Females also present higher risk of 
developing the disease, and although the reason for these differences is unclear it is suggested 
to be related with high estrogen levels [99]. In concordance, articular chondrocytes possess 
functional estrogen receptors and there is evidence that estrogen can upregulate proteoglycan 
synthesis [99]. Obesity is a key risk factor for knee OA, increasing its incidence three-fold 
and suggested to accelerate the progression of the disease [97]. Interestingly, obesity appears 
to affect OA not only because of biomechanical overloading that favours subsequent cartilage 
degeneration, but also due to a metabolic/inflammatory pathway known as the metabolic 
syndrome (MetS) [97]. Metabolic syndrome is a cluster of cardiometabolic disorders that 
result from the increasing prevalence of obesity, having as major components insulin 
resistance, central obesity, dyslipidaemia (abnormal amounts of lipids in circulation) and 
hypertension [108]. Although there is still much to clarify regarding the association between 
MetS and OA, abnormal loading is associated with inflammatory and metabolic imbalances in 
OA in part because it triggers the same signalling pathways as those induced by inflammatory 
cytokines [91]. In fact, a clinical study involving 653 participants revealed that in such group 
almost half of the association between body mass index (BMI) and knee OA was 
accompanied by high serum leptin levels [109]. The authors suggested that the adipokine 
leptin may play an important role in the development of knee OA, possibly through an 
immune-mediated or inflammatory process [109]. In agreement with the existence of 
associations between OA and MetS, risk factors that contribute to this syndrome are generally 
considered risk factors for rheumatic diseases, in particular OA [110]. A common feature 
among OA patients is the existence of comorbidities (presence of one or more additional 
disorders), which generally increase the impact of OA [103]. Genetic predisposition is also a 
risk factor for OA and the influence of genetic factors for disease heritability is comprehended 
between 39 to 65% [111]. Among secondary OA, traumatic joint injury is the major risk 
factor for OA, particularly at the knee [97]. Diseases that cause inflammation of the joint, 
such as rheumatoid arthritis (RA), can also increase the risk of developing OA later in life 
[102]. 
  
1.2.2 Pathophysiology of osteoarthritis  
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Synovial joints are responsible for the movement of articulating bones [111]. They 
contain articular cartilage, subchondral bone, ligaments, a synovial cavity between bones 
filled with synovial fluid, a capsule of dense fibrous connective tissue attached to the 
articulating bones and composed by an outer fibrous membrane and an inner synovial 
membrane, and periarticular muscles (Fig. 1.7) [111].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.7 – Knee joint with severe osteoarthritis. Articular cartilage becomes disrupted and 
fragments are released into the synovial fluid, osteophytes grow at the edges of bone and the 
synovial fluid increases its volume (Adapted from Yavorskyy et al., 2008 [112]). 
 
Joint surfaces are supported by distinct anatomical layers from which articular 
cartilage is the most superficial (Fig.1.8) [111]. In healthy conditions, chondrocytes are 
organized within a three-dimensional matrix, without any signs of proliferation [111]. 
Articular cartilage acts as a low-friction, load-bearing surface, experiencing a range of static 
and dynamic forces which are absorbed by cartilage ECM and subsequently dissipated and 
transmitted to the chondrocytes [111]. The biomechanical properties of articular cartilage are 
ensured by the spatial organization of its ECM, whose main constituents are collagens and 
proteoglycans, in particular Col2a1 and aggrecan, responsible for tensile strength and 
compressive resistance, respectively [113]. Articular cartilage is divided in a superficial 
tangential zone with flattened chondrocytes and very few collagen fibrils, a middle zone with 
thicker collagen fibrils and spherical chondrocytes, and a deep zone, in which collagen fibrils 
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are thickest and chondrocytes are ellipsoid, perpendicular to the articular surface and grouped 
in radially arranged columns (Fig. 1.8) [111]. The transition between the compliant articular 
cartilage and stiff subchondral bone is provided by calcified cartilage (Fig. 1.8), characterized 
by typical hypertrophic chondrocytes, able to mineralize their ECM and expressing high 
levels of Col10a1 [111]. The two types of cartilage are separated by a thick bundle of 
collagen fibrils termed tidemark (Fig. 1.8) [111]. Since cartilage is an avascular tissue, 
chondrocytes live in a hypoxic environment [91]. Oxygen and nutrients come from the 
vascular supply in the joint capsule, synovial membrane and subchondral bone [91]. The 
subchondral bone not only absorbs and distributes loads but is involved in the metabolism of 
the deeper layers of the articular cartilage [111]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.8 – Schematic representation of cartilage organization in healthy joints before cartilage 
damage. In each cartilage zone (calcified, radial, intermediate and superficial), chondrocytes 
have a distinct phenotype and organization. The tidemark separates the non-calcified from the 
calcified cartilage. The calcified cartilage zone differs from the other cartilage zones by the 
mineralization of its extracellular matrix, and the presence of vessels (red) and nerve fibres 
(green) that originate from the subchondral bone (Adapted from Houarda et al., 2013 [91]). 
 
Osteoarthritis is generally the result of abnormal biomechanics, secondary 
inflammation or enforced inactivity [98], which majorly affect cartilage joint surface areas 
[91]. As in endochondral ossification, the critical event in OA is based on ECM remodelling 
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and OA is believed to be a consequence of chondrocytes failure in recovering from disturbed 
catabolic and anabolic processes [111].  
Upon an abnormal stimulus, quiescent chondrocytes undergo a phenotypic shift and 
become activated, characterized by cell proliferation, cluster formation and increased 
production of matrix proteins and matrix-degrading enzymes (Fig. 1.9) [114]. Chondrocyte 
differentiation and remodelling are, amongst others, regulated by BMPs, thus impairments in 
these proteins or their pathways may be involved in chondrocyte hypertrophy and ECM 
degradation, mainly due to the elevated production of MMP13 [115]. In fact, the main 
cartilage matrix-degrading enzymes identified in OA are zinc dependent MMPs and 
ADAMTSs (short for A disintegrin and metalloproteínase with thrombospondin motifs) [91]. 
Chondrocytes sense mechanical stress and changes in the pericellular matrix, largely through 
receptors for ECM components [91]. In particular, aggrecan cleavage by ADAMTS5 is 
believed to uncover a specific receptor to which native Col2a1 binds as a ligand, 
preferentially inducing and activating MMP13, that in turn will originate Col2a1 remodelling 
and degradation [116]. The bioactive peptides arising from Col2a1 degradation will boost OA 
development, stimulating the production by chondrocytes of more MMPs and inflammatory 
cytokines, such as interleukin 1β (IL-1β) and tumour necrosis factor α (TNF-α) [91]. The 
presence of IL-1β and TNF-α induce the production of prostaglandin E2 (PGE2) and reactive 
oxygen species such as nitric oxide (NO), involved in the induction of inflammatory 
mediators [91]. Cartilage matrix degradation products can also stimulate NF-κB transcription 
factors, that control the expression of downstream target genes such as MMP13, ADAMTSs, 
IL-1β, NO synthase (NOS) and cyclooxygenase 2 (COX2), the last involved in PGE2 
production [91]. NF-κB also influences the regulated accumulation and remodelling of ECM 
proteins and has indirect positive effects on downstream regulators of terminal chondrocyte 
differentiation including β-catenin and Runx2, which are believed to lead to premature 
chondrocyte differentiation [117]. In fact, the diminished capacity to limit Wnt/β-catenin 
signalling has been suggested to contribute to cartilage loss [118]. In both OA and RA, the 
inappropriate regulation of NF-κB transcription factors is one of the major causes of setting 
an inflammatory response [111]. NF-κB transcription factors and their immediate upstream 
signalling components represent potential therapeutic targets in OA, because of their pivotal 
roles in most proinflammatory processes and also in important aspects of chondrocyte 
differentiation [111]. Adipokines from the white adipose tissue can also act as an endocrine 
organ, contributing for the induction of inflammatory processes [91]. Interestingly, the 
presence of adipokines in OA is not only resultant from fat tissue but also from joint cells 
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including chondrocytes (Fig. 1.9), induced by an inflammatory stimuli [119]. In turn, 
adipokines may induce chondrocytes to enhance the expression of MMPs, NOS and cytokines 
[91]. Cartilage matrix degradation products are therefore believed to stimulate or feedback 
amplify further ECM destruction (Fig. 1.9) [91]. Chondrocytes at first become activated to try 
keeping the balance between anabolic and catabolic factors, but this triggers improper 
maturation, leading to chondrocyte hypertrophy, followed by cartilage degradation, 
mineralization and vascularization, and the appearance of foci of endochondral ossification 
such as osteophytes (Fig. 1.9) [91]. Cartilage superficial tangential zone gets fibrillated and 
loses the characteristic flattened chondrocytes, matrix loss occurs and fissures appear (Fig. 
1.9) [111]. Hypertrophic chondrocytes express genes encoding Runx2, MMP13, and Col10a1, 
which can all be detected in OA cartilage [91]. Also, there is evidence of cell death and 
formation of chondrons (disoriented chondrocytes) (Fig. 1.9) [111].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.9 – Schematic representation of joint alterations in osteoarthritis. Cartilage extracellular 
matrix (ECM) progressively disappears accompanied by phenotypic modifications, including 
the formation of clusters, catalysis activation, hypertrophic differentiation and chondrocyte 
loss. Subchondral bone remodelling occurs with the development of vessels (red) located in 
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vascular channels, which also contain osteoblasts, osteoclasts, and sensory nerves (black). In 
response to several stimuli, including catabolic factors coming from the subchondral bone, 
chondrocytes modify their phenotype and express a subset of factors, such as cytokines, 
damage-associated molecular patterns (DAMPs), and adipokines. Calcium crystals are also 
released. All these mediators initiate a vicious circle of cartilage degradation and reach the 
synovial membrane, provoking an inflammatory process with the production of factors by 
synovial macrophage-like and fibroblast-like cells, which promote inflammation in the 
synovial membrane and participate in cartilage damage (Adapted from Houarda et al., 2013 
[91]). 
 
As a consequence of cartilage degradation, the joint space narrows between adjacent 
bones [120]. Subchondral bone remodelling takes place particularly in regions beneath 
articular cartilage damage and is accompanied by increased osteoclast activity, associated to 
bone resorption and resulting in bone loss [111]. In fact, the imbalance between bone 
formation and resorption is frequently observed in OA [121]. Ultimately, OA may be 
considered as a disorganized recapitulation of the maturational phenotype seen in 
endochondral ossification [91].  
The synovial fluid is a viscous ultrafiltrate of plasma with high glycoprotein and 
hyaluronic acid content, acting as a lubricant, shock absorbing and source of biochemical 
nutrients to the avascular articular surfaces [122]. Upon OA, molecules and calcium crystals 
released from the damaged cartilage ECM into the synovial fluid are believed to promote the 
release of proteolytic enzymes by synovial cells and the recruitment of inflammatory cells 
into the joint (Fig. 1.9) [91]. These secreted damage-associated molecular patterns (DAMPs), 
also called alarmins, act as ligands of toll-like receptors (TLR) activating inflammatory and 
catabolic events in articular cartilage and other joint tissues [91,123]. Chondrocytes express 
TLRs and this expression is upregulated within an osteoarthritic scenario, induced by 
inflammatory stimuli [124]. Toll-like receptors activation lead to increased expression of 
downstream inflammation-related genes including MMPs and NOS, via NF-κB signalling 
[91]. Plasma proteins present in the osteoarthritic synovial fluid may function as DAMPs and 
thereby contribute to a low-grade inflammatory state [91]. 
The synovial membrane provides a deformable packing that allows the movement of 
adjacent tissues [125]. Additionally, the cellular constituents of this tissue are the major 
source of synovial fluid components, contributing to the unique functional properties of 
articular surfaces and modulating chondrocytes activity [88]. The synovial membrane is 
semipermeable controlling the molecular traffic within the joint space, maintaining the 
composition of the synovial fluid and able to remove the products of chondrocytic 
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metabolism and articular matrix turnover [88]. Healthy synovial membranes consist of a 
distinct intimal lining layer of 1-2 cells thickness and a synovial sublining layer (Fig. 1.9) 
[125]. The major cell types composing this tissue are macrophage-like cells, also termed type 
A synoviocytes, and fibroblast-like cells, or type B synoviocytes (Fig. 1.9) [126]. The 
subintimal layer contains scattered blood vessels, type A synoviocytes, type B synoviocytes, 
few fat cells and lymphocytes [125]. The structure of the former layer can be of three types: 
areolar, adipose and fibrous (Fig. 1.10), and it is possible to detect the three types within the 
same membrane both in healthy or pathological conditions [125]. The areolar type (Fig. 1.10, 
A) is often crimped into folds, which may disappear when stretched, or may form projections, 
and contains capillaries immediately beneath the lining cells. The adipose type (Fig. 1.10, B) 
is found mainly in fat pads, may be avascular and may lie directly on adipocytes, but it is 
often separated by a band of collagen-rich substratum. The fibrous type (Fig. 1.10, C) usually 
consists of fibrous tissue, such as ligaments or tendons, on which lies an intermittent layer of 
cells  [125]. Lubricin and hyaluronic acid are two of the most important molecules produced 
by the synovial lining cells, helping protecting and maintaining the integrity of articular 
cartilage surfaces and reducing friction by providing boundary lubrication at the articular 
surface [127]. In addition, lubricin reduces the pathologic deposition of proteins at the 
articular surface [88]. Under healthy conditions, high molecular weight molecules like 
lubricin and hyaluronic acid are not readily permeable, while small molecules like growth 
factors and cytokines easily diffuse through the membrane [88]. Macrophage-like 
synoviocytes express markers of hematopoietic origin consistent with the monocyte-
macrophage lineage, such as cluster of differentiation 68 (CD68), and are derived from the 
bone marrow [128,129]. They migrate to the synovial membrane and become resident cells, 
although it is not certain if differentiation occurs in situ or prior to arrival [129]. Their 
phenotype is similar to other tissue-resident macrophage populations, they are able to actively 
phagocyte cell debris and wastes in the joint cavity, and are terminally differentiated with 
little capacity to proliferate [129]. Fibroblast-like synoviocytes are mesenchymal cells that 
display many characteristics of fibroblasts, including the expression of collagens type IV and 
V, and vimentin [129].  
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Fig. 1.10 – Healthy human synovial membrane subintimal layer types: Areolar tissue (A), 
adipose tissue (B) and  fibrous tissue (C). Tissue sections were stained with hematoxylin and 
eosin. Scale bars represents 100 µm (Adapted from Smith, 2011 [125]). 
 
 In the setting of OA, cytokines, adipokines and DAMPs attach to the synovial 
membrane (Fig. 1.9) through TLRs present in both type A and B synoviocytes, and initiate 
synovitis [88]. Synovitis is characterized by increased vascularization, hyperplasia of the 
lining cells, infiltration of inflammatory cells, and formation of perivascular lymphoid 
aggregates (Fig. 1.11) [87]. Macrophages, T lymphocytes and mast cells are the most 
abundant cells infiltrating the synovial membrane, although dendritic cells, plasma cells and B 
lymphocytes may also be present (Fig. 1.11) [130]. Upon hyperplasia and infiltration of 
inflammatory cells, the former promoted by type B synoviocytes that express adhesion 
molecules able to trap macrophages and lymphocytes [125], the permeability of the 
membrane is altered [88]. This change is believed to contribute for the decreased 
concentrations of hyaluronic acid and lubricin observed in the synovial fluid, which worsen 
cartilage integrity and raise the concentrations of hyaluronic acid in serum [88]. The 
complement cascade is also one of the major effector mechanisms of immune system 
activation in OA, complementing the ability of antibodies and phagocytic cells to clear 
pathogens from the joints [88,131]. Activated type A synoviocytes play a fundamental role as 
catabolic mediator producers and contribute to the formation of osteophytes, mainly due to 
the synthesis of TGF-β family members, such as BMP2 [132]. The ensuing synovial cellular 
response originated by cytokines, adipokines or DAMPs (Fig. 1.9), culminates in the 
activation of specific transcription factors, with NF-κB playing a prominent role [88,114]. 
The synovial membrane becomes a source of proinflammatory and catabolic products, 
including ILs, TNF-α, MMPs and ADAMTSs, which imbalance the typical synovial fluid 
composition and contribute to cartilage degradation (Fig. 1.9) [88,98,114,133]. Such 
alterations can also result in decreased concentrations of cartilage-protecting factors [88]. In 
response to the produced cytokines by the synovial cells, chondrocytes are activated and start 
producing more matrix-degrading proteínases, inflammatory mediators and cytokines (Fig. 
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1.9), including IL-1β, TNF-α, MMPs, NOS and PGEs [91]. Feedback amplification events are 
therefore initiated and this vicious cycle contributes to the negative shift of the balance 
towards the loss of homeostasis of the joint [91].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.11 – Synovial membrane changes upon synovitis. The synovial joint is infiltrated by T 
cells, B cells, macrophages, plasma cells, dendritic cells and mast cells which together with 
fibroblast-like cells produce cytokines, growth factors, adhesion molecules and matrix 
metalloproteínases (Adapted from Tanaka, 2009 [134]). 
 
The presence of synovitis in OA is therefore associated with disease progression but 
also with pain [133]. In fact, OA is the leading cause of disability worldwide largely due to 
pain, that is the primary symptom of the disease [135]. Unlike many other pain conditions in 
which the underlying injury typically heals or resolves, OA is a disease that does not resolve, 
thus, it is typically accompanied by chronic pain [135]. Although the accurate source of pain 
in OA is still not completely understood, it is believed to be in great extent caused by tissue 
injury and consequent inflammation, with chemical mediators release, which lead to the 
activation of peripheral nociceptors that generate and exacerbate the feeling of joint pain 
[135,136]. Such receptors activation will elicit a painful response to normally innocuous joint 
movements, like walking, a neurophysiological process known by allodynia [135,136]. Over 
time this increased neuronal activity from the periphery can cause plasticity changes in the 
central nervous system and second order neurones in the spinal cord increase their firing rate, 
enhancing the transmission of pain information to the somatosensory cortex is [136]. This 
central sensitization phenomenon intensifies pain sensation and can even lead to pain 
responses in remote regions of the body from the inflamed joint [136]. 
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1.2.2.1 Interplay between ectopic calcification and inflammatory events  
 
Basic calcium crystals and calcium pyrophosphate dihydrate crystals deposition in 
osteoarthritic cartilage is a common feature of OA [48]. Initially, BCP crystals deposition was 
associated with end-stage OA, released from bone at time of major cartilage defects, and 
CPPD crystals deposition was considered an age-related process [48]. However, several 
clinical and experimental data have provided evidences that cartilage calcification occurs as 
an active process and that it clearly plays a pathogenic role in OA, promoting crystal-induced 
stress (Fig. 1.12) [48]. Basic calcium phosphate crystals are believed to be the major calcium 
crystal form associated with OA, identified in 80% to 100% of osteoarthritic cartilage 
according to different studies, while CPPD prevalence is greater than 20% in people over 80 
years old [49,137,138]. Calcium crystals are correlated with OA severity and major joint 
destruction, although crystal accumulation is also found in a smaller percentage of patients 
with early OA, indicating that calcifications are also associated with low-grade OA changes 
[50,137,138]. Calcium pyrophosphate dihydrate crystals occur preferentially in articular 
tissues (hyaline cartilage, fibrocartilage, intervertebral disk, ligaments, synovial membrane 
and capsule) and synovial fluid, whereas BCP crystals are frequent in both articular and extra-
articular tissues, and in the synovial fluid [49]. Calcium-containing crystals have a direct 
effect on chondrocytes and synoviocytes. In particular, BCP and CPPD crystals induce the 
production of MMPs, NO, prostaglandins and inflammatory cytokines such as IL-1β and 
TNF-α from resident articular cells, increasing the articular inflammation process, cartilage 
degradation and chondrocyte apoptosis (Fig. 1.12) [139-142]. Basic calcium phosphate 
crystals may also induce synoviocytes proliferation (Fig. 1.12) [50]. Interestingly, the crystal-
induced stress associated to articular cells seems to rely on physical contact and be size-
dependent, thus crystal-cell interactions and respective inflammatory responses are influenced 
by crystal size and morphology [140]. Accordingly, small crystal sizes of 1 µm result in vitro 
in higher inflammatory responses than 50 µm crystals, and in fact, the detected crystal sizes in 
vivo in OA-affected articular cartilage or synovial membranes are close to 1 µm size [140]. 
Crystal-induced stress both in chondrocytes and synoviocytes is believed to mainly occur via 
endocytosis or phagocytosis of particles, leading to intralysosomal crystal dissolution with 
subsequent elevation of intracellular calcium levels and release of inflammatory cytokines 
[142]. Crystal phagocytosis can be enhanced by opsonisation by immunoglobulins or 
complement components [142]. Intracellular mitogen-activated protein kinases (MAPK) 
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pathways, known to direct cellular responses to a diverse array of stimuli, are also suggested 
to mediate crystal-induced cellular responses through the activation of NOS [143]. Ultimately, 
crystal activation may also involve a direct crystal-cell membrane interaction, which can be 
either due to electrostatic bonds with naked crystal surface or through membrane receptor 
stimulation by naked or protein-coated crystals [142]. Interestingly, it is postulated that 
proteins and other substances bound to crystals affect their ability to initiate inflammation 
[100]. Studies on the effect of kidney stones and crystal effects on VSMCs reinforced older 
findings showing that synthetic crystals are far more injurious than native crystals and that the 
substances bound to crystals can dramatically affect cell-crystal interactions [144,145]. In 
fact, fetuin-A-containing calciprotein particles formation was suggested to help protecting 
macrophages against proinflammatory effects of the sequestered calcium crystals, while 
facilitating the clearance of calcium crystals from extracellular fluids [35]. Notably, a 
circulating MGP-containing CPP was described and suggested to inhibit calcium phosphate 
crystal precipitation [36], thus mineral binding proteins as fetuin-A, MGP and possibly also 
GRP, may play a role in such processes, helping to prevent the crystal-induced stress 
associated with OA. Overall, with the increasing recognition of the importance of 
inflammation in OA and identification of the innate immune system as a potential mediator of 
such inflammation, the role of calcium crystals in the development and progression of this 
disorder gains particular importance. In concordance, the role of calcification inhibitors such 
as the extra-hepatic VKDPs OC, MGP and GRP, should be further explored and regarded as 
potential therapeutic targets for OA. 
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Fig. 1.12 – Model of crystal-induced stress in an osteoarthritic joint. Basic phosphate calcium 
(BCP) crystals are formed in the articular cartilage by chondrocytes and matrix vesicles and 
can be released into the joint space when cartilage lesions occur. BCP crystals stimulate 
synoviocyte proliferation, along with inflammatory cytokine, matrix metalloproteínase 
(MMP), prostaglandins E (PGE) and nitric oxide (NO) production. BCP crystals also directly 
induce chondrocytes to produce the same mediators, and undergo apoptosis. MMP production 
and chondrocyte apoptosis contribute to cartilage destruction. Moreover, cartilage 
calcifications lead to cartilage stiffness with subsequent altered responses to mechanical 
stimuli within the cartilage and/or the subchondral bone (Adapted from Ea et al., 2011 [50]). 
 
1.2.3 Models for the study of osteoarthritis 
 
Despite widespread awareness of OA and its devastating impact, the pathogenesis of 
early OA is not completely understood, hampering the development of effective tools for 
early diagnosis and disease modifying OA drugs [146]. Moreover, most of the human tissue 
available for the study of OA is obtained at the time of joint replacement, when OA lesions 
are at end stage and as a consequence, little can be concluded about the factors that played a 
role in disease development [146]. Therefore, a whole range of in vivo and in vitro systems 
are currently used to study the different aspects of joint physiology in health and disease 
[147]. 
In vivo models may provide the most accurate reflections of naturally-occurring OA 
[148,149]. Reproducing features of OA in animal systems may be extremely important to gain 
a better understanding of disease mechanisms and to assess responses to potential therapies 
[147]. In concordance, these are currently the most widely used systems for translating basic 
findings into therapies for patients [147]. Animal models of OA include naturally occurring 
OA in aging (experimentally accelerated), transgenic models and surgically or chemically 
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induced OA [149-151]. Small animals (mice, rats, rabbits and guinea pigs) are most often 
used to investigate specific disease mechanisms and for pre-clinical drug screenings, for 
reasons of cost-effectiveness, ease of handling and housing, and opportunity for genetic 
manipulations [147]. Among these, mice are probably the most commonly used models, in 
particular the destabilization of the medial meniscus (DMM) surgical model where lesions 
consistent with that of spontaneous age-related OA are observed [152]. Yet, the high cost of 
using animal models, the increasing ethical concerns and the need for adequate conditions for 
animal handling and housing, contrasting with the ease of manipulating and maintaining in 
vitro systems, in addition to models refining, make in vitro modelling of OA a desirable 
approach [147].  
In vitro OA models include monolayer cultures, co-cultures, three-dimensional (3D) 
cultures and explants [153]. Monolayer cultures involve a single layer of cells grown on a flat 
surface of Petri dishes or culture flasks, allowing cellular expansion from a single sample 
[153]. This system is the easiest to manipulate and allows the easiest cell observations, 
measurements and environmental control of all OA models [154]. It is also very suitable for 
the investigation of distinct isolated pathways [153]. Moreover, there is a rich body of 
literature to which results can be compared when using monolayer cultures [154]. However, 
monolayer cultures have the main disadvantages of cells rapidly losing their molecular 
signature when taken out from the joint environment and the impairment of typical cell-to-cell 
and cell-protein interactions, due to the absence of normal extracellular matrices cells [153]. 
Co-cultures systems are able to consider the cross talk between cell types, thus co-cultures of 
chondrocytes and synoviocytes or synoviocytes and macrophages may contribute to identify 
potential relevant mechanisms in OA [147,153,155]. Yet, these models have the same 
disadvantages of monolayer cultures and special attention should be given to the fact that 
different cell types may require different culture conditions [153]. Three-dimensional cultures 
correspond to high-density cell pellets obtained by centrifugation and subsequently seeded or 
not over a synthetic scaffold/matrix [147,156]. These models provide cells a suitable 3D 
environment, allowing them to secret and build typical in vivo components, enable the 
development of central hypoxia and represent more accurately the real microenvironment 
where cells reside in tissues [156,157]. The major disadvantages of 3D models relay on the 
need to first isolate and expand high amounts of cell types, and on the nature of scaffolds, that 
may induce cells to behave differently than in the natural environment [153]. Ultimately, 
explants or ex vivo models involve the direct culture of a small piece of tissue harvested 
directly from the host [158]. Explants are inexpensive, easily produced and cells are 
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maintained in a normal extracellular matrix, resulting in a more controlled and more 
physiologically relevant OA model than 3D models, maintaining intact both the 
morphological and biosynthetic cell characteristics [153,158]. Nevertheless, explants are 
limited in terms of possessing cell death at the edges of the tissue, not allowing many 
replicates (if any) from the same source, possibly requiring more than one tissue type to 
maintain viability and being prone to change their physical attributes while in culture [153]. 
Overall, although in vitro models are great tools to study different aspects of OA, the 
relevance of such models to clinical OA always needs to be carefully interpreted since they 
may not exactly reflect biological features. 
Among in vitro models, one of the most commonly used approach to study OA is 
cytokine-based models. Accordingly, the addition of IL-1β or TNF-α to cell systems of 
chondrocytes or synoviocytes is a frequent procedure, considering that these cytokines 
increase the expression of catabolic proteins in both cell types [153]. When using such 
models, the amounts of loaded cytokines should be carefully considered in order to use a 
concentration that reflects that existing in naturally occurring OA rather than downstream 
effects caused by an excess of the added compounds [153]. The amounts of IL-1β and TNF-α 
assayed in osteoarthritic synovial fluid are usually under 2 ng/mL and close to 3 ng/mL, 
respectively, while those used to exert an effect in vitro are much higher, reaching up to 100 
ng/mL of IL-1β and up to 50 ng/mL of TNF-α [153,159,160]. Also, the choice of whether to 
use a monolayer, a 3D culture or explants will influence the cells response to cytokine stimuli, 
with monolayer cultures having generally the fastest responses and needing lower amounts of 
cytokines to exert an effect [153]. Yet, monolayer cultures or co-cultures are limited for the 
study of extracellular matrix changes and dynamic processes occurring after cytokine 
stimulation comparing to 3D models [157]. In fact, 3D cartilage cultures stimulated with 
cytokines and macrophage conditioned medium were described to be the most appropriate 
OA model, even comparing with animal models, to study aspects of OA progression such as 
the impacts of NO and PGE2 [157]. 
Overall, no consensus on the most appropriate model for the representation of 
particular features of OA has been made since each model has advantages and disadvantages, 
and its own mechanisms for the induction of a general catabolic process. However, the ease of 
using monolayer cultures combined with their reproducibility, rapid response to cytokine 
stimulation and their effectiveness for the study of distinct isolated pathways [153,154], still 
make this system one of the preferential models to use for the study OA.  
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1.2.4 Osteoarthritis diagnosis and treatments 
 
Current diagnostic criteria for OA relies on radiographic evaluations and clinical 
manifestations, including pain symptoms and stiffness of the affected joint [161]. Common 
clinical approaches to radiographic assessment provide a semi-quantitative judgment of the 
extent of OA, the most common corresponding to the Kellgren-Lawrence (KL) and the OA 
research society international (OARSI) classification systems [162]. The OARSI 
classification system is described to be more appropriated to categorize joint space width, 
while the KL system to categorize the general OA status of the joint [162]. The KL 
classification system grades OA from a 0 to 4 stage, in which 0 corresponds to healthy joints 
and 4 to end stage OA (Table 1.I), and the most adequate treatment for each OA patient is 
defined according to the obtained classification degree [162].  However, OA may be a silent 
disease for many years before the typical symptoms and radiographic changes emerge, thus 
articular cartilage damage may have occurred and become irreversible during this long-term 
subclinical stage [161]. 
 
Table 1.I – Kellgren-Lawrence system for classification of OA (Adapted from 
[162]) 
Grade Features 
0 No radiographic features of OA  
1 Doubtful joint space narrowing and possible osteophytic lipping 
2 Definite osteophytes and possible joint space narrowing  
3 Moderate multiple osteophytes, definite joint space narrowing, 
sclerosis, possible bony deformity 
4 Large osteophytes, marked joint space narrowing, severe sclerosis and 
definitely bony deformity 
 
In addition to the late diagnosis of OA, which hampers treatment, there are also no 
effective DMOADs available as a treatment option to potentially halt or slow disease 
progression [96]. Therefore current treatments are mainly based on symptom control trying to 
post-pone whole joint replacement procedures, also termed arthroplasty surgeries, generally 
only performed in patients with stage 4 OA, according to the KL classification system [162], 
when all other strategies have failed [96]. Such surgical interventions are highly effective, 
involving the replacement of the damaged parts of the joint by an artificial device termed 
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prosthesis [163,164]. The prosthesis is designed to replicate the movement of healthy 
articulations correcting the existing deformities, thus patients quality of life is significantly 
improved by the restoration of joint function and consequent enhanced mobility, pain relief 
and independence [163,164]. Yet, complications may occur at long-term including late 
infection, wearing of the bearings and loosening of the prosthesis [163]. Prior to arthroplasty, 
current practices for managing knee OA involve conservative non-pharmacological treatment 
strategies such as weight loss, aerobic exercise, physical therapy and the use of knee braces 
[165-167]. Oral analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) are also 
commonly administrated to relieve the pain, and they can be helpful for managing OA in the 
short-term, but are less effective for long-term management [96]. Accordingly, 
acetaminophen, generally known by paracetamol, is a common first-line therapy in knee OA 
patients with mild to moderate pain [168]. Nonsteroidal anti-inflammatory drugs (e.g. 
ibuprofen) are considered superior than oral analgesics to treat joint pain, however they are 
associated with adverse effects such as gastrointestinal discomfort and therefore a prolonged 
use should be avoided [168]. Glucosamine/chondroitin is a supplement alleged to be absorbed 
and incorporated into articular cartilage, thus potentially allowing the halting of OA 
progression and even promoting a reparative process [169], nevertheless evidences of its 
positive effect remain inconsistent [168].  
Emerging therapies for managing OA involve intra-articular injectables, ranging from 
corticosteroids, hyaluronic acid and more recently platelet-rich plasma (PRP) or even stem 
cells [96]. Intra-articular corticosteroid injections for knee OA appear to be effective against 
pain [170], but they are recommended for short-term applications do to the risk of 
corticosteroid-induced arthropathies [171]. As a natural component of the synovial fluid, 
hyaluronic acid injections may help improving joint lubrication and shock absorbing and have 
proven to be effective relieving knee pain [172]. Platelet-rich plasma injections are believed 
to help structural repair through its growth factors components [173]. Mesenchymal stromal 
cells are multipotent cells that can be isolated from several human tissues and their 
immunomodulatory, reparative, and anti-inflammatory properties have been tested in a variety 
of animal models, indicating to have potential clinical applications in the field of OA [174].  
Ultimately, the existing strategies to treat OA have either limited efficacy or secondary 
effects and none of them is able to completely cure the disease, thus there is an urging need 
for continued research with regards to the management of OA. This research should focus on 
investigating the efficacy of new drugs such as the DMOADs, as well as better understanding 
their safety profiles [96]. Rather than develop treatments that target symptoms, the emphasis 
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should be on developing advanced therapies that can slow or prevent further disease 
progression and hopefully even initiate a regenerative process [96]. Also, the discovery of 
early OA biomarkers should constitute an extremely valuable tool, in order to manage the 
disease in its initial stages.  
 
1.2.4.1 Biomarkers for osteoarthritis 
 
Osteoarthritis dramatically needs reliable, quantitative and dynamic tests to identify 
patients at risk for the progression of the disease, detect early damage and measure the 
progress of DMOADs targeted against joint destruction [81]. Biomarkers, in addition to 
magnetic resonance imaging, are tools that can address these therapeutic shortcomings [175]. 
Structural molecules and fragments derived from cartilage, bone and the synovial membrane, 
are reported as the most promising candidates for OA biomarkers discovery [81]. These 
markers are eventually released into biological fluids like the synovial fluid or serum, where 
they can be more easily detected [176].  
Proteomics, a large-scale analysis of proteins that involves isolation, purification, and 
mass spectrometry (MS) of the proteins of interest, makes it possible to search for such 
biomarkers in a systemic fashion [177]. Quantitative and high-throughput proteomic 
techniques have made important contributions for the discovery of complement components, 
lipoproteins and lower abundance ECM components in body fluids from OA patients [178]. 
Cartilage proteomic analysis has also been applied to search for candidate OA biomarkers, yet 
while affinity depletion is usually conducted to remove abundant proteins that mask the 
signals of less expressed entities in body fluids, cartilage preparation is much more 
challenging [119]. Cartilage proteomic analysis is mainly limited by dominant collagen and 
aggrecan levels that overwhelm the signals from other proteins, anionic macromolecules 
including aggrecan and hyaluronic acid which affect peptide analysis, and cellular proteins 
from chondrocytes that hinder the identification of ECM proteins [179]. 
The identification of biomarkers that can be applied more broadly from the very early 
to the end stages of OA is required, yet advances in the field OA biomarkers still remain 
challenging [81]. Accordingly, several OA biomarkers are recognized, however most of these 
molecules represent advanced stages of OA and only a few early stages of the disease [175]. 
Examples of proposed OA biomarkers are glucosyl-galactosyl-pyridinoline (Glc-Gal-Pyd), 
correlated with synovial membrane damages, MMP13 and COX2, representing inflammatory 
markers, and serum cartilage oligomeric matrix protein (COMP), indicative of cartilage 
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turnover as it represents a cartilage degradation product [180-183]. Since OA is believed to 
onset at cartilage level, markers of cartilage damage are considered the best candidates to 
reflect early OA markers [81]. In agreement, one of the few suggested early OA biomarkers 
are C-terminal telopeptides of Col2a1 (CTX-II), marking Col2a1 degradation [184]. Urine 
levels of CTX-II have been suggested to access the diagnostic and prognostic of knee OA, 
and also to be able to evaluate the efficacy of DMOADs [184,185]. In fact, higher urine levels 
of CTX-II may be identified at stage 1 of the KL classification system [186]. However, the 
question whether urine CTX-II  levels are solely a cartilage degradation biomarker still 
remains [186].  
 Overall, the discovery of early OA biomarkers may greatly contribute for managing 
the disease. The extra-hepatic VKDP GRP, associated to cartilaginous tissues and ectopic 
calcification in humans [14-16], may represent a candidate biomarker for OA and studies 
towards unveiling such possible relation should be performed. 
 
 
1.3 Aims and organization of the thesis 
 
 Despite the worldwide burden of OA there is still much to unveil regarding disease 
incidence and progression. Moreover, OA continues to have a late diagnostic and adequate 
treatments for this progressive joint disorder are also lacking. Therefore, research in the field 
of OA may gratefully contribute for new strides benefiting the managing of the pathology. 
Since one important feature of OA is the occurrence of pathological mineralization, 
calcification inhibitors may play an important role in the pathogenesis of this disorder. In this 
line, the main aim of this study was to investigate the association of Gla-rich protein with 
molecular features of OA, such as ectopic calcification processes. Additionally, studies were 
conducted to further analyse the potential of GRP as a novel biomarker for OA. Within the 
scope of this work, Chapter 2 describes the collection and characterization of a biological 
sample bank suitable for the study of OA, in particular the investigation of GRP potential 
association with pathological mineralization and inflammatory processes, and the search for 
candidate OA biomarkers. In Chapter 3, the involvement of GRP with OA was explored 
through gene expression studies and further analysed through immune-based strategies, which 
also allowed investigating GRP association with the occurring pathological calcification. 
Chapter 4 describes the establishment of an in vitro cell system that was used to further 
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explore GRP involvement with OA, in particular calcification and inflammatory events. 
Finally, Chapter 5 analyses GRP potential as a biomarker for OA and describes the search for 
alternative candidate OA biomarkers using comparative proteomics. Chapter 6 summarizes 
the main conclusions of this project and highlights future perspectives for subsequent studies 
within the scope of this work. 
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Abstract 
   
Osteoarthritis (OA) is the leading form of degenerative joint disorders, mainly 
affecting weight bearing joints like the knee and representing the most frequent source of 
chronic physical disability of the elderly population. Osteoarthritis is believed to onset after 
articular cartilage damage, later evolving to affect the whole joint. Frequent OA features are 
the degradation and loss of articular cartilage, subchondral bone changes and occurrence of 
osteophytes, thickened joints, synovial membrane inflammation and the deposition of calcium 
crystals in articular tissues, correlated with consequent disease progression. Although new 
strides have been achieved during the past decade in the field of OA, this degenerative 
disorder still urges for the discovery of molecular targets and biomarkers that can facilitate 
early OA prediction, the management of the disease and trials of therapies. The present 
chapter reports the collection and characterization of a biological sample bank containing 
human specimens suitable for the study of OA molecular features, by allowing subsequent 
gene expression studies, histological analysis, proteomic approaches and cell culture 
development. This biobank comprised samples of knee articular cartilage, subchondral bone, 
synovial membrane, synovial fluid, and blood, from knee OA patients and individuals with no 
history of joint disorders. Every collected subject specimen was complemented with medical 
information, which also included radiographical and biochemical data in the case of the 
patients, supporting the representation of osteoarthritic or healthy conditions. Tissue 
histological analysis of the collected material was performed using hematoxylin staining, the 
von Kossa method and immunohistochemistry, to characterize and evidence the association of 
osteoarthritic features in the pathological samples, such as cartilage destruction, synovitis and 
ectopic calcification. This biobank was in particular expected to be useful to investigate the 
possible association of Gla-rich protein (GRP) with OA molecular features, such as 
pathological mineralization and inflammatory mechanisms, and the search for candidate OA 
biomarkers, which will be addressed in the following chapters. 
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2.1 Introduction 
 
Osteoarthritis (OA) is the most frequent form of degenerative joint disorders, which 
commonly affects weight-bearing joints like the knee and hip [96,98]. It is one of the most 
common chronic health conditions and a leading cause of pain and disability among the 
elderly population [97]. Global estimates indicate that 9.6% of men and 18% of women over 
60 years old have symptomatic OA [103]. In USA, OA is responsible for 4 million 
hospitalizations and the loss of 68 million labour days per year, and the financial burden of 
the disease has been estimated to be $81 billion in medical costs and $128 billion in total cost 
per year [101,105]. In Portugal, no published data on specific direct and indirect costs was 
identified, yet rheumatic diseases are pointed as the first cause for early retirement [103]. knee 
OA is considered the prevalent form of the disease [97], and recent estimates suggest that its 
global burden affects approximately 250 million people [101].   
Synovial joints are composed of articular cartilage, a synovial cavity between bones 
filled with synovial fluid, and a capsule, attached to articulating bones and characterized by an 
outer fibrous membrane and an inner synovial membrane [111].  Osteoarthritis is believed to 
onset at cartilage level, with extracellular matrix (ECM) remodelling, then evolving to affect 
the entire joint [91,111]. Frequent OA features are articular cartilage degradation and loss, 
subchondral bone changes and osteophytes formation, thickening of the joints, synovial 
membrane inflammation and pathological calcification [99,100].  
Articular cartilage has limited ability to recover from disturbed catabolic and anabolic 
processes, and OA is suggested to result from chondrocytes failure in keeping such balance 
[111]. In addition to cartilage alterations with age, degeneration may occur in response to 
inappropriate mechanical stress and inflammatory processes, associated with conditions such 
as obesity, genetics or trauma, some of the major risk factors for OA development and 
progression [97,98,107,111]. When the origin of OA is idiopathic, the disease is termed 
primary OA, whereas if resulting from a known cause, such as joint injuries or diseases, like 
rheumatoid arthritis (RA), it is categorized as secondary OA [102]. Disruption of the normal 
resting state of chondrocytes leads to increased production of matrix proteins and matrix-
degrading enzymes, inappropriate hypertrophy-like maturation, and eventually cartilage 
pathological calcification [91]. In fact, cartilage ectopic mineralization is a well-known 
feature of OA, resulting from factors like the imbalance between inhibitors and stimulators of 
calcification, alteration of calcium levels, phosphate (Pi) and pyrophosphate (PPi) 
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metabolism, chondrocyte hypertrophy and cell death [49,50]. Cartilage ectopic calcification is 
believed to contribute for joint degeneration, mediate and promote inflammatory processes, 
and is associated with increased OA severity [48,50,137,138].  
In the process of OA, ECM degradation products are released from damaged cartilage 
into the synovial fluid and accumulate in the sinovial membrane [91]. As foreign bodies, an 
inflammatory response termed synovitis is initiated, characterized by the hyperplasia of lining 
cells, infiltration of inflammatory cells, increased vascularization and formation of 
perivascular lymphoid aggregates [87]. Macrophages, T cells and mast cells are the most 
abundant cell types infiltrating the synovial membrane [130]. In advanced stages of OA, 
calcium crystals are also detected in the synovial fluid and synovial membrane, believed to be 
released from the damaged cartilage ECM into the synovial space [88,91]. 
The diagnosis of OA is currently based on radiographic criteria and clinical 
manifestations, that only evidence the disease when significant changes have already occurred 
[81,161]. The Kellgren-Lawrence (KL) classification system is often the used clinical 
approach to radiographically classify OA, using a scale from 0 to 4, where 0 represents 
healthy joints and 4, end stage OA [162]. In addition to the absence of diagnostic techniques 
for early OA, there are no efficient disease modifying OA drugs (DMOADs) to treat the 
disorder [96]. Hence, biomarkers that can facilitate the early diagnosis of OA, inform the 
prognosis, and monitor therapeutic trials, are extremely necessary [81,175]. Synovial fluid or 
serum are the preferable biospecimens for the search of OA biomarkers, because these are 
easily available and may reflect OA progression [176]. Calcification modulators are 
interesting candidates as biomarkers for OA, since the presence of intra-articular calcium 
crystals is suggested to contribute for cartilage destruction in the disorder [48,49]. This 
prompted the study of Gla-rich protein (GRP), a vitamin K-dependent protein (VKDP) 
proposed to act as a modulator of calcium availability in the ECM [14,15] and inhibit 
pathological calcification in the cardiovascular system [16].  
The availability of a well characterized and representative biological sample bank, 
containing osteoarthritic samples and control counterparts, may greatly contribute for the 
study of OA. Therefore, the present chapter reports (i) the collected tissues and body fluids 
from control individuals and knee OA patients for the study of representative pathological 
processes occurring in OA, such as calcification and inflammatory events, and (ii) the 
histological characterization of the collected tissues, to detect typical cellular alterations 
associated with the disease. This sample bank allowed the study of GRP associated to OA in 
Chapters 3 and 4, and the search of novel OA biomarkers in Chapter 5. 
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2.2 Experimental procedures 
 
2.2.1 Biological material and sample processing 
 
This study complies with the guidelines for good clinical practice, was performed in 
concordance with the Declaration of Helsinki and approved by the ethics committees of all 
hospitals and institutions involved. Written informed consent was obtained from all the 
participants.  
Biological material was obtained from patients diagnosed with primary or secondary 
grade 4 knee OA, according to the KL classification system, who had undergone arthroplasty 
interventions (total knee replacement) at Centro Hospitalar do Algarve (Departamento de 
Ortopedia e Traumatologia, Faro, Portugal) or Hospital Particular do Algarve - Gambelas 
(Departamento de Ortopedia, Faro, Portugal). Doctor Acácio Ramos was the main 
collaborator involved in the collection of the former biospecimens and respective subject 
clinical information at both hospitals. The collected samples included articular cartilage, 
subchondral bone, synovial membrane, synovial fluid and blood. Identical biological material 
was obtained from subjects with no history of joint diseases, either following autopsy at 
Delegação do Sul do Instituto Nacional de Medicina Legal e Ciências Forenses (Faro, 
Portugal) or after arthroscopic procedures (minimally invasive surgeries in which the joint 
usually is not fully opened), at Centro Hospitalar do Algarve. Blood samples were also 
obtained from volunteers with no history of joint diseases. Doctor Joana Luz was the main 
collaborator involved in the collection of control biospecimens and respective subject clinical 
information at Delegação do Sul do Instituto Nacional de Medicina Legal e Ciências Forenses 
and Doctor Acácio Ramos at Centro Hospitalar do Algarve.  
Cartilage, bone and synovial membrane tissues were collected into RNAlater (Sigma-
Aldrich, St. Louis, MO, USA) for RNA extraction, or in sterile 4 % w/v paraformaldehyde 
solution for histological analysis. The former tissues were also collected for protein extraction 
purposes, and in this case they were immediately stored at – 20 °C until further use. 
Osteoarthritic cartilage and synovial membrane tissues for cell culture development were 
collected in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA, USA) 
and maintained at room temperature (RT) until processing within 24 h post collection. 
Synovial fluid and clotted blood samples were centrifuged for 15 min at RT and 3.000 x g, 
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before storage at – 80 °C until further use. With this centrifugation step, serum samples were 
obtained from the clotted blood. 
 
2.2.2 Histological techniques  
 
Biospecimens containing both articular cartilage and subchondral bone or cartilage 
only, fixed in 4% w/v paraformaldehyde, were further processed for histological analysis and 
embedded in glycol methacrylate or paraffin, respectively, as described [187,188]. 
Methacrylate embedding was used for the analysis of calcified areas. Synovial membrane 
samples were processed and embedded in paraffin. All paraffin embedding and part of the 
paraffin blocks sectioning was performed by Departamento de Anatomia Patológica at Centro 
Hospitalar do Algarve where technician Alexandra Teixeira was the main collaborator 
involved. Methacrylate sectioning was performed using a tungsten carbide blade. 
Longitudinal sections of 5-7 (methacrylate) or 6-8 (paraffin) µm thick were mounted on 
slides. Hematoxylin staining was used for the identification of structures and morphological 
features. Mineral deposits were detected using the von Kossa method [187] counterstained 
with hematoxylin or toluidine blue. Every staining was repeated at least three times using 
samples of different subjects.  
 
2.2.3 Immunohistochemistry  
 
Immunohistochemistry (IHC) was performed to detect specific antigens in articular 
cartilage and synovial membrane tissues. Articular cartilage IHC was performed as described 
[78]. Briefly, antigen retrieval was achieved by incubation with 2 mg/mL hyaluronidase 
(Sigma-Aldrich) during 1h at 37 °C. Endogenous peroxidase activity was blocked with 3% 
v/v H2O2 in methanol in the dark for 10 min and nonspecific antibody binding was blocked 
with 0.5% (w/v) bovine serum albumin (BSA) in TBST buffer (15 mM NaCl, 10 mM Tris-
HCl buffer pH 8, 0.05% Tween 20). Synovial membrane IHC analysis was performed using a 
similar procedure, yet antigen retrieval was achieved by boiling in 0.2 % v/v citric acid pH 
6.0 for 30 min. Incubations with the primary antibodies mouse monoclonals anti-cartilage 
oligomeric matrix protein (COMP, 4 µg/mL), anti-cluster of differentiation 3 (CD3, 66.7 
µg/mL), anti-CD45 (2 µg/mL) and anti-CD68 (20 µg/mL), from Santa Cruz Biotechnology 
(Texas, TX, USA), were performed overnight at RT. Peroxidase activity was detected using 
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the respective peroxidase-conjugated secondary antibodies (Sigma-Aldrich) and ImmPACT 
NovaRED substrate kit (Vector laboratories Ltd., Peterborough, UK). Negative controls 
consisted of the substitution of the primary antibody with TBST buffer. Final counterstaining 
was achieved using hematoxylin. Images were obtained using an Axio Imager Z2 microscope 
(Zeiss, Jena, Germany) equipped with a digital camera and Axovision imaging software.  
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2.3 Results 
 
2.3.1 Collection of control and osteoarthritic samples   
 
Knee OA was the selected model to conduct studies within the scope of this project 
since it is the prevalent OA-affected joint [97]. Biological material was collected during all 
the time course of this project, from individuals with no history of joint diseases (Control 
group, Table 2.I) and clinically diagnosed knee OA patients (OA group, Table 2.II). The 
collected biospecimens comprised articular cartilage, subchondral bone, synovial membrane 
tissues, synovial fluid and serum samples (Tables 2.I and 2.II).  
 
Table 2.I – List of collected samples for the Control group and subject clinical information  
SF, synovial fluid; S, serum; C, cartilage; B, bone; SM, synovial membrane 
 
 
 
 
 
 
Control group 
Subjects Age Gender Samples Clinical information 
1 52 Male SF, C, B, SM Post mortem (death by acute myocardial stroke) 
2 54 Female SF, C, B, SM Post mortem (death by drug intoxication) 
3 25 Female S Arthroscopy (knee trauma) 
4 39 Female S, C, B, SM Arthroscopy (knee trauma) 
5 36 Female S, C, SM Arthroscopy (knee trauma) 
6 36 Male S, SM Arthroscopy (external meniscal lesion) 
7 44 Female SF, C, B, SM Post mortem (death by drug intoxication) 
8 47 Male S, C, B, SM Arthroscopy (knee trauma) 
9 29 Male S, C, SM Arthroscopy (knee trauma) 
10 18 Female S, SM Arthroscopy (knee trauma) 
11 67 Female C, B, SM Post mortem (death by cranial trauma) 
12 37 Female S No associated pathology 
13 26 Female S No associated pathology 
14 24 Male S No associated pathology 
15 31 Female S No associated pathology 
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Table 2.II – List of collected samples for the OA group and subject clinical information  
SF, synovial fluid; S, serum; C, cartilage; B, bone; SM, synovial membrane; OA, osteoarthritis; RA, 
rheumatoid arthritis; HT, arterial hypertension; DM, type II diabetes mellitus 
  
OA group 
Subjects Age Gender Samples Clinical information 
1 81 Male SF, C, B, SM Secondary OA associated to gout 
2 83 Female SF, C, B, SM Primary OA, HT 
3 71 Female SF, C, B, SM Primary OA, DM 
4 62 Female SF, C, B, SM Primary OA, HT 
5 74 Male SF, C, B Primary OA, HT 
6 83 Female SF, C, B, SM Primary OA, obesity 
7 72 Male SF, C, B, SM Primary OA, dyslipidaemia 
8 80 Male SF, C, B, SM Primary OA, HT 
9 75 Female SF, C, B, SM Primary OA, dyslipidaemia 
10 63 Male SF, C, B, SM Primary OA, HT, dyslipidaemia 
11 75 Male SF, C, B, SM Primary OA, obesity 
12 70 Female SF, C, B, SM Secondary OA associated to RA 
13 70 Female C, B, SM Primary OA, HT 
14 71 Female SF, C, B, SM Primary OA, HT, DM 
15 67 Female C, B, SM Primary OA, obesity 
16 69 Female SF, C, B, SM Primary OA, HT 
17 71 Female SF, C, B, SM Secondary OA associated to RA 
18 72 Female SF, C, B, SM Primary OA, DM 
19 81 Male SF, C, B, SM Primary OA, dyslipidaemia 
20 53 Female SF, C, B, SM Primary OA, HT  
21 64 Female SF, C, B, SM Primary OA, obesity 
22 69 Female SF, C, B, SM Primary OA, obesity 
23 72 Male C, B, SM Primary OA, HT 
24 68 Male SF, C, B Primary OA, DM 
25 53 Female SF, S, C, B, SM Primary OA, HT 
26 68 Female S, C, B, SM Primary OA, HT, DM 
27 80 Female SF, S, C, B, SM Primary OA, HT 
28 74 Female SF, S, C, B, SM Primary OA, obesity 
29 68 Female SF, S, C, B Primary OA, obesity 
30 78 Female S Primary OA, dyslipidaemia 
31 78 Female S Primary OA, HT, DM, obesity  
32 74 Female S Secondary OA associated to RA 
33 84 Female S Primary OA, dyslipidaemia 
34 62 Male S Primary OA, HT, DM 
35 78 Female S Primary OA, HT  
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The control group (Table 1.II) contained biospecimens collected from 15 subjects, 
either following autopsy, arthroscopic procedures or volunteers (in the case of blood 
samples). This group included a reduced number, and in small quantities, of articular cartilage 
(8), subchondral bone (6), synovial membrane (10) and synovial fluid (3) biospecimens, and 
11 serum samples in considerable amounts. The OA group (Table 2.II) contained biological 
material collected from 35 individuals subjected to total knee replacement surgeries. This 
group included a representative number, in most of the cases in considerable amounts, of 
articular cartilage (29), subchondral bone (29), synovial membrane (26), synovial fluid (25) 
and serum (11) samples. The collected biospecimens for the OA group were therefore 
sufficient for the initial planned experiments of the project, however the collected material for 
the control group was limited.  
All the obtained biospecimens were completed with subject clinical information 
(Tables 2.I and 2.II) for characterization of the sample groups. The average age of the control 
group was 38 years old (+/- 13) while in the OA group 72 years old (+/- 8). The prevalence of 
females was observed in both groups, constituting 67% and 71% of the sample, respectively, 
in the control and OA group (Fig. 2.1). Primary OA was the predominant form of the disease 
(89% of the individuals, Fig. 2.2), while a minority of the subjects presented secondary OA 
associated to other types of arthritis, namely gout or RA (Table 2.II). Patients with primary 
OA were clinically diagnosed with OA-associated risk factors, including obesity, arterial 
hypertension, type II diabetes mellitus and dyslipidaemia (abnormal amount of lipids in the 
blood) [108], with hypertension corresponding to the condition with highest incidence in this 
group (Fig. 2.3). 
 
 
 
 
 
 
 
   
 
 
 
Fig. 2.1 – Predominance of the female gender in the collected control and OA groups. 
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Fig. 2.2 – Higher incidence of primary OA relatively to secondary OA in the collected OA 
group.  
 
   
 
 
 
 
 
 
 
 
Fig. 2.3 – Primary OA associated-risk factors clinically diagnosed in the OA group. In 31 of 
the subjects diagnosed with primary OA, 8 suffered from obesity, 16 from arterial 
hypertension (HT), 7 from type II diabetes mellitus (DM) and 6 from dyslipidaemia.    
  
All OA patients were clinically diagnosed with grade 4 knee OA (end stages of the 
disease), according to the KL radiographic classification system [162], at Departamento de 
Ortopedia e Traumatologia of Centro Hospitalar do Algarve or Departamento de Ortopedia of 
Hospital Particular do Algarve - Gambelas. Features such as the presence of osteophytes, 
marked joint space narrowing, severe sclerosis, malalignments and bone deformities, were 
therefore visible in the frontal and lateral plain knee radiographs performed to each patient 
prior to arthroplasty (Fig. 2.4, A and B, OA). For comparisons, frontal and lateral plain 
radiographs of healthy knees taken at Centro Hospitalar do Algarve are also shown in Fig. 2.4 
(A and B, Control).  
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Fig. 2.4 – Frontal (A) and lateral (B) radiographs of healthy (Control) and Kellgren-Lawrence 
(KL) grade 4 osteoarthritic knees (OA). Radiographs of the osteoarthritic knees evidence the 
presence of osteophytes, joint space narrowing, sclerosis and bony deformities. In the 
osteoarthritic knee frontal scan, the presence of misalignment is also detected (Images 
supplied by Doctor Acácio Ramos).  
 
Overall, two well characterized groups containing samples representative of healthy 
and osteoarthritic conditions were collected for the study of OA molecular features. Yet, the 
collection of control tissues and synovial fluid samples was limited both in total number and 
quantities, resulting in a control group that was only suitable for a reduced number of 
applications.  
 
2.3.2 Histological characterization of control and osteoarthritic 
features among the collected biological material 
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Histological analysis was performed to further characterize the collected control and 
osteoarthritic tissues, especially concerning pathological calcification and inflammation 
features, for subsequent studies of GRP association with these OA characteristics. Control and 
osteoarthritic tissue sections of articular cartilage and subchondral bone were stained using 
the von Kossa method, for the analysis of respective calcified structures (Fig. 2.5). The brown 
staining of the subchondral bone and calcified cartilage areas, resultant from von Kossa 
method, evidenced differences between control and osteoarthritic tidemarks, which were 
linear in control tissues while irregular in the pathological (Fig. 2.5, B and D). Sites of ectopic 
calcification were also identified with this staining in 7 of the 12 analysed osteoarthritic tissue 
sections, representing different subjects, particularly in cartilage tangential layer (Fig. 2.5, C), 
whereas no ectopic mineralization was observed in control tissues (Fig. 2.5, A). 
Counterstaining with hematoxylin also showed the presence of vascular invasions in the 
subchondral bone (Fig. 2.5, D), chondrocyte clusters in cartilage deep zone (Fig. 2.5, D) and 
surface fibrillation of cartilage tangential layer in pathological tissues (Fig. 2.5, C). None of 
these features was observed in controls, and typical flattened chondrocytes [111] were 
detected in healthy cartilage tangential layers (Fig. 2.5, A). Overall, results evidenced several 
characteristic features of OA [91,111,114] associated to the pathological tissues, with a high 
prevalence of ectopic mineralization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.5 – Histological characterization of control versus osteoarthritic subchondral bone and 
articular cartilage. Von Kossa staining of control (A and B) and osteoarthritic tissue sections 
of subchondral bone and articular cartilage (C and D) revealing the presence of calcified 
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areas, some of which ectopic in the osteoarthritic cartilage tissues and mostly in the tangential 
layer (C). Hematoxylin counterstaining allowed the visualization of structures and 
morphological features in both tissue types. Tissue areas from the subchondral bone to 
cartilage tangential layer are evidenced in bold. Tissues were embedded with methacrylate. 
Scale bars represent 100 µm (Adapted from Rafael et al., 2014 [189]).  
 
To further support the osteoarthritic nature of the collected cartilage samples for the 
OA group, IHC analyses were performed to immunodetect the OA marker COMP, associated 
to cartilage turnover [183]. The presence of COMP was only detected in pathological samples 
(Fig. 2.6), namely in cartilage ECM (Fig. 2.6, C), chondrocytes (Fig. 2.6, D) and ectopic 
calcification sites (Fig. 2.6, E).  
 
 
 
Fig. 2.6 – Immunodetection of cartilage oligomeric matrix protein (COMP) in osteoarthritic 
cartilage samples. Immunohistochemistry (IHC) was performed using an anti-COMP 
antibody in control (A and B) and osteoarthritic samples, without (C and D) and with ectopic 
calcification sites (E). Positive staining was revealed by a reddish/brown colour. Samples 
without calcification sites were embedded with paraffin and the remaining with methacrylate, 
all counterstained with hematoxylin. Scale bars represent 100 µm (Adapted from Rafael et al., 
2014 [189]). 
 
Differences between control and osteoarthritic synovial membranes could be observed 
macroscopically, since the increased volume of the pathological tissues, comparing to 
controls, was highly frequent (results not shown). To further characterize these differences, 
the two conditions were histologically analysed using hematoxylin staining (Fig. 2.7). Major 
variations between control and pathological tissues were observed in the membranes lining 
layers, which were composed by a monolayer of cells in control tissues (Fig. 2.7, A) and a 
hyperplasia of cells in osteoarthritic tissues (Fig. 2.7, A). The presence of mononuclear cell 
infiltrates in the subintimal layer of the pathological tissues (Fig. 2.7, D), accompanied by an 
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increased vascularization (Fig. 2.7, C), was also detected, in contrast to control tissues, 
indicating the presence of synovitis in the osteoarthritic membranes [88].  
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7 – Histological characterization of control versus osteoarthritic synovial membrane 
tissues. Hematoxylin staining of control (A and B) and osteoarthritic synovial membrane 
tissue sections (C and D) showing the existing structures and morphological features in both 
tissue types. Distinct tissue layers are evidenced in bold. The identified cell types and 
subintimal structure types composing the tissue sections are indicated. Paraffin embedding 
was performed. Scale bars represent 100 µm (Adapted from Rafael et al., 2014 [189]). 
 
To characterize the types of cells infiltrating the osteoarthritic synovial membranes, 
IHC analyses were performed using CD45, CD3 and CD68 antibodies (Fig. 2.8). Positive 
staining for CD45 indicated the presence of leucocytes (Fig. 2.8, CD45) and further staining 
with CD3 (Fig. 2.8, CD3) and CD48 (Fig. 2.8, CD68) suggested the presence of T 
lymphocytes and macrophages, respectively. The same analyses performed in control tissues 
did not detect the presence of inflammatory cells (results not shown).  
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Fig. 2.8 – Immunodetection of T lymphocytes and macrophages in osteoarthritic synovial 
membranes. Immunohistochemistry (IHC) was performed using anti-CD45 (CD45), anti-CD3 
(CD3) and anti-CD68 (CD68) antibodies that mark, respectively, leucocytes, T lymphocytes 
and macrophages. Red arrows indicate stained cells with anti-CD68 antibody (CD68). 
Samples were embedded with paraffin and counterstaining with hematoxylin. Scale bars 
represent 100 µm. 
 
Ultimately, the presence of ectopic calcification was also investigated in synovial 
membrane tissues using the von Kossa staining (Fig. 2.9). Ectopic calcification sites were 
observed in all 12 analysed tissue sections from different OA patients, at smaller or greater 
extent depending on the sample, and spread without any apparent specific localization (Fig. 
2.9, C and D). In control tissues, no pathological calcification was detected (Fig. 2.9, A and 
B). 
    
 
 
 
 
 
 
 
 
 
 
Fig. 2.9 – Detection of ectopic calcification in osteoarthritic synovial membrane through von 
Kossa staining. Control (A and B) and osteoarthritic (C and D) tissue sections of synovial 
membrane were analysed with von Kossa staining for the detection of pathological 
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calcification. Samples were embedded in paraffin and counterstained with toluidine blue. 
Scale bars represent 100 µm. 
 
Altogether, the performed histological sample characterization showed notorious 
differences between control and osteoarthritic samples. Accordingly, results evidenced the 
presence of ectopic calcification in both osteoarthritic articular cartilage and synovial 
membrane tissues, and synovitis in the pathological membranes, clearly indicating their 
suitability for subsequent studies of GRP association with these OA pathological features in 
the following chapters.  
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2.4 Discussion 
 
This chapter describes the collection and characterization of a biological sample bank 
comprising biospecimens from control individuals and knee OA patients, suitable for the 
study of OA. Within the scope of this project, this bank was crucial to investigate the 
involvement of GRP with the pathological mineralization and associated inflammation 
occurring in the disorder, and the search for candidate OA biomarkers, as further detailed in 
the following chapters. 
Recent studies continue to illustrate the high impact of OA worldwide with increasing 
incidence [97], motivating the investigation of this disorder particularly focusing in the search 
for early OA diagnostic tools and the identification of efficient DMOADs to treat the disorder 
[96]. Osteoarthritis is the first cause of permanent job incapacity, one of the most frequent 
motifs of inability in the elderly, and one of the main reasons for primary care visits [104]. 
Therefore, the burden of OA not only involves the health impact of the disorder but also its 
social and economic weight [104]. knee OA is considered the prevalent form of the disease 
worldwide [97]. In Portugal, 6% of the population is estimated to be affected by this joint 
disorder, rheumatic diseases are pointed as the first cause for early retirement and knee OA is 
also indicated as the prevalent form of the disorder [103]. In concordance, knee arthroplasty 
interventions are frequent procedures performed at Centro Hospitalar do Algarve 
(Departamento de Ortopedia e Traumatologia, Faro, Portugal), with estimates of 144 surgeries 
per year. In addition, in the same hospital, it is estimated that 1200 new cases of different 
stages of knee OA are diagnosed every year (data supplied by Doctor Acácio Ramos). As a 
complex multifactorial disease there is still much to unveil about the mechanisms underlying 
OA, nevertheless, there are several known modifiable and preventable risk factors associated 
with OA development and progression [97]. Age is the strongest predictor of OA 
development mainly as consequence of chondrocytes terminal differentiation, which usually 
occurs around the age of 40 in humans [101,107]. Also, higher risk of developing OA is 
associated to the female gender, believed to be related with high estrogen levels [99]. In 
agreement, the collected OA group was characterized by high average age and the prevalence 
of the female gender. Obesity is also a key risk factor for knee OA, increasing its incidence 
three-fold and suggested to accelerate the progression of the disease [97]. In this study, 
obesity was also a present risk factor, with 8 of the 31 primary OA patients suffering from 
excess of weight. Interestingly, obesity has been described to affect OA not only because of 
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biomechanical overloading that favours subsequent cartilage degeneration, but also because of 
the suggested involvement with the metabolic syndrome (MetS) [95]. The MetS corresponds 
to a cluster of cardiometabolic disorders that result from the increasing prevalence of obesity, 
having as major components insulin resistance, central obesity, dyslipidaemia and 
hypertension [108]. Although the precise association between MetS and OA is still unclear, 
abnormal loading is related with inflammatory and metabolic imbalances in OA in part 
because it triggers the same signalling pathways as those induced by inflammatory cytokines 
[91]. Also, and in concordance with MetS association to OA, risk factors that contribute to the 
syndrome are generally considered risk factors for rheumatic diseases including OA [110]. 
Interestingly, comorbidities such as dyslipidaemia and hypertension were identified in the OA 
group of this study. Type II diabetes mellitus is also highly frequent in OA patients and 
considered a risk factor, although causality was not yet clearly demonstrated [110]. A possible 
reason for this association is related to hyperglycaemia, which may promote joint 
inflammation and cartilage degradation through oxidative stress, inflammatory mediators 
induction and advanced glycosylation end products [190]. Notably, type II diabetes mellitus 
was also diagnosed in some of the OA group patients. Among secondary OA, diseases that 
cause inflammation of the joint can also increase the risk of developing the disease later in life 
[102] and in fact, some of the analysed OA group patients presented secondary OA derived 
from gout or RA.  
Calcium crystals deposition has been associated with destructive arthropathies such as 
OA [48]. Pathological calcification is believed to modify the biomechanical properties of 
cartilage, ultimately triggering crystal-induced stress which leads to proinflammatory 
cytokine and metalloproteinase production, and eventually chondrocyte apoptosis [48]. 
Calcium crystals have also been found in the synovial fluid and suggested to promote crystal-
induced stress on synoviocytes, leading to the worsening of OA [91,123]. For subsequent 
studies of GRP association to the pathological calcification occurring in OA and associated 
inflammatory processes, sample histological characterization was performed focusing on 
these particular features. Accordingly, the presence of ectopic calcification was observed both 
in osteoarthritic cartilage and synovial membrane tissues, while no pathological 
mineralization was found in control samples. Also, the presence of synovitis was clearly 
identified in osteoarthritic synovial membranes, with the immunodetection of macrophages 
and T cells, described to be the most abundant leucocyte types infiltrating these tissues upon 
synovitis [87].  
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Altogether, the provided subject clinical information and specific sample  histological 
characterization confirmed that the collected sample bank was suitable for the study of OA, in 
particular ectopic calcification and inflammation features, although the number and quantities 
of most of the biospecimens from the control group was reduced. All the analyses included in 
this project were therefore planned and the available samples distributed between them, 
according with the aims of each task, as described in Table 2.III. Cartilage, bone and 
synovial membrane tissue samples, histologically characterized in the present chapter, were 
further used in Chapter 3 for gene expression analysis and immune-based techniques to get 
the first insights into GRP association with OA, particularly regarding ectopic calcification 
processes. Synovial fluid and serum samples were also analysed in Chapter 3 by western blot 
to detected the presence of GRP in these fluids. Osteoarthritic cartilage and synovial 
membrane tissues from patient 27 of the OA group (Table 2.II and Table 2.III) were used in 
Chapter 4 for the development of an in vitro OA cell system, to further study the involvement 
of GRP in the pathological calcification and inflammatory processes occurring in OA. 
Osteoarthritic cartilage and synovial fluid samples were used in Chapter 5 for two-
dimensional gel electrophoresis (2-DE) analyses aiming to study GRP potential as a 
biomarker for OA and search for novel OA biomarkers. A comparative proteomic analysis for 
the search of OA biomarkers was ultimately performed using the available serum samples 
from the collected sample bank. 
 
Table 3.III – Identification of the samples from the collected biological bank used in the 
analysis performed in each chapter of this study  
  Subjects 
Chapter Analysis Control group OA group 
2 Histology 1, 2, 4 1-12 
 
 
3 
Gene expression 1, 2, 4-9, 11 1-11, 13-15, 18-28  
Comparative gene expression 1, 2, 4, 6-9, 11 1-3, 9, 14, 18, 20-23, 25, 27 
SDS-PAGE 1-4 1-13, 16, 17, 27 
Histology 1, 2, 4 1-12, 16, 19, 27, 28 
4 Cell culture development - 27 
 
5 
SDS-PAGE 3, 13-15 28-31 
2-DE 6, 10, 12-14 3, 17, 28, 30-32, 35 
Calcium quantification 6, 7, 10-15 28-35 
Comparative proteomics 6, 10, 12-14 28, 30-32, 35 
SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; 2-DE, two-dimensional gel 
electrophoresis 
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Abstract 
 
The extracellular matrix mineralization of articular tissues is a common feature of 
osteoarthritis (OA), contributing for disease progression and frequently associated to severe 
forms of the pathology. Ectopic calcification-related proteins, such as Gla-rich protein (GRP), 
are therefore potential targets to study the mechanisms involved with OA development. In this 
chapter, the association of GRP with OA was for the first time investigated at transcription 
and translational levels. Four alternatively spliced transcripts of GRP gene, GRP-F1, F2, F3, 
and F4, were previously identified in mice and zebrafish. Using a RT-PCR strategy, two 
novel GRP splice variants were unveiled in human and termed GRP-F5 and F6. Both 
alternative transcripts were characterized by the loss of carboxylation motifs and GRP-F6 also 
lacked secretion motifs. Moreover, GRP-F2, F3, and F4 were not detected in human. Notably, 
GRP-F1 transcript, corresponding to the full length protein, was found to be the predominant 
expressed variant in articular tissues, empathizing that it should be the variant with greater 
contribution for OA development. Moreover, GRP-F1 was shown to be upregulated in 
osteoarthritic cartilage. GRP accumulation patterns in osteoarthritic tissues and fluids was 
evaluated using a combination of immune-based techniques, namely western blot, 
immunohistochemistry and immunofluorescence, and specific antibodies against total, 
carboxylated (cGRP) and undercarboxylated (ucGRP) GRP. Such approaches demonstrated 
that both protein forms are immunodetected in human osteoarthritic bone, articular cartilage, 
synovial membrane, synovial fluid and serum, and accumulated in sites of ectopic 
calcification. Importantly, it was shown that ucGRP was the predominant entity associated to 
osteoarthritic cartilage and synovial membrane, whereas cGRP was preferentially 
accumulated in the same tissues, in control conditions. Similarly, undercarboxylated matrix 
Gla protein was also the predominant form accumulating in osteoarthritic cartilage, 
suggesting that the impairment of γ-carboxylation in these vitamin K-dependent proteins 
might be associated with OA. Overall, the obtained results relate for the first time GRP with 
OA, indicating the predominance of GRP-F1 transcript in articular tissues, associating GRP to 
sites of pathological mineralization and clearly relating ucGRP with OA-affected tissues. 
Moreover, our immunohistochemistry results revealed that GRP association with OA was not 
restricted to sites of ectopic calcification in synovial membrane tissues, suggesting the 
involvement in other cell mediated processes, which will be addressed in the following 
chapter.   
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3. 1 Introduction 
 
Several determinants are known to contribute for the pathogenesis and progression of 
osteoarthritis (OA), including the deposition of calcium-containing crystals in articular 
cartilage [48]. Basic calcium phosphate (BCP) and calcium pyrophosphate dihydrate (CPPD) 
are the two major forms of calcium crystals accumulating in osteoarthritic cartilage 
[49,137,138]. In addition, the accumulated crystals are prone to be released into the synovial 
fluid and spread to other joint tissues, such as the synovial membrane [91,123]. The presence 
of pathological calcification in OA is associated with increased disease severity, and the 
regulation of calcium availability and subsequent deposition in chondrocyte extracellular 
matrix (ECM) is regarded as a determinant factor for disease progression [48,50,137,138]. 
Cartilage calcification is a multifactorial process including the imbalance between pro-
mineralization factors and inhibitors [49,50]. In fact, the dysregulation in the production of 
mineralization inhibitors has been considered a crucial factor favouring cartilage calcification 
and the deposition of calcium-containing crystals [50]. Therefore, the role of calcification 
inhibitors in the pathogenesis of OA was highlighted, prompting the study of vitamin K-
dependent proteins (VKDPs), in particular Gla-rich protein (GRP), and its potential 
association with this joint disorder. 
Vitamin K is an essential cofactor for the post-translational modification of VKDPs, 
where specific glutamate (Glu) residues can be modified to calcium binding γ-
carboxyglutamic acid (Gla) residues [1]. Vitamin K is essential for preventing soft tissue 
mineralization and VKDPs such as osteocalcin (OC), matrix Gla protein (MGP) and, more 
recently, GRP, are associated with skeletal metabolism [3,56]. Also, subclinical vitamin K 
levels have been related with increased risk of OA development [82-84] and both OC and 
MGP proteins have already been associated with the disease. While the presence of 
undercarboxylated OC (ucOc) in serum is considered a biomarker for OA, associated to 
vitamin K metabolism deficiency [94], the absence of carboxylated MGP (cMGP) in 
osteoarthritic chondrocytes was suggested as an important mechanism for increased 
osteoarthritic cartilage mineralization [92].  
Gla-rich protein, the most recently discovered VKDP, is composed by a high density 
of γ-carboxylated Glu residues which indicated a strong calcium binding capacity [54]. Gla-
rich protein mineral binding capacity was further confirmed by several studies showing its 
accumulation at sites of pathological calcification in human tissues [14-16] and in vitro 
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calcium mineral-binding capacity [15]. Although the function and molecular mechanisms of 
action remain to be clarified, GRP has been suggested as a modulator of calcium availability 
in the ECM [14,15] and an inhibitor of calcification in the cardiovascular system depending 
on its γ-carboxylation status [16]. In concordance, and although GRP-deficient mice did not 
reveal evident phenotypic alterations in bone and cartilage, GRP knockdown in zebrafish 
resulted in severe growth retardation and perturbance of skeletal development [72]. Moreover, 
warfarin treatment mimicked the GRP knockdown phenotype, suggesting an essential role of 
γ-carboxylation for GRP function [72]. Although GRP has been shown to function as a 
negative regulator of osteogenic differentiation [74,75] and to be downregulated by bone 
morphogenetic protein 2 (BMP2) in chondrogenic cells  [75], recent data suggested that GRP 
is upregulated by both runt-related transcription factor 2 (Runx2) and osterix (Osx), 
stimulating osteoblast differentiation and nodule formation [77]. Altogether, this conflicting 
data reinforce the need for additional characterization of GRP association with human 
pathological conditions such as OA. In mice, four alternatively spliced transcripts of GRP 
gene were identified - GRP-F1, F2, F3, and F4 - differing by exon 2, exon 4, or both, which 
were associated with early stages of chondrogenesis and suggested as possibly implicated in 
skeletal pathologies in case of an imbalanced expression [76]. The same variants were also 
detected in zebrafish [72,73], however, no splice variants were ever described in humans.  
In this chapter, GRP potential association with OA was studied for the first time at 
gene and protein levels, using the biological sample bank described in the previous chapter. 
Accordingly, here is described (i) the analysis of GRP splice variants existing in the human 
gene, (ii) the in silico characterization of human GRP protein isoforms, (iii) the expression 
pattern of each variant in control and osteoarthritic tissues, (iv) the immunodetection of total, 
carboxylated (cGRP) and undercarboxylated (ucGRP) GRP in OA-affected tissues and body 
fluids, (v) GRP immunodetection in osteoarthritic bony cells, and (vi) the spatial distribution 
of c/ucGRP in control and osteoarthritic tissues.  
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3.2 Experimental procedures 
 
3.2.1 Biological material and sample processing 
 
Control and osteoarthritic articular cartilage, subchondral bone and synovial 
membrane tissues, and osteoarthritic synovial fluid and clotted blood samples, were obtained 
and processed as described in Chapter 2, section 2.2.1. 
 
3.2.2 RNA extraction 
 
Total RNA was extracted from control and osteoarthritic articular cartilage, bone and 
synovial membrane samples as described by Chomczynski and Sacchi [191]. RNA 
concentration was determined by spectrophotometry at 260 nm and quality evaluated by 
agarose denaturating gel electrophoresis. 
 
3.2.3 Human GRP cDNA amplification 
 
One microgram of total RNA was treated with DNase I (Promega, Madison, WI, 
USA) and reverse-transcribed using Moloney-murine leukemia virus reverse transcriptase 
(MMLV-RT), RNase Out (both from Invitrogen, Carlsbad, CA, USA), and an oligo(dT) 
adapter (5’-ACGCGTCGACCTCGAGATCGATG(T)13-3’), according to manufacturer’s 
recommendations. GRP coding sequences were amplified by nested PCR starting with 250 ng 
of reverse-transcribed RNA and Taq DNA polymerase (Invitrogen) using primers listed in 
Table 3.I (Complete CDS, CDS nested).  
All nested PCR products were size-separated onto a 2 % w/v agarose gel and selected 
fragments were purified using the GFX Gel Band Purification kit (GE Healthcare, Waukesha, 
WI, USA), cloned into pCRII-TOPO vector (Invitrogen) and sequenced (Centro de Ciências 
do Mar, CCMar, Faro, Portugal). 
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Table 3.I – List of primers used for RT-PCR  
Gene Primer Fw Primer Rv Amplicon 
18S GGAGTATGGTTGCAAAGCTGA ATCTGTCAATCCTGTCCGTGT Loading control 
 
GACGCCTGGTCTGCCTTGTGGG GAAGCCAGGGGAAGCCACTGTAGGT Complete CDS 
 
TCCTGGACGGAGCCCCTACCT ACACGGGGATGCCAATGGTGCTAC CDS nested 
GRP GTCCCCCAAGTCCCGAGATGAGG CCTCCACGAAGTTCTCAAATTCATTCC F1 
 
TCCTGGACGGAGCCCCTA GCTTCTGCCTGTTTTCCACTTCAC F5 
 
TCCTGGACGGAGCCCCTA GCTTCTGCCTGTTTTCCATAGACA F6 
 
3.2.4 Expression profile 
 
To determine the presence of GRP alternative transcripts among several samples of 
control and osteoarthritic articular cartilage and synovial membrane, specific primers 
designed in order to specifically amplify each of the splice variants were used (F1, F5 and F6, 
Table 3.I), while human ribosomal 18S was used as a reference gene (18S, Table 3.I). RT-
PCR amplification was achieved using 25 ng cDNA and SsoFast EvaGreen supermix (Bio-
Rad, Richmond, CA, USA) in reactions of 50 cycles. 
 
3.2.5 Genomic sequence analysis 
 
Human genomic sequences (GenBank accession numbers NC_000010) were used to 
confirm the transcript structure using Spidey mRNA-to-genomic alignment tool at National 
centre for biotechnology information (NCBI). Prediction of signal peptide, protein targeting, 
glycosylation and phosphorylation sites was performed using SignalP, TargetP, NetNGlyc, 
NetOGlyc and NetPhos, respectively, available at Centre for Biological Sequence analysis 
(CBS) portal (http://www.cbs.dtu.dk/services). All the obtained predictions were confirmed 
using available tools at Expasy portal (http://www.expasy.org/). 
 
3.2.6 Protein extraction 
 
Two distinct protein extraction procedures were used in this study: mineral-bound 
proteins were extracted from osteoarthritic bone using a previously described method [192], 
while total protein extracts were obtained from osteoarthritic articular cartilage and synovial 
membrane samples using Laemmli buffer.  
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Bone was reduced to powder using a mortar and liquid nitrogen. A portion of 100 g 
was washed three times for 8-10 h with a 10-fold excess of 6 M guanidine HCl v/w to remove 
the proteins that were not sequestered in the mineralized matrix, followed by extensive 
washes with water and finally with acetone. Mineral-bound proteins were extracted from the 
clean bone powder using a 10-fold excess of 10 % formic acid during 4 h at 4 °C as described 
[192]. The resulting soluble acid extract was separated from the insoluble collagenous matrix 
by fibreglass filtration and dialyzed at 4 °C against 50 mM HCl, using 3500 molecular weight 
tubing (Spectra-Por 3, Spectrum, Gardena, CA, USA), during 2 days to remove all dissolved 
mineral. The dialyzed acid extract was freeze-dried, dissolved in 6 M guanidine HCl, 0.1 M 
Tris pH 9, and dialyzed against 5 mM ammonium bicarbonate to precipitate GRP. The 
obtained pellet was dissolved in 6 M guanidine HCl, 0.1 M Tris pH 9, and dialyzed against 50 
mM HCl. The protein content of the extract was estimated based on the general reference 
setting that a protein solution with an extinction coefficient (E) of 0.1% (1 mg/ml) produces 
an absorbance of 1.0 at 280 nm (whit a path length of 1 cm) [193].  
Cartilage and synovial membrane samples were reduced to powder using a mortar and 
liquid nitrogen and 5 g of each tissue were lysed in Laemmli buffer and following sonicated 
on a Vibra-cell apparatus (Sonics & Materials, Inc., Newtown, MA, USA) using 5 cycles of 
30 sec, with intervals of 15 sec on ice, at 60 % amplitude. The protein content of the extracts 
was estimated by absorbance at 280 nm. 
 
3.2.7 SDS-PAGE and western blot  
 
Aliquots of total protein extracts obtained in the previous section and direct samples of 
osteoarthritic synovial fluid and serum were dissolved/diluted in lithium dodecyl sulphate 
(LDS) sample buffer (NuPage, Invitrogen) containing reducing agent, and boiled during 5 
min at 95 ᵒC. Samples were then size-separated by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) on a 4-12 % w/v gradient polyacrylamide precast gel 
containing 0.1 % w/v SDS (NuPage, Invitrogen) and the protein profiles were revealed by 
staining with coomassie brilliant blue (CBB) (Bio-Rad). The bony tissue extract profile was 
also analysed with DBS (Gla-specific stain; 8.5 mM 4-diazobenzene sulfonic acid (Sigma-
Aldrich, St. Louis, MO, USA), as described [194].  
For western blot (WB) analysis, proteins separated by SDS-PAGE were subsequently 
transferred onto a nitrocellulose membrane [192]. Detection of total, cGRP and ucGRP was 
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performed incubating the membranes overnight with the primary antibodies polyclonal rabbit 
CTerm-GRP [14] and chicken cGRP [15] (5 µg/mL and 1 µg/mL, respectively, GenoGla 
Diagnostics, Faro, Portugal), and mouse monoclonal ucGRP [15] (7.3 µg/mL, Vitak BV, 
Maastricht, the Netherlands), respectively. Detection of carboxylated (cMGP) and 
undercarboxylated (ucMGP) MGP in bony tissue extract was performed using the primary 
antibodies mouse monoclonals cMGP and ucMGP (10 µg/mL, both from IDS, Bolton, UK). 
Antibodies were diluted in 5% w/v bovine serum albumin (BSA) powder in TBST (15 mM 
NaCl, 10 mM Tris-HCl buffer pH 8, 0.05% Tween 20). Immunodetection was achieved using 
species-specific secondary horseradish peroxidase conjugated antibodies (Sigma-Aldrich) and 
Western Lightning Plus-ECL (PerkinElmer Inc., Waltham, MA, USA). All WB analysis were 
repeated at least three times using samples of different subjects. To estimate the molecular 
weight of the proteins bands both in SDS-PAGE and WB, Precision Plus Protein Dual Xtra 
Standard (Bio-Rad) was used. 
 
3.2.8 N-terminal amino acid sequence analysis  
 
The mineral-bound protein extract obtained from osteoarthritic bone in section 3.2.6 
was separated by SDS-PAGE, as previously described, in several gel lanes and blotted onto a 
polyvinylidene fluoride (PVDF) membrane (Applied Biosystems, Foster city, CA, USA) for 1 
h at constant 80 mA [195]. After transfer, the PVDF membrane was washed with water for 5 
min, stained with 0.2%  w/v CBB in 50% v/v methanol for 5 min, de-stained with 7.5% v/v 
acetic acid, 10% v/v methanol until bands were visible, and washed with 20% v/v methanol to 
remove salts or contaminants. Target bands were cut off for further analysis by automatic 
Edman degradations, using an Applied Biosystems 491 HT sequencer, at Instituto de Biologia 
Experimental e Tecnológica (IBET) (Analytical Laboratory, Oeiras, Portugal). The search for 
protein sequences showing homology with the obtained N-terminal sequences was performed 
at NCBI in the same institute. 
 
3.2.9 Protein identification by mass spectrometry and data analysis 
 
Protein analysis of the mineral-bound protein extract obtained from osteoarthritic bone 
in section 3.2.6 was also performed by mass spectrometry (MS). For that, gel bands were 
excised from SDS-PAGE gels, performed as described in section 3.2.7, and sent to Instituto 
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de Tecnologia Química e Biológica (ITQB) (Mass Spectrometry Laboratory, Oeiras, 
Portugal) for subsequent protein sequencing by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Proteins were first in gel digested and the tryptic peptides 
processed also as described [196]. Protein sequencing was conducted using a Thermo 
Finnigan LTQ mass spectrometer (Thermo Scientific) coupled with MALDI (matrix-assisted 
laser desorption/ionization). Protein identification using LC-MS/MS raw data was performed 
at the same institute with Mascot Daemon software (Matrix science, Boston, MA, USA) and 
results of the database search were analysed using NCBI. 
 
3.2.10 Histological techniques  
 
Cartilage, bone and synovial membrane samples for histological analysis were 
embedded in paraffin and glycol methacrylate, then sectioned and analysed with the von 
Kossa method as described in Chapter 2, section 2.2.2. When sections were counterstained, 
toluidine blue was the method of choice.  
 
3.2.11 Immunohistochemistry 
 
Immunohistochemistry (IHC) was performed as described in Chapter 2, section 2.2.3, 
to detect specific antigens in articular cartilage, bone and synovial membrane samples. 
Antigen retrieval of bone tissue sections was performed by incubation with 2 mg/mL 
hyaluronidase (Sigma-Aldrich) during 1h at 37 °C. As primary antibodies, polyclonal rabbit 
CTerm-GRP and chicken cGRP (5 and 1 µg/mL, respectively, GenoGla Diagnostics), and 
mouse monoclonals ucGRP (7.3 µg/mL, Vitak BV), cMGP and ucMGP (both at 10 µg/mL, 
IDS) were used. Images were obtained using an Axio Imager Z2 microscope (Zeiss, Jena, 
Germany) equipped with a digital camera and Axovision imaging software.  
 
3.2.12 Tartrate-resistant acid phosphatase localization 
 
Tissue sections of osteoarthritic bone were saturated with 0.1 M acetate buffer 
containing 50 mM dehydrated disodium tartrate, pH 5.5. Then, 2 ml of 4 % w/v NaNO2 were 
added to 1 ml of pararosaniline (PRS) (Sigma-Aldrich) to promote the hexazotization. The 
incubation media was prepared using 30 ml of the first acetate buffer containing 1 ml 
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hexazotized PRS, 600 µl 2 % w/v MgCl2 and 2 ml of the enzymatic substrate (2 mg naftol 
AS-TR phosphate in 2 ml N,N-dimethylformamide). The tartrate-resistant acid phosphatase 
(TRAP) reaction is sensitive to light, thus, tissue sections were maintained in the dark while 
in incubation media for 2-3 h. Images were obtained using an Axio Imager Z2 microscope 
(Zeiss, Jena, Germany) equipped with a digital camera and Axovision imaging software.  
 
3.2.13 Immunofluorescence  
 
Immunofluorescence (IF) analysis were performed in paraffin sections of control and 
osteoarthritic synovial membrane tissues. Antigen retrieval was performed by boiling in 0.2 % 
v/v citric acid, pH 6. After peroxidase and nonspecific antibody blockings, performed as 
described in Chapter 2, section 2.2.3, incubations with the primary antibodies polyclonal 
chicken cGRP (5 µg/mL, GenoGla Diagnostics) and mouse monoclonals ucGRP (14.6 
µg/mL, Vitak BV) were performed overnight at room temperature (RT). Samples analysed 
with cGRP were then incubated with biotinylated goat anti-chicken antibody (2 µg/mL, 
Vector laboratories Ltd.) for 1h and then with avidin kit A1100 (Vector laboratories Ltd.) also 
for 1h at RT. Samples analysed with ucGRP were directly incubated for 1h with the 
secondary antibody Dylight 549 HAM (Vector laboratories Ltd.) at RT. Negative controls 
consisted of the substitution of the primary antibody with TBST buffer. Cell nuclei were 
stained with cell nuclei were stained with 6-diamidino-2-phenylindole (DAPI). Images were 
obtained using a Zeiss Axioplan 2 (Zeiss, Jena, Germany) equipped with a digital camera and 
Image-Pro Plus acquisition software (version 6, MediaCybernetics, Bethesda, MD, USA). 
Final images were processed using Image J Version 1.41m. 
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3.3 Results 
 
3.3.1 Identification of two novel GRP splice variants in human  
 
The first approach towards investigating the possible association of GRP with OA was 
the analysis of GRP gene expression in OA-affected tissues. Four GRP splice variants had 
been previously identified in mouse and zebrafish [72,73,76], thus, the presence of the same 
transcripts was investigated in osteoarthritic samples of articular cartilage, bone and synovial 
membrane. For that, a nested RT-PCR strategy was used with primers designed in exons 1 
and 5 (Table 3.I, Complete CDS and CDS nested and Fig. 3.1, A), in order to amplify the 
complete coding sequence including the five exons of GRP gene. Three different fragments 
were detected in all the analysed tissues with sizes approximately between 300 bp and 500 bp 
(Fig. 3.1, B). Genomic sequence analysis revealed that the longest fragment composed of 504 
bp (Fig. 3.1, B), corresponded to the complete open reading frame for full length GRP (GRP-
F1, GenBank accession number JX169863). The remaining cDNA fragments of 408 and 342 
bp (Fig. 3.1, B) were also confirmed to be GRP after analysis, however, the sequences were 
not identical to any of the previously described transcripts, representing two novel GRP splice 
variants. The two new GRP alternative transcripts were therefore named GRP-F5 and F6 
(GenBank accession numbers JX169864 and JX169865, respectively), following the previous 
nomenclature adopted for mouse and zebrafish models [72,76].  
  
 
 
 
 
 
 
 
 
Fig. 3.1 – Schematic representation of the design primers and respective amplified GRP 
transcripts in human osteoarthritic cartilage. (A) Primers localization is indicated by two 
arrows pairs: the outside set was used in a first PCR, while the internal set was used in a 
second nested PCR. SP indicates signal peptide; Pro, propeptide; Mature, mature protein; E1 
to E5 represent the sequence exons. (B) Nested RT-PCR analysis from OA cartilage RNA 
showing amplification of GRP-F1, F5 and F6 splice variants. Approximated transcript sizes 
(in base pairs, bp) are indicated (Adapted from Rafael et al., 2014 [189]). 
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The presence of the newly identified or additional GRP alternative transcripts was 
investigated in a small group of control and osteoarthritic samples of articular cartilage, bone 
and synovial membrane and no other GRP splice variant was identified apart from GRP-F1, 
F5 and F6 (data not shown). These preliminary results were further supported by subsequent 
studies ongoing in the laboratory using control and osteoarthritic samples of cartilage, bone 
and synovial membrane, from which a total of 43 GRP positive clones were sequenced, and 
only the same three variants were detected [189].  
 
3.3.2 In silico characterization of human GRP protein isoforms 
 
For the three detected GRP transcripts, GRP-F1, F5 and F6, splicing sites and coding 
regions were predicted using the Spidey mRNA-to-genomic alignment tool at NCBI (Fig. 3.2, 
A). Considering the unprocessed protein isoforms, full length GRP-F1 encodes 138 aa, while 
the two novel transcripts encode putative proteins of 106 (GRP-F5) and 84 (GRP-F6) aa (Fig. 
3.2, B and C). Both GRP-F5 and F6 variants lack exon 3, an exon skipping that had never 
been described in previously analysed species, which results in the loss of the γ-glutamyl 
carboxylase (GGCX) recognition site and the furin-like cleavage site (RGKR, Fig. 3.2, A and 
B). This is of particular interest since the binding to carboxylase and propeptide cleavage 
occurring in GRP-F1 would be lost, and consequently the γ-carboxylation of Glu residues and 
mature protein processing could possibly be altered. In addition to the modifications produced 
in GRP-F5, the F6 variant also lacks exon 2, which codes for the C-terminal region of the 
signal peptide that will be shorter in this variant (Fig. 3.2, A-C).  
Prediction of signal peptide and protein targeting was analysed using SignalP and 
TargetP CBS tools. The analysis revealed that despite the probability of GRP-F6 shorter 
signal peptide functionality is lower (D = 0.634) than for F1/F5 variants (D = 0.731), all D-
scores were above SignalP algorithm cut off [197], indicating that targeting to the secretory 
pathway is still possible and cannot be discarded. Moreover, and considering the signal 
peptide processing for both variants, GRP-F5 and F6 will be 80 and 67 aa long, respectively, 
comparable to the 74 aa of F1 mature isoform in terms of protein size (Fig. 3.2, C). 
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Fig. 3.2 – Identification of novel GRP alternative splice variants in human. (A) Schematic 
representation of the new GRP splice variants (F5 and F6) and previously known data for 
mouse and zebrafish (F1, F2, F3 and F4) [72,76]. Arrow indicates putative signal peptide 
cleavage site; arrow head, furin-like cleavage site; SP, signal peptide; Pro, propeptide; MP, 
mature protein; GGCX, γ-glutamyl carboxylase putative recognition site; E1 to E5 represent 
the sequence exons. (B) Alignment of human GRP splice variants deduced proteins. Triangles 
indicate intron insertion sites; underlined sequence, GGCX putative recognition site; 
rectangle, furin-like proteolytic site (RGKR); black dots, putative γ-carboxylated Glu 
residues; circles, predicted tyrosine and serine phosphorylated residues; signal peptide is 
shown in dark grey while propeptide in light grey. First residue of mature protein in F1 
isoform is assigned as number 1 and signal peptide, propeptide and mature protein are 
indicated accordingly. (C) Unprocessed and mature protein structures and length (aa, on the 
right) of the three human GRP variants. The question mark highlights the doubt concerning 
F6 variant signal peptide processing (Adapted from Rafael et al., 2014 [189]).  
 
Regarding post-translational modifications the probability of N- or O-glycosylation 
and tyrosine or serine phosphorylation was analysed using NetNGlyc, NetOGlyc and NetPhos 
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tools, respectively, from CBS. Results revealed no indications of glycosylation in any of the 
human variants, but high probability of phosphorylation in one tyrosine residue in all variants, 
and in one or two serine residues in GRP-F1 or GRP-F5/F6, respectively (Fig. 3.2, B). 
 
3.3.3 GRP-F1 variant is the predominant transcript in both control 
and osteoarthritic tissues  
 
To further explore the expression pattern of human GRP-F1, F5 and F6 transcripts, 
primers that specifically amplified individual variants were used (Table 3.I, F1, F5 and F6, 
Fig. 3.3). These variant-specific primers were strategically designed and validated in the 
laboratory [189] prior its use in this project. The expression pattern of GRP-F1, F5 and F6 
transcripts in control and osteoarthritic cartilage and synovial membrane samples was 
therefore analysed to investigate a possible association with OA (Fig. 3.4). As described in 
Chapter 2, the reduced number of collected control samples and their low quantities was a 
limitation in this study, therefore the analysis of gene expression was only quantitatively 
evaluated by RT-PCR (subject information of each sample used in this analysis is described in 
Chapter 2, sections 2.3.1 and 2.4.1, Tables 2.I, 2.II and 2.III). Results suggested a higher 
expression of GRP-F1 in cartilage samples of OA patients (Fig. 3.4, A) when compared to 
controls, while no clear association could be determined in synovial membrane tissues (Fig. 
3.4, B). GRP-F5 was clearly less represented than F1 in both tissue types, (Fig. 3.4, A and B) 
whereas GRP-F6 could not be detected in any of the analysed cartilage samples, either control 
or osteoarthritic (Fig. 3.4, A), but it was found in certain synovial membrane samples (Fig. 
3.4, B) suggesting a restricted expression pattern.  
 
 
 
 
 
 
 
Fig. 3.3 – Schematic representation showing the localization of transcript-specific sets of 
primers for GRP amplification. F1, F5 and F6 indicate the respective GRP variant and arrows 
indicate the primers localization. E1 to E4 represent the respective exons (Adapted from 
Rafael et al., 2014 [189]). 
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Fig. 3.4 – Evidences for the predominance of GRP-F1 variant in human cartilage and synovial 
membrane and higher expression in osteoarthritic cartilage. The expression pattern of the 
three human GRP splice variants (F1, F5 and F6) was investigated in cartilage and synovial 
membranes of controls and osteoarthritic patients by RT-PCR, using transcript variant 
specific primers. 18S was used as a loading control (Adapted from Rafael et al., 2014 [189]). 
 
Overall, GRP-F1 transcript appears to be the predominant expressed form in both 
control and osteoarthritic cartilage and synovial membrane tissues, and with apparent higher 
expression in OA-affected cartilage comparing to controls, whereas GRP-F5 and F6 are 
barely or not detectable. 
 
3.3.4 Carboxylated and undercarboxylated GRP forms are  
accumulated in OA-affected tissues and fluids  
 
After confirming the predominance of GRP-F1 variant, corresponding to the full 
length GRP, both in control and OA-affected tissues, the patterns of protein accumulation and 
γ-carboxylation status were studied. For that, three different antibodies against the total 
(CTerm-GRP), carboxylated (cGRP) and undercarboxylated (ucGRP) GRP forms were used. 
All three antibodies were developed against synthetic peptides (Fig. 3.5) [14,15] and 
previously tested and validated for conformation specificity using several human tissues, 
namely breast, skin and heart valves, and calcified aortic valves protein extracts, as described 
[14-16].  
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Fig. 3.5 – Total GRP (CTerm-GRP) and conformation-specific antibodies for γ-carboxylated 
(cGRP) and undercarboxylated (ucGRP) GRP forms. Amino acid sequence alignments of 
mature human GRP-F1 form (HuGRP), limited to a portion of exon 3 (white) and complete 
exons 4 (light grey) and 5 (grey), and synthetic peptides used as antigens for development of 
the three antibodies are shown. Underlined E in cGRP correspond to Gla residues while E in 
ucGRP to Glu residues. The circle in the peptide sequence used for the development of 
CTerm-GRP antibody highlights the different amino acid between human and rat GRP 
sequences (Adapted from Viegas et al., 2014 [15]).  
 
GRP was first identified in sturgeon calcified cartilage [54], thus, a similar extraction 
procedure, specifically designed to isolate mineral-bound proteins, was chosen to analyse 
human GRP accumulation in osteoarthritic bone. The content of the mineral-bound protein 
extract was revealed on SDS-PAGE gels with CBB staining (Fig. 3.6, CBB) and the presence 
of Gla proteins was assessed with DBS analysis (Fig. 3.6, DBS). Two protein bands with 
apparent molecular weights of 13 and 18 kDa were observed with CBB and DBS staining 
(Fig. 3.6, CBB and DBS), indicating the presence of Gla-containing proteins in the extract. 
Results were correlated with those of sturgeon calcified cartilage extracts, performed under 
the same gel analysis conditions and where two Gla-containing entities with similar migration 
behaviours were identified as GRP (18 kDa) and MGP (13 kDa)  [54]. Comparing with the 
sturgeon extract, the two bands showed lower DBS staining intensity in the analysed human 
osteoarthritic bone extract suggesting a decreased degree of γ-carboxylation.  
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 – SDS-PAGE and western blot (WB) analysis of mineral-bound proteins isolated 
from human osteoarthritic bony extracts. Gels were stained with coomassie brilliant blue 
(CBB) (20 µg) and diazobenzene sulfonic acid (DBS) (40 µg) and WB analysis (2 µg) were 
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performed using CTerm-GRP, cGRP, ucGRP, cMGP and ucMGP antibodies. Relevant 
molecular mass markers (kDa) are indicated on the left of the panels. 
 
The presence of GRP in the human bone extract was further investigated by WB using 
the three available antibodies and the positive immunodetection of an 18 kDa entity (Fig. 3.6, 
CTerm-GRP, cGRP and ucGRP), indicated the presence of both c/ucGRP forms in this tissue. 
The presence of MGP in the extract was also investigated by WB and the results showed that 
the 13 kDa entity visualized with CBB and DBS staining (Fig. 3.6, CBB and DBS) could 
represent MGP, since both c/ucMGP specific antibodies revealed a positive reaction (Fig. 3.6, 
cMGP and ucMGP). Altogether these results evidenced the accumulation of GRP and MGP in 
the osteoarthritic human bone extract and gave strong indications for the association of both 
carboxylated and undercarboxylated GRP and MGP protein forms with the bone mineral 
phase.  
In addition to the SDS-PAGE and WB analysis, attempts to further characterize both 
GRP and MGP protein forms present in the human osteoarthritic bone extract were performed 
by N-terminal sequencing and LC-MS/MS analysis. Since the initial identification and 
characterization of GRP from sturgeon calcified cartilage extracts was achieved through N-
terminal amino acid sequencing [54], the N-terminal sequence of the 13 and 18 kDa protein 
bands (Fig. 3.6, CBB and DBS) was performed. Results showed that none of the protein 
bands corresponded to a single protein entity, with multiple amino acids detected in each 
Edman cycle. However, the first 5 amino acids corresponding to the N-terminal of human 
MGP were identified in the 13 kDa indicating the presence of MGP (results not shown). 
Notably, a Glu residue was identified in position 2 where a Gla residue was expected [11], in 
concordance with WB positive results for undercarboxylated MGP (Fig. 3.6, ucMGP). The 
obtained results for the 18 kDa band evidenced phospholipase A2 as the predominant protein, 
suggesting that GRP might be present in the extract in very low amounts, which combined 
with sample complexity, might require more sensitive methods, such as MS, for sequence 
identification and characterization. Accordingly, both 13 and 18 kDa protein bands were 
excised from SDS-PAGE gels and analysed by LC-MS/MS. In agreement with the N-terminal 
sequencing results, MGP was identified as the prevalent protein in the 13 kDa band, whereas 
GRP tryptic peptides were not detected in the 18 kDa band, and ribonuclease 5 was identified 
as the predominant protein. These results evidenced that the characterization of GRP protein 
through sequence determination from complex extracts would be a very challenging task, and 
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further procedure optimization, and probably additional approaches would be required to 
achieve this goal.  
In parallel, the immunodetection of GRP in human osteoarthritic articular cartilage and 
synovial membrane was achieved using a previously described extraction method with 
Laemmli lysis buffer, used to immunodetect GRP in mouse cartilage extracts [78]. The 
Laemmli extracts were analysed by SDS-PAGE with CBB staining and the presence of GRP 
investigated through WB (Fig. 3.7, CBB and WB). In agreement with the WB results 
previously obtained for mouse cartilage extracts [78], two positive GRP bands were 
immunodetected in human cartilage extracts with apparent molecular weights around 16 and 
18 kDa (Fig. 3.7, WB, C).  In the synovial membrane extracts only one GRP positive band of 
approximately 16 kDa was detected (Fig. 3.7, WB, SM). Interestingly, all the bands 
immunodetected with the CTerm-GRP antibody were also positive for the c/ucGRP 
conformation-specific antibodies, indicating the presence of both c/ucGRP forms in these 
OA-affected tissues.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7 – SDS-PAGE and western blot (WB) analysis of human osteoarthritic articular 
cartilage and synovial membrane in Laemmli buffer extracts. Gels were stained with 
coomassie brilliant blue (CBB) (cartilage, C, 50 µg and synovial membrane, SM, 45 µg) and 
WB analysis (C, 50 µg and SM, 45 µg) were performed using CTerm-GRP, cGRP and 
ucGRP antibodies. Relevant molecular mass markers (kDa) are indicated on the left of the 
panels. 
 
Since GRP has been described as a circulating protein [14], its presence in 
osteoarthritic synovial fluid and osteoarthritic serum was also investigated. For that, direct 
samples of both fluids were analysed by SDS-PAGE with CBB staining and WB using all the 
available GRP-specific antibodies (Fig. 3.8, CBB and WB). Results showed a single 
immunoreactive band with 25 kDa of apparent molecular weight (Fig.  3.8, WB). The 
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detected protein band was positive for both c/ucGRP antibodies, although cGRP appeared to 
be the predominant circulating form in these OA-affected fluids (Fig. 3.8, WB). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8 – SDS-PAGE and western blot (WB) analysis of human osteoarthritic synovial fluid 
and serum samples. Gels were stained with coomassie brilliant blue (CBB) (1 µl of synovial 
fluid, SF and 1 µl of serum, S) and WB analysis (1 µl of SF and 1 µl of S) were performed 
using CTerm-GRP, cGRP and ucGRP antibodies. Relevant molecular mass markers (kDa) are 
indicated on the left of the panels. 
 
Overall, although the presence of c/ucGRP was detected in all analysed samples, 
further characterization of GRP γ-carboxylation status through N-terminal sequence and LC-
MS/MS analysis was hampered, requiring additional studies to determine the pattern of GRP 
γ-carboxylation and its association with OA-affected tissues. In addition, due to limitations 
related with control tissue sampling availability (Chapter 2), such studies could not be 
performed using a SDS-PAGE and WB strategy. In alternative, to investigate GRP 
accumulation and γ-carboxylation patterns in control and OA-affected tissues, an IHC 
strategy using the conformation-specific c/ucGRP antibodies was conducted. This 
experimental approach allows the analysis of protein spatial distribution at the cell level and 
requires low quantities of tissue samples. 
 
3.3.5 Gla-rich protein is present in bone and associated with human 
osteoblasts, osteocytes and osteoclasts 
 
 Immunohistochemistry analysis of GRP in human osteoarthritic bone and articular 
cartilage was initially performed using glycol methacrylate and conventional paraffin 
embedding, the last with previous tissue decalcification. In the methacrylate embedded 
samples, positive GRP signal was observed in calcified cartilage and bone matrices 
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(calcification confirmed through von Kossa staining, Fig. 3.9, A) using the CTerm-GRP 
antibody, while an uneven signal was detected in the articular cartilage ECM (Fig. 3.9, B). 
Resin sections are prone to falling off the slides during IHC [198], thus deplasticization was 
not performed to prevent tissue lost and the obtained uneven signal in the ECM could be due 
to lower antibody accessibility and/or effect of antigen retrieval in some areas of the 
methacrylate tissue section. Because of this constrain, the use of this embedding in these types 
of tissues was restricted to the analysis of bone and ectopic cartilage calcification.  
 
 
  
Fig. 3.9 – GRP immunolocalization in human osteoarthritic bone and articular cartilage using 
methacrylate embedding. Tissue calcified areas where accessed using von Kossa staining (A) 
and GRP immunolocalization in consecutive tissue sections was achieved with CTerm-GRP 
antibody (B). Positive immunoreactive signal was evidenced by the brown colour. Panel C, 
contains a negative control in consecutive sections. Final counterstaining was achieved with 
toluidine blue. ac, articular cartilage; cc, calcified cartilage; sb, subchondral bone; scale bars 
represent 50 µm. 
 
For comparison, IHC analysis of the same tissue samples was performed with paraffin 
embedding. Tissue decalcification prior embedding (confirmed through von Kossa staining, 
Fig. 3.10, A) was necessary due to the hard nature of bone that difficults tissue sectioning. 
IHC analysis with CTerm-GRP antibody revealed a lower positive GRP signal in the bone 
matrix (Fig. 3. 10, B and C) when compared with the analysis in methacrylate sections (Fig. 
3.9, B). These results suggest protein loss with mineral removal, and are in concordance with 
the known calcium binding ability of GRP [15]. Interestingly, the preservation of cellular 
morphology in paraffin allowed the detection of GRP in all three cell types existing in bone: 
osteoblasts, osteocytes and osteoclasts (Fig. 3.10, C). Although GRP has been previously 
detected in rat osteoblasts and osteocytes at mRNA and/or protein levels [14], its association 
with osteoclasts had never been previously described.  
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Fig. 3.10 – GRP immunolocalization in human osteoclasts, osteoblasts and osteocytes. Bony 
tissue was analysed in paraffin tissue sections after tissue decalcification, which  was 
confirmed through von Kossa staining (A) and  GRP was immunodetected in consecutive 
tissue sections using CTerm-GRP antibody (B and C). Positive immunoreactive signal was 
evidenced by the brown colour. ob, osteoblasts; ocy, osteocytes; ocl, osteoclasts (ocl); scale 
bars represent 50 µm.  
 
The accumulation of GRP in osteoclasts was further confirmed using TRAP, a marker 
for osteoclasts and bone resorption [199], and IHC analysis with CTerm-GRP antibody in 
consecutive tissue sections of osteoarthritic bone. A co-localization of TRAP and GRP was 
obtained by immunolocalization in consecutive tissue sections (Fig. 3.11), indicating, for the 
first time, the presence of GRP in human osteoclasts, in addition to its detection in osteoblasts 
and osteocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11 – GRP is immunodetected in human osteoclasts. The reddish colour indicative of 
endogenous tartrate-resistant acid phosphatase (TRAP) presence (A and B) was detected in 
methacrylate osteoarthritic bone tissue sections and co-localized with GRP, using CTerm-
TRAP                                      CTerm-GRP 
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GRP antibody (C and D) in consecutive sections. Arrows indicate osteoclast localization. 
Final counterstaining was achieved with hematoxylin. Scale bars represent 50 µm. 
 
3.3.6 Uncarboxylated GRP is the predominant protein form 
accumulated in osteoarthritic tissues  
 
 Gla-rich protein accumulation pattern between control and osteoarthritic samples, and 
GRP γ-carboxylation status associated with the pathological processes occurring in OA, in 
particular ectopic calcification events, was analysed by IHC using the conformation-specific 
antibodies against cGRP and ucGRP protein forms. Synovial membrane samples and articular 
cartilage samples without adjacent bone or ectopic calcification were embedded in paraffin, 
while articular cartilage samples containing pathological mineralization were analysed using 
methacrylate embedding.  
Both c/ucGRP forms were found accumulated in control and osteoarthritic 
chondrocytes (Fig. 3.12, A-D and G-J), although ucGRP was more evident than cGRP in 
osteoarthritic cartilage ECM, especially in the tangential layer (Fig. 3.12, G-J and A-D, 
respectively). Also, the majority of the analysed tissue sections of osteoarthritic cartilage 
samples were characterized by the presence of ectopic calcification (Fig. 3.12, F), and both 
cGRP and ucGRP were co-localized at sites of cartilage pathological mineralization (Fig. 
3.12, E and K). These observations were confirmed with CTerm-GRP antibody (Fig. 3.12, L-
P).    
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Fig. 3.12 – Undercarboxylated GRP is the predominant form accumulating in osteoarthritic 
cartilage. Specific antibodies for carboxylated (cGRP) (A-E), undercarboxylated (ucGRP) 
(G-K) and total GRP (CTerm-GRP) (L-P) were used for immunolocalization in control and 
osteoarthritic cartilage extracellular matrix (ECM) and chondrocytes, and sites of ectopic 
calcification in the pathological tissues. Panel F represents the von Kossa staining of 
osteoarthritic cartilage showing sites of pathological mineralization (arrows). Samples without 
ectopic calcification sites were embedded with paraffin while the remaining with methacrylate 
and final counterstaining was achieved with hematoxylin. Tg, tangential layer; scale bars 
represent 50 µm (Adapted from Rafael et al., 2014 [189]). 
 
In parallel, the accumulation of c/ucGRP in the synovial membrane was also analysed 
(Fig. 3.13). Carboxylated GRP accumulation was mainly detected in the lining layer of 
control tissues (Fig. 3.13, A), while in osteoarthritic tissues ucGRP was the predominant 
protein form detected (Fig. 3.13, F). The presence of pathological mineralization was detected 
in all analysed samples of osteoarthritic synovial membrane (Fig. 3.13, D) and at ectopic 
calcification sites, both cGRP and ucGRP were co-localized (Fig. 3.13, C and G). 
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Fig. 3.13 – Undercarboxylated GRP is highly accumulated in osteoarthritic synovial 
membrane lining cells and both GRP protein forms accumulate at ectopic calcification sites. 
Specific antibodies for carboxylated (cGRP) (A-C), undercarboxylated (ucGRP) (E-G) and 
total (CTerm-GRP) (H-J) GRP were used for immunolocalization in the lining layer cells of 
control and osteoarthritic tissues and sites of ectopic calcification, detected using von Kossa 
staining (D, arrows), in the pathological membranes. Samples were embedded with paraffin 
and final counterstaining was achieved with hematoxylin. Scale bars represent 50 µm 
(Adapted from Rafael et al., 2014 [189]).  
 
The prevalence of cGRP in the lining layer of control synovial membranes, contrary to 
the predominance of ucGRP in osteoarthritic tissues was further confirmed through IF 
analysis (Fig. 3.14). 
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Fig. 3.14 – Undercarboxylated GRP is the predominant form accumulating in osteoarthritic 
synovial membrane lining cells. Immunofluorescence (IF) imaging was obtained for γ-
carboxylated (cGRP) (green, A-B) and undercarboxylated GRP (ucGRP) (red, C-D) protein 
forms using the respective specific antibodies. Samples were embedded with paraffin and cell 
nuclei were stained with DAPI. Scale bars represent 100 µm.  
 
Altogether, the IHC and IF results showing GRP pattern of accumulation in 
osteoarthritic samples of cartilage and synovial membrane, evidenced the predominance of 
the ucGRP form in OA-affected tissues, while control cartilage and synovial membrane 
tissues appear to mainly accumulate the cGRP form. 
Since MGP is another VKDP related to ectopic calcification and previously associated 
with OA [92], the accumulation patterns of the carboxylated (cMGP) and undercarboxylated 
(ucMGP) MGP forms were also analysed between control and osteoarthritic cartilage and 
synovial membrane tissues. Immunohistochemistry results showed that, as for GRP, the 
undercarboxylated form of MGP is highly accumulated in osteoarthritic cartilage when 
compared to control tissues (Fig. 3.15). Moreover, while in control chondrocytes only cMGP 
is detected, OA chondrocytes only exhibited ucMGP (Fig. 3.15, A-D and F-I). At sites of 
ectopic calcification, both MGP protein forms were found co-localized (Fig. 3.15, E and J).  
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Fig. 3.14 – Undercarboxylated MGP is highly accumulated in osteoarthritic cartilage. Specific 
antibodies for carboxylated (cMGP) (A-E) and undercarboxylated (ucMGP) (F-J) MGP 
forms were used for immunodetection in control and osteoarthritic cartilage extracellular 
matrix (ECM) and  chondrocytes, and sites of ectopic calcification in the pathological tissues. 
Samples without ectopic calcification sites were embedded with paraffin while the remaining 
with methacrylate and final counterstaining was achieved with hematoxylin. Tg, tangential 
layer; Scale bars represent 50 µm (Adapted from Rafael et al., 2014 [189]). 
 
In the synovial membrane, no positive MGP signal was detected in control and 
osteoarthritic lining cells (Fig. 3.15, A and C), while both c/ucMGP were found co-localized 
at sites of ectopic calcification co-localized (Fig. 3. 15, B and D).  
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Fig. 3.15 – Both carboxylated and undercarboxylated forms of MGP are accumulated in 
osteoarthritic synovial membrane ectopic calcification sites. Specific antibodies for 
carboxylated (cMGP) (A and B) and undercarboxylated (ucMGP) (C and D) MGP forms 
were used for immunodetection in the lining layer cells of control and osteoarthritic tissues 
and sites of ectopic calcification, in the pathological membranes. Samples were embedded 
with paraffin and final counterstaining was achieved with hematoxylin. Scale bars represent 
50 µm (Adapted from Rafael et al., 2014 [189]). 
 
Overall, the IHC results clearly showed the prevalence of a lower γ-carboxylation 
status of both GRP and MGP in osteoarthritic conditions and allowed the association of GRP 
γ-carboxylation impairment with OA pathology. 
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3.4 Discussion 
 
In this chapter evidences for the involvement of GRP with OA were addressed for the 
first time, at gene and protein levels. GRP-F1 was found to be the predominant expressed 
variant in articular cartilage and synovial membrane, and upregulated in osteoarthritic 
cartilage comparing to controls. Undercarboxylated GRP was found to be the prevalent GRP 
form accumulated in both osteoarthritic tissues. Moreover, GRP association with OA was not 
restricted to sites of ectopic calcification evidencing a possible role in other OA-associated 
processes such as inflammation.  
The first evidences for GRP association with OA were obtained from gene expression 
analysis in OA-affected tissues, which confirmed the consistent presence of the transcript 
coding for full length GRP (GRP-F1) and unveiled two novel GRP alternative transcripts 
(GRP-F5 and F6). In contrast, the presence of the previously described mouse and zebrafish 
splice variants, GRP-F2, F3 and F4 [72,73,76], were not detected in this study. These results 
were further supported by parallel studies ongoing in the laboratory for screening and 
identification of additional GRP splice variants using a wide panel of human tissue samples. 
Despite the extensive efforts and high number of screened GRP clones, no additional spliced 
transcripts were identified, neither the previously described F2, F3 and F4 GRP transcripts 
[189]. In addition, the same study failed to detect GRP-F5 and F6 variants in mice using a 
similar gene expression strategy [189]. Altogether, the results indicated that the newly 
discovered GRP-F5 and F6 forms may be human-specific, and strongly suggest the 
prevalence of these variants, in particular GRP-F1, in human, although the possibility that 
other alternatively spliced transcripts may exist in man cannot be completely excluded.  
The discovered GRP-F5 and F6 variants are characterized by the loss of carboxylase 
binding and propeptide cleavage domains, raising questions about the possibility of altered γ-
carboxylation of Glu residues and mature protein processing. Parallel studies ongoing in the 
laboratory performed transient transfections of HEK293T cells with GRP-mkate2 fusion 
protein, showing that all protein isoforms were translated and detected intracellularly [189]. 
Yet, the secretion of the F6 form occurred later than for F1 and F5 variants [189], indicating a 
lower secretory efficiency as predicted by the 9 aa loss of the signal peptide C-terminus. 
Detection of Gla residues in the secreted GRP protein isoforms using the M3B Gla-specific 
antibody, indicated the presence of Gla residues only in GRP-F1 [189], consistent with the 
predicted loss of γ-carboxylase recognition site in F5 and F6 variants. However, since in vitro 
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cell systems are known to have limited γ-carboxylation capacity, particularly when VKDPs 
are overexpressed [200], the presence of Gla residues in GRP-F5 and F6 in physiological 
conditions cannot be completely ruled out.  
Despite the identification of novel variants, in addition to the full length GRP-F1, the 
predominant transcript expressed in control or osteoarthritic tissues was found to be GRP-F1, 
as also reported for other pathological and control human tissues [15,16,189]. In fact, GRP-F5 
and F6 transcripts were found almost restricted to fetal tissues [189] and their biological 
function in humans should be further evaluated throughout development. Phosphorylation of 
serine and tyrosine residues are in silico predicted for all human putative GRP isoforms, and 
their occurrence should be further investigated, particularly because three phosphorylated 
serine residues of human MGP were previously demonstrated to be determinant for its 
function as a calcification inhibitor in vascular smooth muscle cells [201]. 
Previous functional studies on GRP had shown contradictory results. While GRP-
deficient mice did not exhibit a clear phenotype in bone and cartilage [78], zebrafish 
functional data indicated an essential role of GRP in skeletal development and calcification 
[72]. Results here obtained reinforce the notion that the GRP-deficient mouse has 
shortcomings since the data achieved from this model cannot be directly translated to the 
human situation [78]. 
The unequivocal predominant expression of GRP-F1 transcript and the barely 
detectable expression of GRP-F5 and F6 in the majority of the tissue samples analysed, 
further supports the fact that the immune-based studies using available GRP antibodies, either 
CTerm-GRP for total GRP or the conformational c/ucGRP antibodies, should reflect the 
accumulation pattern of GRP-F1 isoform, with negligible contribution of other variants. 
Detection of GRP by WB showed a complex patterning with multiple immunodetected bands, 
ranging from 16 to 25 kDa of apparent molecular weights, depending on the tissue or fluid 
analysed, although multiple bands were consistently detected with all available anti-GRP 
antibodies. Since the conformation-specific antibodies were raised against synthetic peptides 
comprising partial Gla/Glu domains, multiple patterning may represent different degrees of γ-
carboxylation. Moreover, since the analysed samples correspond to biological tissues and 
fluids from different individuals, potentially represents a higher γ-carboxylation 
heterogeneity. In fact, altered γ-carboxylation status have been shown to modify Gla-
containing proteins migration behaviour on SDS-PAGE [202]. Also, similar multiple GRP 
patterning was recently shown in calcified aortic valves extracts, using the same three 
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different antibodies against GRP employed in this study, where GRP identity was further 
confirmed in two out of three immunodetected bands [16].  
Attempts to obtain further GRP identification followed by characterization of Gla 
content in the immunoreactive bands was performed by N-terminal sequence and LC-MS/MS 
analysis, although the detection of GRP was not achieved using these techniques. N-terminal 
sequencing is not a high sensitive technique and generally requires pure peptides for an 
accurate identification [203]. When the protein of interest is present in low amounts in a 
mixture, as proposed for GRP, assigning the phenylthiohydantoin (PTH)-amino acid 
derivatives of its sequence will be most unlikely [203]. Mass spectrometry has a higher 
sensitivity, nevertheless, major problems associated with protein identification using this 
technique are often related with the generation of peptides suitable for fragmentation, and in 
the particular case of VKDPs, with the identification of Gla residues [200]. This subject 
which will be further discussed in Chapter 5. Altogether, protein sequencing results suggested 
that GRP is a low abundant protein in the analysed extracts, therefore more sensitive and 
powerful resolution techniques, such as two-dimension gel electrophoresis (2-DE), could be 
an alternative to obtain further molecular data for protein characterization. The use of this 
approach will be addressed in Chapter 5.  
The comparative IHC results obtained in this chapter revealed the presence of both 
c/ucGRP and c/ucMGP proteins in osteoarthritic tissues. Such results were not surprising, 
since it was previously shown that both GRP protein forms coexist, even in control tissues, 
indicating incomplete γ-carboxylation in physiological conditions [15]. Also, such results 
were consistent with the knowledge that all extrahepatic VKDPs presently investigated are 
undercarboxylated in non-vitamin-K-supplemented healthy individuals [204], a condition that 
might be aggravated in pathological conditions such as OA. At sites of ectopic calcification in 
osteoarthritic cartilage and synovial membrane co-localization of c/ucGRP and c/ucMGP was 
clear, evidencing the proteins association to the pathological mineralization occurring in OA 
and the calcium binding capacity of all forms. In agreement, previous in vitro studies 
evidenced the calcium binging capacity of both c/ucGRP [15]. Moreover, results showed that 
OA patients accumulate predominantly ucGRP in cartilage and in the lining cells of the 
synovial membrane, whereas control subjects, showing no signs of mineral deposition in both 
tissues, exhibit mostly the γ-carboxylated protein in both tissues. Interestingly, the fact that 
GRP accumulation was not restricted to sites of ectopic calcification in osteoarthritic tissues, 
evidenced its possible involvement in other OA processes. Overall, the IHC results confirmed 
the association of GRP with the pathological calcification events occurring in OA and clearly 
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associate ucGRP to the pathological tissues, suggesting that GRP γ-carboxylation should be 
crucial for the prevention of pathological features of OA. In concordance, ucGRP 
predominance relative to cGRP was also recently seen in calcified aortic valves by IHC [16]. 
Matrix Gla protein immunodetection in this study also supports the relevance of γ-
carboxylation for pathology development, since osteoarthritic cartilage tissues showed 
significantly higher amounts of ucMGP accumulation. Previous studies, both in mice and 
human, have shown that MGP-deficient chondrocytes are hypertrophic, exhibiting an 
abnormal maturation and organization that can lead to endochondral ossification due to the 
lack of this calcification inhibitor [12,65,89]. Specific γ-carboxylase activity has also been 
found to be higher in cultured control chondrocytes when compared to the ones derived from 
osteoarthritic tissue, and human osteoarthritic chondrocytes contained significantly less 
cMGP when compared to control cells [92]. Decreased cMGP, probably reflecting diminished 
γ-carboxylase activity, has been in fact suggested as responsible for the increased cartilage 
mineralization occurring in OA [92]. Ultimately, these data reinforce the notion that lower 
levels of functional VKDPs observed in OA may be the result of decreased γ-carboxylase 
activity associated with the pathology, possibly accompanied by a loss of vitamin K function 
that may be intimately related with its subclinical levels in OA [82]. 
Insufficient vitamin K levels in OA have been associated with impaired functions of 
MGP and OC, and associated to pathology abnormalities [12,83,94,205]. Accordingly, GRP 
biosynthesis is also possibly affected by vitamin K availability and consequently related to 
OA pathophysiological features, however, subclinical vitamin K insufficiency studies in OA 
have never considered GRP as a target protein. Moreover, vitamin K is not only associated 
with the prevention of soft tissue mineralization [12,206] but also regarded as protective agent 
producing anti-inflammatory cytokines that affect articular cartilage and subchondral bone 
through different molecular mechanisms [26], and ucMGP was also proposed as an 
inflammatory marker of arthritis through the combined analysis of serum and local synovial 
fluid accumulation [95]. Thus, the obtained results showing a relation between GRP and MGP 
γ-carboxylation deficiency and OA might also be linked with recent findings, suggesting that 
vitamin K metabolism may be associated with synovitis in OA patients [94], evidencing the 
possibility that GRP may not only be associated with mineralization events but also with 
inflammatory processes.  
Overall, this chapter revealed the existence of two novel GRP spliced variants, that 
seem to be human-specific, yet evidenced the predominance of GRP-F1 transcript in articular 
tissues, which is upregulated in osteoarthritic cartilage comparing to controls. Also, lower 
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levels of γ-carboxylated GRP were shown to be intimately associated with OA pathology, and 
such impaired γ-carboxylation will most likely affect the ectopic calcification events 
occurring in OA. Interestingly, the obtained IHC data also suggests GRP involvement in other 
OA-associated processes. Gla-rich protein γ-carboxylation status correlation with OA-
associated mineralization and GRP possible involvement with inflammatory events in OA 
will be further addressed in the following chapter.  
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Abstract 
 
Two of the major molecular processes affecting the whole-joint disease osteoarthritis 
(OA) are inflammation and the pathological mineralization of articular tissues, both events 
intimately correlated. Gla-rich protein (GRP) was associated to sites of pathological 
calcification in human osteoarthritic cartilage and synovial membrane tissues in the previous 
chapter. Moreover, our immunohistochemistry results (Chapter 3) revealed that GRP 
accumulation was not restricted to sites of ectopic mineralization in osteoarthritic synovial 
membrane tissues, suggesting a role in other cell mediated processes. In this chapter, the 
involvement of GRP with OA mineralization and inflammation was investigated using a 
chondrocyte and synoviocyte monolayer OA cell system. The induced extracellular matrix 
(ECM) mineralization of the in vitro articular model, revealed an upregulation of GRP 
expression following cell differentiation towards a hypertrophic (chondrocytes) or 
macrophage-lineage (synoviocytes) phenotype. Also, the induced inflammation of the cell 
system using the cytokine interleukin 1β, resulted in the increased expression of  the 
inflammatory mediators cyclooxygenase 2 and matrix metalloproteinase 13, concomitant with 
GRP upregulation. These results further associated GRP with OA-associated mineralization 
and for the first time, with OA-related inflammatory processes. Importantly, while treatment 
of articular cells with carboxylated GRP (cGRP) inhibited ECM calcification, treatment with 
either GRP or GRP-coated basic calcium phosphate crystals, resulted in the down regulation 
of inflammatory mediators, which was independent of GRP γ-carboxylation status. Thus, 
while the proposed calcification inhibitory function of cGRP was strengthened in the 
particular case of OA, our results also strongly suggest the association of GRP with 
inflammatory processes occurring in this degenerative disorder, apparently independently 
from its γ-carboxylation status. Since these two processes are widely associated with OA 
progression, GRP should be considered a strong candidate target to develop new therapeutic 
approaches for OA.  
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4. 1 Introduction 
 
Synovial inflammation, also termed synovitis, is frequently observed in osteoarthritis 
(OA), however, the respective development and how it affects disease progression is still 
unclear [100]. Abnormal mechanical and oxidative stress resulting from cartilage degradation 
in OA are associated with the induction of inflammation [91]. Also, another frequent feature 
known to modulate inflammatory responses in OA pathology is articular tissues ectopic-
calcification [139-142]. Although, basic calcium phosphate (BCP) and calcium 
pyrophosphate dihydrate (CPPD) are the major forms of crystals associated with OA 
pathology, the first type is more intimately related with primary OA [49,137,138]. The 
prevailing theory is that proinflammatory and catabolic mediators, such as nitric oxide (NO), 
cytokines, prostaglandins (PGEs) and matrix metalloproteinases (MMPs), are released from 
cartilage into the synovial space, and the presence of BCP crystals amplifies the production of 
such mediators, contributing to whole-joint inflammation and further cartilage degradation 
[88,91,123].  
Vitamin K is essential for preventing soft tissue mineralization [3,56] and it has been 
further suggested as a protective agent against inflammation [24,25]. While subclinical 
vitamin K levels have been associated with increased risk of OA development [82-84], 
several vitamin K-dependent proteins (VKDPs) such as matrix Gla protein (MGP), 
osteocalcin (OC), and now also Gla-rich protein (GRP) (Chapter 3), have been associated 
with the disease. The presence of undercarboxylated OC (ucOC) in serum, related to vitamin 
K metabolism deficiency, is associated to synovitis and considered a risk marker for OA [94]. 
Moreover, impaired γ-carboxylation of MGP has not only been associated with increased 
mineralization of osteoarthritic cartilage [92], but also to inflammatory events, with the 
combined assessment of ucMGP in serum and synovial fluid suggested as a joint 
inflammatory marker in arthritis patients [95].  
Gla-rich protein, proposed to act as a modulator of calcium availability in the 
extracellular matrix (ECM) [14,15] and an inhibitor of calcification in the cardiovascular 
system [16], was for the first time associated with OA in Chapter 3. Accordingly, GRP was 
verified to be upregulated in osteoarthritic cartilage comparing to controls and 
undercarboxylated GRP (ucGRP) was shown to be the predominant protein form 
accumulating in osteoarthritic cartilage and synovial membrane. Interestingly, GRP 
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association with OA was not restricted to ectopic calcification areas, indicating a possible 
involvement in other osteoarthritic processes such as inflammatory events.  
To better understand the pathophysiology of OA, several disease models have been 
developed in the past years. One of the major barriers overcome by these models is the 
limitation of human osteoarthritic tissues that are collected only at time of joint replacement, 
representing end stage lesions [146]. The use of such samples hampers the study of the factors 
that play a role in disease development [146]. Also, disease models overcome the common 
limitation of human control samples [153]. A wide variety of in vitro cell models are 
described and, among them, monolayer cell cultures are still one of the most useful tools for 
the study of OA pathology [153]. Monolayer systems are easy available and easy 
manipulated, allowing the research of disease causes and progression, and subsequent design 
and testing of potential therapeutics [153,154].  
In this chapter, the involvement of GRP with mineralization and inflammation 
processes occurring in OA was investigated using an in vitro monolayer chondrocyte and 
synoviocyte cell system. In concordance, here is described (i) the establishment of an in vitro 
cell system aimed at studying OA-associated mineralization and inflammation, (ii) GRP and 
genes involved in the γ-carboxylation machinery association with OA, (iii) GRP involvement 
with chondrocytes and synoviocytes induced ECM mineralization and related cell 
differentiation, (iv) carboxylated GRP (cGRP) ability to reduce mineral deposition in 
chondrocytes and synoviocytes ECM, (v) GRP association with inflammatory events in OA, 
(vi) GRP cross talking between calcification and inflammatory events, and (vi) c/ucGRP anti-
inflammatory effect in an osteoarthritic scenario.  
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4.2 Experimental procedures 
 
4.2.1 Biological material and sample processing 
 
Osteoarthritic articular cartilage and synovial membrane tissues were obtained and 
processed for subsequent cell culture development, as described in Chapter 2, section 2.2.1. 
 
4.2.2 Cell culture development and maintenance  
 
Osteoarthritic articular cartilage and synovial membrane tissues were digested 
overnight with 2 mg/mL collagenase in DMEM (Invitrogen, Carlsbad, CA, USA) at room 
temperature (RT). Fragments were washed three times with DMEM, placed in 24-well plates 
and cultured in the same medium supplemented with 1% v/v penicillin-streptomycin, 1 mM 
L-glutamine and 10% v/v fetal bovine serum (FBS) at 37 ᵒC in a humidified atmosphere with 
5% CO2. Osteoarthritis-derived chondrocytes (OA-HAC, osteoarthritic human articular 
chondrocytes) and synoviocytes (OA-HFLS, osteoarthritic human fibroblast-like 
synoviocytes) were allowed to migrate from fragments and adhere to the wells for 
approximately 2 weeks, then collected using trypsin solution (Invitrogen) for cell passage and 
placed into new plate dishes with fresh media. Cultures were routinely sub-cultured (1:2) at 
early confluence by trypsinization. The culture media used throughout the study was 
advanced DMEM (Invitrogen) supplemented with 1% (v/v) penicillin-streptomycin, 1 mM L-
glutamine and 10% (v/v) FBS. Cells used in the following experiments were between 
passages 4 and 14. Cells were observed and photographed with a Motic AE 31 inverted light 
microscope equipped with a digital camera, using Motic Images Plus 2.0 software. 
As controls, primary chondrocytes (NHAC, normal human articular chondrocytes, 
Lonza, Visp, Switzerland) and synoviocytes (HFLS, human fibroblast-like synoviocytes, 
ECACC, Sigma-Aldrich, St. Louis, MO, USA) were commercially obtained. A second set of 
OA and control-derived primary chondrocytes (OAC, osteoarthritic chondrocytes and NC, 
normal chondrocytes) and synoviocytes (SOAR, osteoarthritic fibroblast-like synoviocytes 
and SNR, normal fibroblast-like synoviocytes) cultures were developed by collaborators from 
Grupo de Bioingeniería Tisular y Terapia Celular (Servicio de Reumatología, Instituto de 
Investigación Biomédica de A Coruña, Complejo Hospitalario Universitario de A Coruña, 
Sergas, Universidad de A Coruña, A Coruña, Spain) and Centro de Investigación Biomédica 
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en Red de Bioingeniería, Biomateriales y Nanomedicina (Madrid, Spain) and used to 
strengthen the results obtained with of the first set of cells. 
 
4.2.3 Cellular proliferation measurement  
 
Cells were seeded in 96-well plates at 2 × 104 cells/well and cultured in DMEM and 
advanced DMEM supplemented with 1% v/v penicillin-streptomycin, 1 mM L-glutamine and 
10% v/v FBS. Both culture conditions were analysed for cell viability using the CellTiter 96 
cell proliferation assay (Promega, Madison, WI, USA), following manufacturer’s instructions. 
Briefly, cells were incubated during 1 h with 20 µl of reagent mixture, a tetrazolium 
compound combined with an electron coupling reagent, and cell proliferation was determined 
from absorbance at 490 nm. The tetrazolium compound is reduced by cells into a colored 
formazan product and 1 h was the previously determined optimal incubation period to obtain 
linearity between the number of cells and formazan absorbance at 490 nm (results not shown).  
Cultures in advanced DMEM supplemented with 5.4 mM CaCl2, 500 ng/mL of 
purified sturgeon GRP [54], human recombinant GRP [15] or bovine MGP [16], 5 ng/mL of 
interleukin 1β (IL-1β) (Peprotech EC Ltd., London, UK) or 100 µg/mL of produced BCP 
crystals (section 4.2.12), were also analysed for cell cytotoxicity using the CellTiter 96 cell 
proliferation assay (Promega) as formerly described.  
 
4.2.4 RNA extraction 
 
Total RNA was isolated from cell cultures as described by Chomczynski and Sacchi 
[191]. RNA concentration was determined by spectrophotometry at 260 nm and quality 
evaluated by agarose-denaturating gel electrophoresis. 
 
4.2.5 Amplification of cDNA and quantitative real-time PCR  
 
Five hundred nanograms of total RNA were treated with DNase I (Promega) and 
reverse-transcribed using Moloney-murine leukemia virus reverse transcriptase (MMLV-RT) 
(Invitrogen), RNase Out (Invitrogen), and an oligo(dT) adapter (5’-
ACGCGTCGACCTCGAGATCGATG(T)13-3’), according to the manufacturer’s 
recommendations.  
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Quantitative real-time PCR reactions were performed using the StepOne system (Life 
Technologies, Carlsbad, CA, USA), SsoFast Eva Green Supermix (Bio-Rad, Richmond, CA, 
USA), 300 nM of forward and reverse gene-specific primers (final concentration) for genes of 
interest (Table 4.I) and a 1:5 dilution of reverse-transcribed RNA solution. The following 
PCR conditions were used: initial denaturation/enzyme activation step at 95 ᵒC for 5 min, 50 
cycles of amplification (one cycle is 30 s at 95 ᵒC and 15 s at 66 ᵒC); 18S was used as a 
housekeeping gene to normalize expression. 
 
Table 4.I – Gene-specific primers used in this study  
Gene Primer name Sequence (5’ to 3’) 
18S 18S_F 
18S_R 
GGAGTATGGTTGCAAAGCTGA 
ATCTGTCAATCCTGTCCGTGT 
OC OC_F 
OC_R 
CAGCGAGGTAGTGAAGAGACCCAGG 
AGGGCAAGGGGAAGAGGAAAGAAGG 
COMP COMP_F 
COMP_R 
CTGCCTTCAATGGCGTGGACTTCG 
GGAAGGGGTTCGCCTGCCAATAC 
Col2a1 Col2a1_F 
Col2a1_R 
CCTCGTGGGTCCCAGGGGTGAA 
TGAAGACCTGGAGGGCCCTGTGCG 
Col10a1 Col10a1_F 
Col10a1_R 
AGCTGCCAAGGCACCATCTCCA 
AGTGGGCCTTTTATGCCTGTGGGC 
MMP13 MMP13_F 
MMP13_R 
AACCGTATTGTTCGCGTCATGCCAG 
GATAGCTCTTCTTCCCCTACCCCGC 
Vimentin Vimentin_F 
Vimentin_R 
TGCGTCTCTGGCACGTCTTGACCT 
AGGGCGTCATTGTTCCGGTTGGCA 
CD68 CD68_F 
CD68_R 
ACAGGACAACCACCACAGGCACCA 
GTGGCAGTGCTGTTGCTTGTTGGA 
GRP-F1 GRPF1_F 
GRPF1_R 
GTCCCCCAAGTCCCGAGATGAGG 
CCTCCACGAAGTTCTCAAATTCATTCC 
MGP MGP_F 
MGP_R 
TGGAGGCTGGCACCTGATTTTG  
AAAAGGGGTGCAGCCAGACAAG 
GGCX GGCX_F 
GGCX_R 
TTACACAGAGTCGGCGATGGAAGGAT 
TACTGGATGTCAGGTCTGCGAAA 
VKORC1 VKORC1_F 
VKORC1_R 
AGGGCAAGGCTAAGAGGCACTGAG 
CTGGGCAATGGAAAGAGCTTTGGAGAC 
Osx Osx_F 
Osx_R 
CAAGGTGTATGGCAAGGCTTCGCA 
TGCTGGCGAGGCAGAAGGTCGGGGCGT 
OPN OPN_F 
OPN_R 
ACGGACCTGCCAGCAACCGAAGT 
TACTGGATGTCAGGTCTGCGAAA 
COX2 COX2_F 
COX2_R 
TGGTCTGGTGCCTGGTCTGATGATGT 
GCCTGCTTGTCTGGAACAACTGCTCA 
 
4.2.6 Immunofluorescence  
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Immunofluorescence (IF) was performed in sub-confluent cultures seeded the previous 
day. Cells were washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate, 
1.8 mM potassium phosphate) and fixed for 10 min in 4% v/v paraformaldehyde. Fixed cells 
were incubated at RT for 1 h with rabbit polyclonal CTerm-GRP (10 µg/mL, GenoGla 
Diagnostics, Faro, Portugal) or mouse monoclonals cGRP (10 µg/mL, GenoGla Diagnostics), 
ucGRP [15] (7.3 µg/mL, VitaK BV, Maastricht, The Netherlands) and cluster of 
differentiation 68 (CD68) (20 µg/mL, Santa Cruz Biotechnology, Texas, TX, USA) primary 
antibodies. After the first incubations, cells were incubated for 1 h at RT with Alexa488 (anti-
rabbit) or Alexa594 (anti-mouse) labelled secondary antibodies (Invitrogen). Cell nuclei were 
stained with 6-diamidino-2-phenylindole (DAPI). Fluorescence images were obtained using 
an Axio Imager Z2 microscope (Zeiss, Jena, Germany) equipped with a digital camera and 
Axovision imaging software. Final images were processed using Image J Version 1.41m.  
 
4.2.7 SDS-PAGE analysis 
 
Aliquots of bovine MGP, purified within the scope of a parallel project [16], were 
quantified, freeze-dried and dissolved in lithium dodecyl sulphate (LDS) sample buffer 
(NuPage, Invitrogen) containing reducing agent. Separation was then performed by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) as described in Chapter 3, 
section 3.7, and the gel stained with coomassie brilliant blue (CBB) (Bio-Rad) and 
diazobenzene sulfonic acid (DBS) (Sigma-Aldrich). This approach was used to confirm MGP 
γ-carboxylation status. 
 
4.2.8 Extracellular matrix mineralization assay  
 
To induce ECM mineralization, confluent cultures grown in advanced DMEM were 
supplemented with either β-glycerophosphate (BPG) salts, inorganic phosphate (Pi), or CaCl2 
to final calcium concentrations of 10 mM, 2 mM, and 5.4 mM, respectively. Extracellular 
matrix mineralization experiments were performed during three weeks with media changes 
twice a week and each week set as an experimental time point (T0 to T3). Mineral content 
was detected by von Kossa staining as described [207]. Formation of mineralized nodules in 
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the ECM was observed and images taken with a Motic AE 31 inverted light microscope 
equipped with a digital camera and Motic Images Plus 2.0 software.  
To analyse the effect of GRP on mineralization and the influence of γ-carboxylation, 
confluent chondrocytes and synoviocytes were grown for 3 weeks in advanced DMEM under 
mineralizing conditions (CaCl2) supplemented with 500 ng/mL of cGRP or ucGRP, and 
compared with cells grown during the same period in the same conditions but without GRP 
supplementation. The addition of 500 ng/mL of γ-carboxylated MGP (cMGP) was also 
analysed, as a positive control for calcification inhibition. Sturgeon GRP and human 
recombinant GRP, purified within the scope of a parallel project [15], were used as cGRP and 
ucGRP, respectively, while purified bovine MGP [16], was used as cMGP. At appropriate 
times, calcium/protein ratios of the cell system were determined, as described in section 4.2.9.  
 
4.2.9 Calcium and total protein quantification  
 
At appropriate times, cell cultures grown in control or mineralizing conditions, were 
washed twice with PBS and mineral was dissolved with 1 M HCl, overnight at 4 ᵒC. 
Extracellular matrix calcium concentration was determined using a commercially available 
colorimetric kit (Calcium assay CA-590, Randox, Co. Antrim, UK). Equimolar amounts of  
NaOH containing 5 % w/v SDS were then used to neutralize the remaining HCl-mineral 
phase and determine the total protein concentration using the micro BCA protein assay kit 
(Thermo Scientific, Waltham, MA, USA).  
Aliquots of purified sturgeon GRP, human recombinant GRP and bovine MGP, were 
quantified based on the general reference setting that a protein solution with an extinction 
coefficient (E) of 0.1% (1 mg/ml) produces an absorbance of 1.0 at 280 nm (whit a path 
length of 1 cm) [193].  
 
4.2.10 Immunohistochemistry  
  
 Osteoarthritic synovial membrane tissues for histological analysis were embedded in 
paraffin and sectioned as described in Chapter 2, section 2.2.2. Immunohistochemistry (IHC) 
was performed as described in Chapter 2, section 2.2.3, to detect specific antigens in synovial 
membrane samples. As primary antibodies, rabbit polyclonal CTerm-GRP (5 µg/mL) and 
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mouse monoclonal cluster of differentiation 45 (CD45) (2 µg/mL, Santa Cruz Biotechnology, 
Texas, TX, USA) were used.  
 
4.2.11 Inflammation assay  
 
Confluent chondrocytes and synoviocytes were cultured in advanced DMEM or 
supplemented with 500 ng/mL of cGRP, ucGRP or cMGP, or 2 µM dexamethasone (DXM), 
during 24 h. Cells were washed twice with PBS and media was changed for advanced DMEM 
supplemented with 5 ng/mL of IL-1β for 72 h. At appropriate times, cell media was collected 
for prostaglandin E2 (PGE2) quantification and cells washed twice with PBS for RNA 
extraction. Prostaglandin E2 measurement was achieved using an available ELISA kit 
(Thermo Scientific) following manufacturer's protocol. 
 
4.2.12 Basic calcium phosphate crystals assay 
 
Basic calcium phosphate crystals were produced based on a previously described 
procedure [15]. Briefly, 2 mM CaCl2 and 10mM sodium phosphate buffer pH 7.0 were 
incubated for 2 h at 37 ᵒC, and centrifuged at 20.000 x g for 20 min at RT. The resulting 
crystals were washed three times with Milli-Q water and reduce to fine particles by sonication 
during 4 min at a 40 % amplitude (Vibra-cell apparatus, Sonics & Materials, Newtown, MA, 
USA). Crystals were observed and photographed with a Motic AE 31 inverted light 
microscope equipped with a digital camera, using Motic Images Plus 2.0 software. The BCP 
nature of the obtained crystals was confirmed by infrared (IR) spectroscopy at Universidade 
Nova de Lisboa (Departamento de Química, Lisboa, Portugal). 
Protein-mineral complexes were prepared by incubating BCP crystals (100 µg) in 
Milli-Q water for 30 min at 37 ᵒC with approximately 500 ng of cGRP, ucGRP or cMGP. 
Pellets containing BCP crystals and BCP crystals coated to GRP or MGP were added to 
confluent chondrocytes and synoviocytes and assayed for 72 h (controls had culture media 
only). At appropriate times, cells were washed twice with PBS prior to RNA extraction and 
cell media was collected for PGE2 measurement as previously described.  
 
4.2.13 Statistical analysis  
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GraphPad Prim 6 software (GraphPad Software, Inc., San Diego, CA, USA) was used 
for graphic design and statistical analysis. Data are presented as mean (n>2) ± standard error. 
Ordinary one-way ANOVA was used for comparisons within the same group. Multiple t-tests 
were used for comparison between two groups. For two groups submitted to a variable, 
significance was determined using two-way Anova and multiple comparisons were achieved 
with the Tukey’s test. Statistical significance was defined as P≤0.05 (*), P≤0.005 (**) and 
P≤0.0005 (***). 
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4.3 Results 
 
4.3.1 Establishment of an in vitro cell model suitable for the study of 
OA-associated mineralization and inflammation   
 
To further explore the association of GRP with pathological features of OA, namely 
mineralization and inflammation processes, an OA-derived in vitro cell system containing the 
two main articular cell types was developed. Accordingly, OA-derived primary monolayer 
cultures of chondrocytes (OA-HAC) and synoviocytes (OA-HFLS) were developed from 
articular cartilage and synovial membrane tissues, respectively, collected from the knee joint 
of an OA patient (subject information is described in Chapter 2, sections 2.3.1 and 2.4.1, 
Tables 2.II and 2.III). Control primary monolayer cultures of chondrocytes (NHAC) and 
synoviocytes (HFLS) were achieved for comparisons. At early passages, OA-HAC and 
NHAC cells revealed the typical polygonal morphology of chondrocytes, while OA-HFLS 
and HFLS cells shown the bipolar morphology characteristic of fibroblast-like synoviocytes 
(Fig. 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1 – Phase-contrast micrographs of confluent monolayers of developed OA-derived 
chondrocytes (OA-HAC) and synoviocytes (OA-HFLS), and commercial control-derived 
chondrocytes (NHAC) and synoviocytes (HFLS) primary cell lines at passages 4 or 5. Scale 
bars represent 100 µm.  
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In order to establish the optimal conditions for the in vitro cultivation of OA-derived 
and control primary cultures, growth performances of OA-HAC, OA-HFLS, NHAC and 
HFLS cells were analysed in DMEM, previously used for the cultures development, and 
Advanced DMEM, enriched in normal-serum constituents (Fig. 4.2). Higher proliferation 
capacities for all cell cultures were observed in Advanced DMEM (Fig. 4.2), and for that this 
was the culture media selected for further cells cultivation. Accordingly, cells were grown 
continuously in Advanced DMEM supplemented with 10% v/v FBS at 37ᵒ C and 5% CO2, 
and were sub-cultured with a ratio of 1:2 upon reaching confluency. Passaging by 
trypsinization did not significantly reduce the number of viable cells, and subsequent freezing 
and thawing did not significantly affect viability (results not shown). At confluence, cells 
formed confluent monolayers but not multilayer aggregates, and initial morphology (Fig. 4.1)  
was maintained for more than 15 passages.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 – Control and OA-derived chondrocyte (NHAC/OA-HAC) and synoviocyte 
(HFLS/OA-HFLS) cultures have higher growth performances in Advanced DMEM (Adv) 
comparing to DMEM, both supplemented with 10% fetal bovine serum (FBS). Cell 
proliferation was analysed every 3 days during a 12-day period using a colorimetric method. 
All experiments were repeated at least three times. 
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Since synovial membrane tissue is composed of two cell types, macrophage-like and 
fibroblast-like cells, further characterization of the developed OA-HFLS culture was 
performed by IF immunodetection of the macrophage marker CD68 (Fig. 4.3),  to support the 
apparently predominant fibroblast-like cells phenotype. Results showed a barely detectable 
staining for CD68 in OA-HFLS cells, in contrast with the high levels found in the 
macrophage-derived THP1 cells (THP1-MAC), used as positive control (Fig. 4.3), indicating 
an almost absence of macrophage-like cells on the developed synovial membrane-derived 
primary cultures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3 – Evaluation of the macrophage marker cluster of differentiation 68 (CD68) in the 
developed OA-HFLS primary cell line. Immunofluorescence (IF) analysis of CD68 were 
performed in OA-HFLS cells (A and B) and THP1-MAC cells and positive immunoreactions 
were evidenced by the reddish colour. Cell nuclei were stained with DAPI in panels A and C. 
Scale bars represent 100 µm.  
 
Further characterization of control and OA-derived chondrocytes (NHAC/OA-HAC) 
and synoviocytes (HFLS/OA-HFLS) was achieved through gene expression profiling of 
differentiation and known OA-related markers (Fig. 4.4). Higher levels of OC, cartilage 
oligomeric matrix protein (COMP) and collagen type X (Col10a1), and lower levels of 
collagen type II (Col2a1) were detected in OA-HAC cells (Fig. 4.4, A), confirming an 
osteoarthritic chondrocyte phenotype. Also, OA-HFLS cells, exhibited higher levels of the 
Chapter 4 – Gla-rich protein is a novel cross talk factor linking calcification and inflammation processes in 
osteoarthritis  
 
110 
 
OA-associated gene markers OC, MMP13 and CD68, and lower vimentin expression (Fig. 
4.4, B).  
 
 
 
 
Fig. 4.4 – Gene expression of differentiation and OA markers in control and OA-derived 
chondrocyte and synoviocyte primary cell cultures. The expression pattern of OA (OC, 
COMP and MMP13) and differentiation (Cola2, Cola10, CD68 and vimentin) gene markers 
in control (NHAC) and OA-derived (OA-HAC) chondrocytes (A) and control (HFLS) and 
OA-derived (OA-HFLS) synoviocytes (B) was analysed. Values are relative to a reference 
sample (control cell culture) set to 1. All experiments were repeated at least three times. 
Multiple t-tests were performed. Statistical significance was defined as P≤0.05 (*), P≤0.005 
(**) and P≤0.0005 (***) (Adapted from Cavaco et al., 2015 [208]). 
 
Gene expression results revealed significant differences between control and OA-
derived cells, representative of healthy and osteoarthritic conditions, respectively, indicating 
the suitability of this in vitro cell system as a model for the study of osteoarthritis.  
 
4.3.2 Association of GRP and genes involved in the γ-carboxylation 
machinery with osteoarthritis  
 
The expression pattern of GRP, MGP and genes related to γ-carboxylation processing 
was analysed in control and OA-derived cultures, to access possible differences between the 
two conditions (Fig. 4.5). GRP was found to be upregulated  in both OA-derived cultures 
(Fig. 4.5, A and B), in agreement with the higher GRP expression associated with OA-
affected cartilage described in Chapter 3. MGP was also found to be upregulated in the OA-
derived cells (Fig. 4.5, A and B). In contrast, γ-carboxylase (GGCX) and vitamin K epoxide 
reductase (VKOR) were shown to be downregulated in OA-derived cells (Fig. 4.5, A and B).  
Chapter 4 – Gla-rich protein is a novel cross talk factor linking calcification and inflammation processes in 
osteoarthritis  
 
111 
 
 
 
 
 
 
Fig. 4.5 – Gene expression of GRP and genes involved in the γ-carboxylation machinery in 
control and OA-derived chondrocyte and synoviocyte cell cultures. The expression of GRP, 
MGP, GGCX and VKOR genes in control (NHAC) and OA-derived (OA-HAC) chondrocytes 
(A) and control (HFLS) and OA-derived (OA-HFLS) synoviocytes was analysed (B). Values 
are relative to a reference sample (control cell culture) set to one. All experiments were 
repeated at least three times. Multiple t-tests were performed. Statistical significance was 
defined as P≤0.05 (*), P≤0.005 (**) and P≤0.0005 (***) (Adapted from Cavaco et al., 2015 
[208]). 
  
To access GRP γ-carboxylation status in control and OA-derived chondrocytes and 
synoviocytes, the protein accumulation pattern was analysed by IF using the conformation-
specific monoclonal antibodies cGRP and ucGRP and the polyclonal CTerm-GRP 
recognizing total GRP (Fig. 4.6). Both cGRP and ucGRP were detected in pathological and 
control chondrocytes, whereas only ucGRP was found associated with the OA-HFLS cells, 
suggesting the predominance of the undercarboxylated form associated with the disease, like 
observed in Chapter 3. 
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Fig. 4.6 – Accumulation patterns of GRP protein forms in control (NHAC and HFLS) and 
OA-derived (OA-HAC and OA-HFLS) chondrocytes and synoviocytes, respectively. 
Immunofluorescence (IF) imaging was obtained for total GRP (CTerm-GRP), γ-carboxylated 
(cGRP) and undercarboxylated GRP (ucGRP) protein forms using the respective specific 
antibodies. Cell nuclei were stained with DAPI. Scale bar represents 100 µm. All experiments 
were repeated at least two times (Adapted from Cavaco et al., 2015 [208]). 
 
Overall, the collected information indicates that OA-derived cells, showing 
osteoarthritic features, have GRP upregulation and indications of a reduced γ-carboxylation 
capacity. 
 
4.3.3 Gla-rich protein is associated with calcification and cell 
differentiation in osteoarthritis   
 
To analyse the association of GRP with pathological mineralization, the in vitro model 
was induced to mineralize its ECM. In chondrocytes, induced ECM mineralization has been 
previously described [209,210], however, no information was found at the time these studies 
were conducted for synoviocytes. Therefore, several conditions were tested to promote ECM 
mineralization in the two cell types, based on existing information [207,209-211]. In 
agreement, the effect of β-glycerophosphate (BGP), inorganic phosphate (Pi), and CaCl2 
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supplementation in OA-HAC and OA-HFLS cells was analysed at week 3 of treatment (Fig. 
4.7). Von Kossa staining and calcium quantification of the mineral deposited in the ECM 
indicated that both cell cultures were able to mineralize their ECM in all tested conditions but 
with different levels (Fig. 4.7). Although higher calcium levels and mineral deposition were 
found in chondrocytes, also synoviocytes were shown to produce a mineralized ECM, 
particularly under CaCl2 treatment (Fig. 4.7).  
 
 
 
Fig. 4.7 – Comparative analysis of OA-derived chondrocytes and synoviocytes (OA-HAC 
and OA-HFLS, respectively) in vitro mineralization using different supplementations. 
Mineralization rate and von Kossa staining at week 3 of OA-HAC and OA-HFLS cells 
induced to mineralize their extracellular matrix (ECM) with 10 mM β-glycerophosphate 
(BPG), inorganic phosphate (Pi) and 5.4 mM CaCl2 (Ca). C represents control conditions. 
Calcium accumulation was normalized to protein levels. Data is representative of one 
experiment. Ordinary one-way ANOVA was performed. Statistical significance was defined 
as P≤0.05 (*) and P≤0.005 (**). 
 
Since higher ECM mineralization was achieved with CaCl2 supplementation in 
chondrocyte and synoviocyte cell cultures, without affecting cell proliferation capacity (Fig. 
4.8), subsequent mineralization experiments in control and OA-derived cells were induced 
with CaCl2 during 3 weeks (Fig. 4.9). Von Kossa and calcium quantification results revealed 
that all cell cultures were able to mineralize their ECM, and higher calcium levels and mineral 
deposition were found in chondrocyte-derived cultures when compared to synoviocytes, after 
the 3 weeks of treatment (Fig. 4.8, A and B, T3). Significant differences in calcium 
quantification between OA and control chondrocytes were evident at week 1 (T1), although 
during subsequent weeks the differences gradually disappeared.  
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Fig. 4.8 – Effect of 5.4 mM CaCl2 media supplementation on OA-derived and control 
chondrocytes (OA-HAC and NHAC, respectively) and synoviocytes (OA-HFLS and HFLS, 
respectively) proliferation. Cell proliferation was analysed every 3 days during a 12-day 
period using a colorimetric method. All experiments were repeated at least three times. 
Chapter 4 – Gla-rich protein is a novel cross talk factor linking calcification and inflammation processes in 
osteoarthritis  
 
115 
 
 
 
Fig. 4.9 – Control and OA-derived chondrocytes and synoviocytes (NHAC and OA-HAC, 
and HFLS and OA-HFLS, respectively) are able to mineralize their extracellular matrix 
(ECM) in vitro. (A) Representative von Kossa staining at week 3 (T3) in control or induced 
mineralizing conditions with 5.4 mM CaCl2 (Ca). Scale bar represents 100 µm. (B) 
Mineralization rate determined every week (T0 to T3) with calcium accumulation normalized 
to protein levels. Data is representative of three independent experiments. Two-way Anova 
and multiple comparisons were achieved with the Tukey’s test. Statistical significance was 
defined as P≤0.05 (*) and P≤0.005 (**) (Adapted from Cavaco et al., 2015 [208]). 
 
The patterns of gene markers for cell differentiation and mineralization were 
simultaneously investigated in control and osteoarthritic primary cells to correlate with the 
calcification process (Fig. 4.10). After the first week of treatment (T1), OA-derived 
chondrocytes showed higher expression levels of GRP, MGP, OC, Osx and Col10a1, and 
lower levels of Col2a1, compared to control cells (Fig. 4.10). The progressive downregulation 
of Col2a1 simultaneously with the upregulation of Col10a1, Osx and OC throughout the 
treatment, in both cultures, was consistent with the differentiation occurring in chondrocytes 
towards a hypertrophic phenotype and ECM calcification (Fig. 4.10). The most significant 
differences between control and OA-derived cells were observed at T1, suggesting that 
primary OA-derived chondrocytes probably represent later stages of differentiation than 
control cells, with a faster response to the calcification stimuli. At T3, most of the gene 
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markers were found similarly expressed, in concordance with the similar levels of 
calcification obtained for both cultures (Fig. 4.9, B). Notably, levels and patterns of GRP and 
Osx gene expression were found similarly upregulated in OA derived chondrocytes 
throughout mineralization treatment, with higher levels in OA-derived cells at all-time points.  
 
 
 
Fig. 4.10 – GRP is associated with calcification and cell differentiation in OA-HAC cells. 
Gene expression patterns of GRP, mineralization (MGP, OC and Osx) and differentiation 
(Col2a1 and Col10a1) markers in mineralizing chondrocytes (NHAC and OA-HAC). Gene 
expression was determined every week during 3 weeks (T0 to T3). Relative gene expression 
values are relative to the reference sample (control cell culture) and set to 1. Data is 
representative of three independent experiments. Two-way Anova and multiple comparisons 
were achieved with the Tukey’s test. Statistical significance was defined as P≤0.05 (*) and 
P≤0.005 (**) (Adapted from Cavaco et al., 2015 [208]).   
 
In synoviocytes, vimentin downregulation and CD68 upregulation was observed 
during induced calcification, in both control and OA-derived cells, suggesting a phenotypic 
change from fibroblast-like synoviocytes towards a macrophage-lineage (Fig. 4.11). Gla-rich 
protein, MGP, OC and osteopontin (OPN) were gradually upregulated throughout 
mineralization, with slight differences observed between OA-derived and control cells (Fig. 
4.11). 
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Fig. 4.11 – GRP is associated with calcification and cell differentiation in OA-HFLS cells. 
Gene expression patterns of GRP, mineralization (MGP, OC and OPN) and differentiation 
(vimentin and CD68) markers in mineralizing synoviocytes (HFLS and OA-HFLS). Gene 
expression was determined every week during 3 weeks (T0 to T3). Relative gene expression 
values are relative to the reference sample (control cell culture) and set to 1. Data is 
representative of three independent experiments. Two-way Anova and multiple comparisons 
were achieved with the Tukey’s test. Statistical significance was defined as P≤0.05 (*) and 
P≤0.005 (**) (Adapted from Cavaco et al., 2015 [208]).   
 
The results described in this section point for a role of GRP during cell differentiation 
processes, highly associated with pathological calcification, in agreement with GRP 
accumulation at sites of ectopic calcification in osteoarthritic articular cartilage and synovial 
membrane tissues, shown in Chapter 3.  
 
4.3.4 Carboxylated GRP reduces mineral deposition in chondrocytes 
and synoviocytes ECM  
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To determine the direct effect of GRP in ECM mineralization of chondrocytes and 
synoviocytes and further unveil the relevance of its γ-carboxylation status, cells cultured 
under control and mineralizing conditions where supplemented with cGRP or ucGRP. The 
effect of the calcification inhibitor cMGP in the mineralizing cells was also analysed as a 
positive control. Before initiating the analysis, the γ-carboxylation of the used RP-HPLC 
purified bovine MGP [16] was confirmed by positive DBS staining (red) on SDS-PAGE, a 
specific staining for Gla-containing proteins (Fig. 4.12). Subsequently, cell proliferation 
assays were performed for both c/ucGRP protein forms and cMGP, to confirm that the protein 
supplementation had no cytotoxic effect (Fig. 4.13). 
 
 
 
 
 
 
 
 
Fig. 4.12 – Evaluation of purity and γ-carboxylation status of purified bovine MGP through 
SDS-PAGE and DBS staining. Reverse phase-high performance liquid chromatography (RP-
HPLC) purified bovine MGP [16] analysis on SDS-PAGE by staining with coomassie 
brilliant blue (CBB) (5 µg) and diazobenzene sulfonic acid (DBS) (30 µg). Relevant 
molecular mass markers (kDa) are indicated on the left of the panels. 
 
 
 
 
Fig. 4.13 – Effect of 500 ng/mL of carboxylated/undercarboxylated GRP (c/ucGRP) and 
carboxylated MGP (cMGP) media supplementation on NHAC and HFLS cultures 
proliferation. Cell proliferation was analysed every 3 days during a 12-day period using a 
colorimetric method. All experiments were repeated at least three times. 
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Results showed that the addition of cGRP significantly decreased mineral deposition 
after three weeks of treatment in both chondrocytes and synoviocytes, while no effect was 
observed with ucGRP treatment (Fig. 4.14). As expected, with cMGP supplementation, a 
decreased mineral deposition was observed after three weeks of treatment, similar to that 
induced by cGRP (Fig. 4.14).  
 
 
 
Fig. 4.14 – Carboxylated GRP reduces mineral deposition in chondrocytes (NHAC) and 
synoviocytes (HFLS) extracellular matrix (ECM). Mineralization rate was determined by 
calcium measurement using a colorimetric kit (normalized to protein levels) after 3 weeks of 
treatment with 5.4 mM CaCl2 (Ca) or Ca supplemented with 500 ng/mL undercarboxylated 
GRP (Ca+ucGRP), carboxylated GRP (Ca+cGRP) or carboxylated MGP (Ca+cMGP). 
Control corresponds to cells cultured in non-supplement media. Data is representative of three 
independent experiments. Ordinary one-way ANOVA was performed. Statistical significance 
was defined as P≤0.05 (*) (Adapted from Cavaco et al., 2015  [208]). 
 
Similar responses to c/ucGRP and cMGP supplementation were obtained for OA-
derived cells, representative of later stages of differentiation (results not shown). These results 
are in agreement with those presented in section 4.3.3, showing similar expression of 
calcification and differentiation gene markers between control and OA-derived cells at week 3 
of induced mineralization.  
 
4.3.5 Gla-rich protein is associated with inflammatory events in OA 
 
To study the involvement of GRP with mineralization and inflammatory events 
occurring in OA, the inflammatory response of control and OA-derived chondrocytes and 
synoviocytes, associated with the induced mineralization, was determined through the 
expression patterns of OA-related inflammation markers (Fig. 4.15). The increased 
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expression of COX2 and MMP13, throughout the time course indicated that the 
mineralization stimulus was able to trigger an inflammatory response in both chondrocytes 
and synoviocytes (Fig. 4.15). No significant differences were observed between control and 
OA-derived cells regarding COX2 and MMP13 expression, except at T0, where COX2 was 
upregulated in OA-HAC cells and MMP13 in OA-HFLS cells (Fig. 4.15), in agreement with 
the described increased expression of inflammatory mediators in osteoarthritic cells 
[88,98,114,133]. 
 
 
 
 
  
Fig. 4.15 – Gene expression of inflammation markers in control and OA-derived 
chondrocytes and synoviocytes under mineralization conditions. Cyclooxygenase 2 (COX2) 
and matrix metalloproteínase 13 (MMP13) gene expression over 3 weeks of mineralizing 
treatment (5.4 mM calcium) was evaluated in NHAC/OA-HAC and HFLS/OA-HFLS cells. 
Each week represents a set point (T0 to T3). Values of gene expression are relative to the 
reference sample (T0) and set to 1. Data is representative of three independent experiments. 
Two-way Anova and multiple comparisons were achieved with the Tukey’s test. Statistical 
significance was defined as P≤0.05 (*) and P≤0.005 (**) (Adapted from Cavaco et al., 2015 
[208]).  
 
Interestingly, the upregulation of COX2 and MMP13 gene expression associated to 
induced EMC mineralization in chondrocytes and synoviocytes was parallel to GRP 
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upregulation (Fig. 4.10 and Fig. 4.11), suggesting a possible involvement of this VKDP with 
inflammatory processes. Therefore, GRP hypothetical association with inflammation in OA 
was further studied in vivo, through IHC analysis of GRP and CD45 in consecutive tissue 
sections of osteoarthritic synovial membrane tissues, showing sites of abnormal infiltration of 
inflammatory cells (Fig. 4.16, A-D). CD45 is a selective marker for leukocytes [212], and 
notably, its positive immunoreactive signal located at sites of inflammatory cells infiltration 
(Fig. 4.16, A and B) was co-localized with GRP immunoreactive signal (Fig. 4.16, C and D).   
 
 
 
Fig. 4.16 – In vivo studies of GRP association with inflammatory events in osteoarthritis. 
Immunodetection of CD45 (A and B), showing leukocyte infiltration sites, and total GRP (C 
and D, CTerm-GRP antibody) in consecutive sections of osteoarthritic synovial membrane 
samples. Tissues were embedded with paraffin and final counterstaining was achieved with 
hematoxylin. Scale bars represent 100 µm (Adapted from Cavaco et al., 2015 [208]).  
 
The involvement of GRP with inflammation was also studied in vitro by inducing 
chondrocytes and synoviocytes with an inflammatory stimulus and evaluating GRP 
expression pattern. Interleukin-1β was the chosen cytokine to promote an inflammatory 
response in the cell system using previously described concentrations [130], and after 
verifying it was not cytotoxic for the cells (Fig. 4.17). A sharp rise in GRP expression 
concomitant with an upregulation of COX2 and MMP13 was obtained 3 h after IL-1β 
treatment (Fig. 4.18). The expression of GRP and inflammatory gene markers was 
progressively decreased until control levels, from 6 to 72 h of stimulation (Fig. 4.18). Since 
MGP is also associated to calcification events and was previously suggested as a joint 
inflammatory marker in arthritis patients [95], its expression pattern during IL-1β-induced 
inflammation was also analysed, and showed a similar pattern of gene expression to that of 
GRP (Fig. 4.18). Both NHAC/OA-HAC and HFLS/OA-HFLS cells responded similarly to 
the inflammatory stimulus, although control cells appeared to have slightly higher expression 
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of the four analysed genes 3 h after IL-1β treatment (Fig. 4.18). The higher initial response of 
control cells may reflect an unprecedented contact with inflammatory conditions to which 
OA-derived cells were probably already exposed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.17 – Effect of 5 ng/mL interleukin 1β (IL-1β) media supplementation on control and 
OA-derived chondrocytes (NHAC and OA-HAC, respectively) and synoviocytes (HFLS and 
OA-HFLS, respectively) proliferation. Cell proliferation was analysed every 2 days during a 
6-day period using a colorimetric method. All experiments were repeated at least three times. 
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Fig. 4.18 – In vitro studies of GRP and MGP association with inflammatory events in 
osteoarthritis. Gene expression levels of COX2, MMP13, GRP and MGP in NHAC/OA-HAC 
and HFLS/OA-HFLS cells, after 72 h inflammatory stimulation with 5 ng/mL interleukin 1β 
(IL-1β). Values are relative to the reference sample (0 h) set to one. Data is representative of 
three independent experiments. Two-way Anova and multiple comparisons were achieved 
with the Tukey’s test. Statistical significance was defined as P≤0.05 (*)(Adapted from Cavaco 
et al., 2015 [208]). 
 
Ultimately, the obtained results in this section indicate for the first time a possible 
association of GRP with the inflammation processes occurring in OA, and further correlate 
MGP to inflammation in this pathology. 
 
4.3.6 Gla-rich protein is a novel factor in the cross talk between 
calcification and inflammation processes  
 
Basic calcium phosphate crystals deposition is associated with inflammatory responses 
in OA [88,91,123]. Since GRP was recently described to be able to bind BCP crystals [15], a 
study was designed to access the effect of GRP coating to BCP crystals supplementation in 
the established in vitro cell system, in comparison to the effect of supplementing BCP crystals 
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only. For that, BCP crystals were produced following a previous described procedure [15] and 
subsequently sonicated, since the induced inflammatory response of these crystals is 
considered to be size dependent [140]. Optical microscopy observations revealed that crystals 
were heterogeneous concerning their size, ranging from >1 µm (the optical limit of the used 
microscope) to approximately 8 µm (Fig. 4.19). The nature of the crystals was confirmed to 
be hydroxyapatite through IR spectroscopy (results not shown). 
 
 
 
 
 
 
 
 
 
Fig. 4.19 – Micrographs of the basic calcium phosphate (BCP) crystals generated within the 
scope of this work, before (A) and after sonication (B). Scale bars represent 10 µm. 
 
Before initiating the experiment, the cytotoxicity of BCP crystals addition to the cell 
system was evaluated, showing that the treatment did not affect cell proliferation (Fig. 4.20). 
To evaluate the BCP-induced inflammatory responses, control chondrocyte and synoviocyte 
cells were treated during 72 h with the BCP crystals, in previously described amounts [213] 
(Fig. 4.21). The inflammatory response of BCP crystals coated with c/ucGRP or cMGP was 
also evaluated (Fig. 4.21). The upregulation of COX2 and MMP13 expression in BCP-treated 
cells confirmed the inflammatory response mediated by the crystals both in chondrocytes and 
synoviocytes cell cultures (Fig. 4.21). Treatment of cells with BCP crystals coated with cGRP 
or ucGRP resulted in decreased COX2 and MMP13 expression, and similar results were 
obtained with BCP crystals coated with cMGP (Fig. 4.21). Similar results were also obtained 
with the OA-derived cultures (results not shown). 
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Fig. 4.20 – Effect of 100 µg/mL basic calcium phosphate (BCP) crystals media 
supplementation on NHAC and HFLS cells proliferation. Cell proliferation was analysed 
every 2 days during a 6-day period using a colorimetric method. All experiments were 
repeated at least three times. 
 
 
 
 
Fig. 4.21 – Effect of GRP and MGP in the inflammatory process promoted by the addition of 
basic calcium phosphate (BCP) crystals to articular cells. Gene expression of cyclooxygenase 
2 (COX2) and matrix metalloproteinase 13 (MMP13) in NHAC (A) and HFLS (B) cells 
supplemented for 72 h with basic calcium phosphate (BCP) crystals or BCP crystals coated 
with undercarboxylated GRP (BCP + ucGRP), carboxylated GRP (BCP + cGRP) or 
carboxylated MGP (BCP + cMGP) is represented. Values are relative to the reference sample 
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(untreated cells, 0 h). Data is representative of three independent experiments. Two-way 
Anova and multiple comparisons were achieved with the Tukey’s test. Statistical significance 
was defined as P≤0.05 (*), P≤0.005 (**) and P≤0.0005 (***) (Adapted from Cavaco et al., 
2015 [208]). 
 
A corresponding significant reduction of PGE2 accumulation in control-derived  cell 
media was detected after 72 h of treatment with BCP coated to ucGRP/cGRP protein-mineral 
complexes when compared with cells treated with BCP crystals (Fig. 4.22). Such results 
further corroborated with the reduction of BCP-induced inflammatory response mediated by 
GRP-BCP coated crystals. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.22 – Effect of GRP in the inflammatory process promoted by the addition of basic 
calcium phosphate (BCP) crystals to articular cells. Prostaglandin E2 (PGE2) accumulation in 
NHAC and HFLS conditioned media after 72 h of cells supplementation with BCP crystals 
(BCP), or BCPs coated with undercarboxylated GRP (BCP + ucGRP) or carboxylated GRP 
(BCP + cGRP). Control corresponds to culture media of non-treated cells. Ordinary one-way 
ANOVA was performed. Statistical significance was defined as P≤0.05 (*), P≤0.005 (**) and 
P≤0.0005 (***) (Adapted from Cavaco et al., 2015 [208]). 
 
Altogether, results showed that both c/ucGRP coating significantly diminished the 
inflammatory reaction associated with BCP crystals. Accordingly, the collected information 
points GRP as a new mediator factor linking mineralization and inflammatory processes, 
independently of its γ-carboxylation status. MGP coating also appears to significantly 
diminish the inflammatory reaction associated with BCP crystals, although additional studies 
are required to evaluate the dependency of MGP γ-carboxylation in this process. 
 
4.3.7 Gla-rich protein acts as an anti-inflammatory agent in an 
osteoarthritic scenario  
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To determine whether GRP could have an effect on inflammatory processes and if this 
response was dependent of its γ-carboxylated status, chondrocytes and synoviocytes 
stimulated with IL-1β were pre-treated with ucGRP/cGRP or dexamethasone (DXM) (Fig. 
4.23). DXM is a corticosteroid, widely known for its anti-inflammatory effect over IL-1β-
mediated responses, and was used as a positive control in amounts according to literature 
[214]. In both control chondrocytes and synoviocytes systems stimulated with IL-1β, the 
treatment with either c/ucGRP resulted in significant lower levels of COX2 and MMP13 
expression relatively to non-treated cells (Fig. 4.23), indicating an anti-inflammatory effect of 
GRP.  
 
 
 
 
Fig. 4.23 – In vitro anti-inflammatory effect of GRP observed through the gene expression of 
inflammatory mediators in control-derived chondrocytes (NHAC) and synoviocytes (HFLS) 
stimulated with interleukin 1β (IL-1β). Gene expression of cyclooxygenase 2 (COX2) and 
matrix metalloproteinase 13 (MMP13) in NHAC and HFLS cells pre-treated with 500 ng/mL 
of undercarboxylated GRP (ucGRP) or carboxylated GRP (cGRP), or 2 µM dexamethasone 
(DXM) followed by IL-1β stimulation (5 ng/mL) during 72 h. Cells untreated with GRP or 
DMX were also analysed (IL-1β). Control corresponds to cells grown in advanced DMEM 
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only. Values are relative to the reference sample (0 h). Data is representative of three 
independent experiments. Two-way Anova and multiple comparisons were achieved with the 
Tukey’s test. Statistical significance was defined as P≤0.05 (*), P≤0.005 (**) and P≤0.0005 
(***) (Adapted from Cavaco et al., 2015 [208]).  
 
To further confirm these results, PGE2 accumulation in NHAC and HFLS cell media 
after 24 h of pre-treatment with cGRP and ucGRP was measured (Fig. 4.24), and results 
showed lower levels of PGE2 in media of pre-treated cells relatively to non-treated cells (Fig. 
4.24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.24 – In vitro anti-inflammatory effect of GRP observed through the accumulation of 
prostaglandin E2 (PGE2) in control-derived chondrocytes (NHAC) and synoviocytes (HFLS) 
stimulated with interleukin 1β (IL-1β). PGE2 accumulation in cell media of NHAC and HFLS 
24 h after a pre-treatment with 500 ng/mL of undercarboxylated GRP (ucGRP) or 
carboxylated GRP (cGRP), or 2 µM dexamethasone (DXM) followed by IL-1β stimulation (5 
ng/mL). Cells without the pre-treatment, only IL-1β stimulation (IL-1β) were also analysed. 
Control corresponds to culture media of non-treated cells. Ordinary one-way ANOVA was 
performed. Statistical significance was defined as P≤0.05 (*), P≤0.005 (**) and P≤0.0005 
(***) (Adapted from Cavaco et al., 2015 [208]). 
 
A similar anti-inflammatory effect was observed in OA-derived chondrocytes and 
synoviocytes, but notably, in chondrocytes, the effect of both ucGRP and cGRP on COX2 and 
MMP13 expression 3 h after IL-1β stimulation, was comparable to that obtained with DXM 
(Fig. 4.25).  
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Fig. 4.25 – In vitro anti-inflammatory effect of GRP observed through the gene expression of 
inflammatory mediators in OA-derived chondrocytes (OA-HAC) and synoviocytes (OA-
HFLS) stimulated with interleukin 1β (IL-1β). Gene expression of cyclooxygenase 2 (COX2) 
and matrix metalloproteinase 13 (MMP13) in OA-HAC and OA-HFLS cells pre-treated with 
500 ng/mL of undercarboxylated GRP (ucGRP) or carboxylated GRP (cGRP), or 2 µM 
dexamethasone (DXM) followed by IL-1β stimulation (5 ng/mL) during 72 h. Cells untreated 
with GRP, MGP or DMX were also analysed (IL-1β). Control corresponds to cells grown in 
advanced DMEM only. Values are relative to the reference sample (0 h). Data is 
representative of three independent experiments. Two-way Anova and multiple comparisons 
were achieved with the Tukey’s test. Statistical significance was defined as P≤0.05 (*), 
P≤0.005 (**) and P≤0.0005 (***)(Adapted from Cavaco et al., 2015 [208]).  
 
Matrix Gla protein effect on inflammatory processes stimulated by IL-1β was also 
investigated in control chondrocytes and synoviocytes (Fig. 4.26). Treatment with cMGP 
resulted in significant lower levels of COX2 and MMP13 expression relatively to non-treated 
cells (Fig. 4.26), indicating an anti-inflammatory effect of this VKDP. These results were 
supported by lower PGE2 accumulation in NHAC and HFLS cell media after 24 h of pre-
treatment with cMGP (Fig. 4.27).  
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Fig. 4.26 – In vitro anti-inflammatory effect of MGP observed through the gene expression of 
inflammatory mediators in control-derived chondrocytes (NHAC) and synoviocytes (HFLS) 
stimulated with interleukin 1β (IL-1β). Gene expression of cyclooxygenase 2 (COX2) and 
matrix metalloproteinase 13 (MMP13) in NHAC and HFLS cells pre-treated with 500 ng/mL 
of carboxylated MGP (cMGP), or 2 µM dexamethasone (DXM) followed by IL-1β 
stimulation (5 ng/mL) during 72 h. Cells untreated with MGP or DMX were also analysed 
(IL-1β). Control corresponds to cells grown in advanced DMEM only. Values are relative to 
the reference sample (0 h). Data is representative of three independent experiments. Two-way 
Anova and multiple comparisons were achieved with the Tukey’s test. Statistical significance 
was defined as P≤0.05 (*), P≤0.005 (**) and P≤0.0005 (***).  
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Fig. 4.27 – In vitro anti-inflammatory effect of MGP observed through the accumulation of 
prostaglandin E2 (PGE2) in control-derived chondrocytes (NHAC) and synoviocytes (HFLS) 
stimulated with interleukin 1β (IL-1β). PGE2 accumulation in cell media of NHAC and HFLS 
24 h after a pre-treatment with 500 ng/mL of carboxylated MGP (cMGP) or 2 µM 
dexamethasone (DXM) followed by IL-1β stimulation (5 ng/mL). Cells without the pre-
treatment, only IL-1β stimulation (IL-1β) were also analysed. Control corresponds to culture 
media of non-treated cells. Ordinary one-way ANOVA was performed. Statistical 
significance was defined as P≤0.05 (*), P≤0.005 (**) and P≤0.0005 (***). 
 
These results strongly suggest the involvement of GRP with inflammation in OA, 
indicating that this VKDP might be a powerful anti-inflammatory agent in this pathology, 
exerting this function independently of its γ-carboxylation status, although further work is 
required to confirm such indications. MGP also appears to be associated with OA-related 
inflammatory processes. 
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4.4 Discussion 
 
In this chapter, the involvement of GRP with two of the major molecular processes 
affecting OA, mineralization and inflammation, was addressed for the first time. Accordingly, 
the previously proposed role for GRP as an ECM mineralization inhibitor was strenghned in 
the particular case of OA and GRP was associated to inflammatory processes occurring in the 
disease, both in chondrocytes and synoviocytes, the main articular cell types. Moreover, while 
GRP γ-carboxylation status was shown to be essential for its calcification inhibitor effect, it 
was apparently irrelevant for the observed GRP anti-inflammatory actions, suggesting 
differential roles for undercarboxylated and carboxylated GRP.  
Most of the collected results in the present chapter were achieved using an in vitro 
chondrocyte and synoviocyte cell system, which allowed studying different parameters of 
interest in osteoarthritic and control cells. For that, OA-derived primary chondrocytes and 
synoviocytes were developed and control counterparts were commercially acquired. A second 
set of OA-derived and control primary chondrocyte and synoviocyte cultures, developed by 
collaborators as indicated in section 4.2.2, was used to strengthen the results obtained with the 
first set of cells. 
Gla-rich protein gene expression was found to be upregulated in OA-derived 
chondrocytes and synoviocytes, associated with higher levels of OA-related gene markers 
such as OC, COMP and Col10a1. These results are in agreement with the increased GRP 
expression associated with OA, observed in Chapter 3, using control and osteoarthritic 
cartilage tissue samples. Higher gene levels of the calcification inhibitor MGP were also 
associated to OA-cells, thus, results are in concordance with the higher demand of 
calcification inhibitors required to balance the increased cell differentiation and ECM 
calcification occurring in OA [50,137]. 
Carboxylated GRP was shown to decrease calcification in both chondrocytes and 
synoviocytes, and the increase of GRP expression accompanied cell differentiation towards 
ECM mineralization in both cell types. The upregulation of GRP during osteochondrogenic 
differentiation, characterized by a decrease in Col2a1 and concomitant increase in Col10a1, 
was recently shown during osteogenic differentiation of mouse osteoblastic MC3T3 cells, 
supporting the suggested upregulation of GRP gene by Osx [77]. Nevertheless, previous 
studies have shown that GRP is repressed by bone morphogenetic protein 2 (BMP2), known 
to be responsible for Osx upregulation during osteogenesis [75]. These controversial data 
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emphasize that the molecular mechanism of GRP action requires further clarification. Also, 
while GRP was suggested as a stimulating factor in osteoblast differentiation and nodule 
formation [77], previous results have shown an impairment of osteogenic differentiation by 
GRP using a similar approach [74,75]. Nevertheless, none of these studies has taken into 
consideration the fact that GRP is a γ-carboxylated protein, and although previous results 
evidenced that both forms, cGRP and ucGRP, have mineral binding capacity [15], only cGRP 
is able to inhibit ECM calcification in the vascular system [16]. In concordance, GRP 
knockdown in zebrafish evidenced severe growth retardation and perturbance of skeletal 
development, while warfarin treatment mimicked GRP knockdown phenotype, suggesting an 
essential role of γ-carboxylation for GRP function [72]. The gathered new information using 
GRP media supplementation in the established cell system strengthens the proposed 
calcification inhibitory function of GRP and reinforces the importance of its γ-carboxylation 
status. Carboxylated GRP probably alters calcium availability in the local environment or 
changes the dynamics of crystal growth [16].  
Increased extracellular calcium levels have been shown to drive chondrocyte 
differentiation towards a mineralizing phenotype, while calcium depletion from culture media 
maintains a stable cellular phenotype [209]. However, despite the upregulation of GRP in 
OA-derived cells, GGCX and VKOR genes, coding for crucial enzymes involved in γ-
carboxylation [1], were downregulated. This suggests a reduced γ-carboxylation capacity of 
OA cells, and consequently a decrease in the γ-carboxylation of target proteins such as GRP 
and MGP. In fact, the predominance of ucGRP and ucMGP in osteoarthritic articular cartilage 
and synovial membrane samples was previously shown in Chapter 3. Moreover, reduced 
vitamin K-dependent γ-carboxylase activity was previously reported in OA chondrocytes, and 
correlated with decreased γ-carboxylation of MGP and increased matrix mineralization [92].  
The triggers for articular cartilage calcification associated with OA are still not 
completely understood. Nevertheless, dysregulation of mineral metabolism, such as calcium 
and phosphate, and an imbalance in the production of mineralization inhibitors, are crucial 
factors favouring cartilage calcification and deposition of calcium-containing crystals, like 
BCPs [49,50]. Also, these are important to avoid chondrocyte phenotype alterations such as 
hypertrophic differentiation, apoptosis, as well as altered responses to inflammatory cytokines 
and mediators of inflammation [50]. Interestingly, the obtained results also showed that 
synoviocytes were able to produce a mineralized ECM, with OC and OPN upregulation and 
vimentin downregulation. These results were further supported by recent cell culture studies 
where osteoarthritic synoviocytes were able to produce and accumulate calcium mineral 
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crystals when stimulated with ATP [215]. Altogether, these findings suggest that 
synoviocytes are not passive bystanders but are active players in the pathological calcification 
process occurring in OA, contributing to the production of BCP crystals in OA articular 
joints. 
Calcium crystals have been shown to play an important role in the onset and 
progression of OA and are considered an early phenomena, affecting the whole joint even 
before any evidence of cartilage breakdown [50,137,138]. Basic calcium phosphate crystals 
are therefore found in the cartilage, synovial fluid and synovial membrane of OA patients 
[49]. The former are currently considered damage-associated molecular patterns (DAMPs), 
signalling to the immune system a state of stress, and potentially contributing to OA-
associated inflammation through the stimulation of articular cells  [91,123]. Basic calcium 
phosphate crystals induce synoviocyte proliferation and the production of inflammatory 
cytokines, MMPs and prostaglandins, and stimulate articular chondrocytes to produce 
prodegradative soluble factors, such as nitric oxide, and to undergo apoptosis [50,139-142]. 
MMPs production and chondrocyte apoptosis contribute to cartilage destruction, while 
cartilage breakdown products continue driving inflammatory events in a pathological 
mineralization-inflammation tissue degradation cycle [139-142]. Chapter 3 IHC results 
evidenced that GRP association to OA was not restricted to ectopic calcification events. In 
concordance, the possible involvement of GRP with both OA-associated mineralization and 
inflammation processes was studied through the evaluation of GRP ability to modulate 
inflammatory events triggered by a mineralization stimulus. COX2 and MMP13 upregulation 
was observed during mineralization in chondrocytes and synoviocytes and confirmed that, in 
this cell system, calcification can stimulate proinflammatory signalling that parallels cell 
differentiation and calcification. Notably, the high expression of COX2 and MMP13 was 
accompanied by an upregulation of GRP expression. These results reinforce the concept that 
other cells of the joint, including fibroblast-like synoviocytes and chondrocytes, besides 
synovial macrophages, directly contribute to the innate immune activation and the production 
of inflammatory mediators in OA. Importantly, the concomitant increase in GRP expression 
with inflammation, triggered by mineralization conditions, suggests a calcium-mediated role 
in inflammatory processes.  
Increased GRP expression after inducing inflammation with IL-1β was also verified, 
with a highly similar pattern to that of the inflammatory markers COX2 and MMP13. These 
results suggest that the involvement of GRP in inflammatory-mediated processes might not be 
exclusively mediated by mineralization events, opening new perspectives for GRP as a novel 
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cross talk factor linking calcification and inflammation processes occurring in articular cells. 
Such interactions should became relevant for the study of OA development and progression. 
Regarding the cytokine-based model used to stimulate inflammation in vitro, although OA 
synovial fluid levels of IL-1β are usually under 2 ng/mL [153] and in this study 5 ng/mL were 
used, differences are not so significant comparing with those typically used to exert an effect 
in vitro, that may reach up to 100 ng/mL [153,159,160]. Therefore, the used quantities of IL-
1β should reflect approximately the IL-1β-mediated inflammatory processes occurring in OA. 
As previously reported, GRP is able to bind BCP crystals in vitro and the calcification 
inhibitory function of GRP might be through the modulation of crystal formation and/or 
growth [16]. Moreover, BCP crystals have been suggested to have a direct pathogenic role in 
OA driving synovial inflammation and cartilage degradation [139-142]. Based on these facts, 
the potential role of GRP in the inflammatory response mediated by BCP crystals was further 
investigated in the established cell system. Results clearly demonstrated that coating BCP 
crystals with GRP reduces the associated proinflammatory effect, protecting cells from the 
increased expression of MMP13 and COX2 production. It has been proposed that calcium-
containing crystals may activate articular cells, either by leading to an increase in intracellular 
calcium levels after crystal endocytosis, by phagocytosis with consequent intralysosomal 
crystal dissolution, or through direct crystal-cell membrane interaction [142]. The former may 
occur via electrostatic bonds with the naked crystal surface or by membrane receptor 
stimulation with naked or protein-coated crystals [142]. Although the mechanisms behind 
GRP-BCP mediated anti-inflammatory effect in articular cells are currently unknown, it is 
possible to speculate that GRP binding to BCP will probably interfere with crystal-cell 
membrane interaction, modulating the production of proinflammatory mediators. 
Interestingly, fetuin-A-containing calciprotein particles (CPP), well known for their role in 
the prevention of uncontrolled mineralization, were recently reported to decrease cytokine 
production in macrophages, compared with cells stimulated with naked hydroxyapatite 
crystals [58]. Moreover, serum-derived CPP have been shown to produce a higher protective 
effect than synthetic CPP in macrophage activation [58], probably reflecting the inhibitory 
activity of other serum components, such as GRP and MGP. Notably, the association between 
GRP, MGP and fetuin-A was recently shown at sites of aortic valves calcification. Here, the 
calcification inhibitory function of both VKDPs was proposed to occur constitutively, via this 
potent inhibitory system formed by proteins with strong calcium phosphate binding capacity 
[16]. In the present study, the parallel upregulated gene expression of GRP and MGP in OA-
derived chondrocytes and synoviocytes and accompanying cell differentiation towards ECM 
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mineralization in both cell types, also suggests that the VKDPs may function together against 
OA-associated pathological calcification. Furthermore, pre-treatment of chondrocytes and 
synoviocytes with GRP and MGP, followed by IL-1β stimulation, mirrored the anti-
inflammatory effect observed with the VKDPs coated BCP crystals, showing a clear anti-
inflammatory role by downregulation of the inflammatory modulators COX2 and MMP13, in 
some cases at levels comparable to DXM. The anti-inflammatory effect of GRP had never 
been suggested while MGP had already been proposed as an inflammatory marker in arthritis 
[95,216]. Moreover, the indication that both VKDPs might have parallel functions as anti-
inflammatory agents in OA, leads to speculate that GRP and MGP may function together in a 
complex such as the CPP reported in macrophages, described to act both in the prevention of 
uncontrolled mineralization and protective effect against cytokine production [58]. 
Interestingly, the anti-inflammatory mediated effect of GRP was apparently 
independent of its γ-carboxylation status, suggesting additional functions for 
undercarboxylated GRP. Despite the fact that undercarboxylated VKDPs have been regarded 
as non-functional and related to pathological states [217,218], decreased γ-carboxylation of 
OC has been implicated in the regulation of energy metabolism, with novel metabolic roles 
[219]. Moreover, in the past decade, vitamin K biological functions other than acting as a 
coenzyme of GGCX have been proposed, namely regarding anti-inflammatory and 
antioxidant actions [24,25]. Vitamin K2 has been associated to anti-inflammatory effects 
through the suppression of the NF-κB pathway, with a dual pro-anabolic and anti-catabolic 
activity in bone [29]. In fact, inappropriate regulation of anti-catabolic activity in bone has 
been shown as one of the major causes of setting an inflammatory state in both OA and 
rheumatoid arthritis (RA) [220]. Although it was shown in this work that GRP is associated to 
inflammation in osteoarthritic synovial membranes undergoing synovitis, its involvement in 
immune cells inflammatory responses is presently unclear. Also, additional characterization 
of the anti-inflammatory activity of GRP and correlation with γ-carboxylation status is 
necessary to further unveil the molecular pathways involved. Regarding MGP, further work is 
required to access the impact of its γ-carboxylation status on inflammation.  
Notably, the collected data throughout the present chapter evidenced that both control 
and OA-derived cell cultures, characterized by different gene expression of OA and 
differentiation markers, and probably reflecting later stages of differentiation in OA-derived 
cells, responded similarly to all the developed assays. These observations indicate that both 
pathological calcification inhibition and anti-inflammatory functions exerted by GRP might 
be effective at different stages of OA development.  
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Overall, in a context of OA with induced cell hypertrophic differentiation and ECM 
calcification, the obtained results suggest that the increased expression of VKDPs, such as 
GRP and MGP, might function to counteract calcification. However, system overload could 
lead to hampered γ-carboxylation capacity resulting in increased levels of undercarboxylated 
GRP and MGP. Undercarboxylated GRP might contribute to control the levels of 
inflammatory mediators through still unknown mechanisms, thereby protecting the joint 
structures from damage. GRP may therefore be considered a new player acting in 
osteoarthritic pathological calcification and inflammatory processes, and eventually a 
potential candidate for therapeutics in OA, which should be further explored. 
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Abstract 
 
The diagnosis of osteoarthritis (OA) is generally based on clinical and radiographic 
analyses, which are only able to detect the disease after significant joint damage has already 
taken place. Hence, there is an urgent need to identify reliable biomarkers that facilitate the 
early diagnosis and contribute to the prognosis and monitoring of therapeutics for OA. 
Proteomic studies have been used in the field of OA for the search of candidate disease 
biomarkers, mainly focused on synovial fluid and serum analysis. A common feature found 
associated with OA is the occurrence of pathological calcification, thus calcification inhibitors 
such as Gla-rich protein (GRP) or fetuin-A-containing calciprotein particles (CPP) could 
represent interesting candidates as OA biomarkers. In this chapter, the efforts made to clarify 
the potential of GRP as a biomarker for OA and to unveil alternative candidate biomarkers for 
the disease are described. The results obtained from the two-dimensional gel electrophoresis 
(2-DE) analysis aiming to study GRP as a marker for OA, using knee OA-affected cartilage 
extracts and GRP purified protein standards, clearly lead to the conclusion that this approach 
has serious limitations for the analysis of this highly insoluble protein. However, the 
comparative 2-DE analysis of CPP-like entities isolated from serum of control and 
osteoarthritic patients, coupled with protein sequencing by liquid chromatography-tandem 
mass spectrometry analyses, allowed the identification of 19 differentially expressed proteins. 
Interestingly, some of the identified proteins had been previously associated to OA, 
strengthening their potential as OA biomarkers. Moreover, the protein content found to be 
differentially expressed and associated to the fetuin-A-containing CPP-like entities, suggests a 
possible involvement of this complex with OA, although further work is necessary to 
elucidate the function of CPP associated to the pathological processes occurring in OA.  
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5. 1 Introduction 
 
Current criteria for diagnosing osteoarthritis (OA) mainly relies on clinical 
manifestations and radiographic evaluations of the disease [161]. However, OA may be a 
silent disorder for many years before typical symptoms and radiographic changes emerge 
[161]. During this subclinical stage, damage of articular cartilage may have occurred and 
become irreversible [161]. Thus, it is extremely important to discover reliable biomarkers that 
can identify patients in risk for the progression of OA, facilitate the earlier diagnosis, 
contribute for advances in the prognosis and monitor therapeutics for the disease [81]. 
Structural molecules and fragments derived from cartilage, bone and the synovial membrane, 
are reported as the most promising candidates for early OA biomarkers discovery [81]. 
Nevertheless, since most of these extracellular matrix (ECM) turnover and/or cellular 
metabolism products are released into biological fluids, molecular markers can be measured 
in the synovial fluid or serum, which are easily obtained comparing with joint tissues [176].  
Proteomic studies, a large-scale analysis of proteins involving the isolation, 
purification and mass spectrometry (MS) of the entities of interest, may enable the search for 
OA biomarkers in a systemic fashion [177]. Two-dimensional gel electrophoresis (2-DE) has 
preceded and accompanied the birth of proteomics and it is still one of the most valuable 
approaches for the separation and visualization of complex protein mixtures [221]. Using 2-
DE, proteins are separated by isoelectric focusing (IEF) in the first dimension, and size-
separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) in the 
second dimension [221]. High-resolution 2-DE can resolve up to 5.000 different proteins 
simultaneously, and detect and quantify less than 1 ng of protein per spot [221]. To date, 
differential expression patterns of proteins in OA have been focussed on  synovial fluid or 
serum proteomic analyses, often using 2-DE approaches [177,179]. The synovial fluid 
contains higher concentrations of joint degradation products than any other biological fluid, 
making it an interesting target for assessing joint tissues metabolism analysis [179]. Serum 
samples containing the same degradation products although more diluted, represent however a 
more accessible biospecimen [179]. Despite the fact that both fluids contain high abundant 
proteins that might hamper the detection of lower abundant entities, several methods for 
affinity depletion of high abundant proteins are currently well described and available [179]. 
Cartilage 2-DE should provide a more direct insight into the pathogenesis of OA [177], yet 
the dynamic range of articular cartilage proteins is problematic [179]. The dominant nature of 
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macromolecules including the network of poorly soluble collagens, highly sulphated 
proteoglycans and hyaluronan, overwhelm the signals from less abundant proteins [179]. 
Therefore, a number of strategies for enrichment of the less abundant cartilage proteins and 
removal of contaminants have been developed, encompassing ultrafiltration, differential 
protein solubilisation procedures and proteoglycan subtraction [179,222]. Moreover, anionic 
molecules, such as aggrecan and hyaluronan, interfere with the IEF, making their removal 
advisable [179,222]. Ultimately, a combination of physical disruption and chemical extraction 
is generally suggested for articular cartilage protein extraction, which should be followed by 
proteoglycans removal, protein precipitation and solubilisation [177,179,223]. Importantly, 
although it is challenging to establish cartilage proteomic analysis methods, studies have 
reported the results of differential proteomic analysis of cartilage tissues in healthy and OA 
conditions using 2-DE [224,225]. 
The occurrence of pathological mineralization is a common feature of OA [48]. 
Therefore, calcification inhibitors such as Gla-rich protein (GRP), previously suggested as a 
calcification inhibitor and an anti-inflammatory agent in OA (Chapters 3 and 4), or fetuin-A-
containing calciprotein particles (CPP) [57,58], could represent interesting candidates as OA 
biomarkers. Fetuin-A, is a glycoprotein synthesized in the liver and secreted into circulation, 
considered the most important systemic inhibitor of soft-tissue calcification [57]. Fetuin-A 
binds and sequesters mineral nuclei, forming soluble colloidal high molecular weight CPP, 
inhibiting crystal growth and aggregation [57,58]. This mechanism is believed to facilitate the 
clearance of calcium crystals from extracellular fluids, that otherwise could seed and possibly 
promote ectopic calcification [58]. Fetuin-A-containing CPP formation was first discovered in 
the serum of rats treated with the bone-active bisphosphonate etidronate, suggested to inhibit 
normal bone mineralization [226]. It was later proposed that this entity could be originated 
from bone, associated with bone resorption processes [59]. In circumstances where bone 
formation and resorption are imbalanced, like in OA [121], upon bone resorption increase, 
calcium phosphate crystal nuclei were probably formed in a bone-remodelling compartment 
(BRC) and released into the circulation [59]. This process should be accompanied by fetuin-
A-containing CPP formation in the BRC, to stop crystal growth [59]. The fetuin-A detected in 
bone is believed to arise via serum, attracted by its high affinity for hydroxyapatite (HA) 
[227]. Interestingly, BRC structures were also identified in the vasculature [60], suggesting 
that calcium crystals and CPP may be formed in other locations, such as sites of pathological 
calcification. In chronic kidney disease (CKD) patients, serum fetuin-A-containing CPP levels 
were strongly correlated with coronary artery calcification and the complex was suggested to 
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reflect extraosseous calcification stress [228]. Fetuin-A-containing CPP formation was also 
suggested to help protecting macrophages against proinflammatory effects of the sequestered 
calcium crystals [58]. Notably, CPP entities are not exclusive of serum and were detected in 
different human body fluids, including the synovial fluid [229]. The same study showed that 
although the protein content of each fluid-derived CPP mirrored the protein composition of 
the contacting fluid, entities such as fetuin-A, albumin and apolipoprotein A1, were 
consistently associated to all complexes and should therefore be considered markers of CPP 
[229]. The fact that proteins with different functions were observed as CPP constituents, 
suggests that each complex might interfere with distinct biochemical pathways, thus the 
identification of the protein content of such entities may be critical to assess their biological 
activity [229].  
In this chapter, efforts were made to clarify the potential of GRP as a biomarker for 
OA and unveil novel candidate biomarkers for the disease using 2-DE approaches. Therefore, 
here is described (i) the 2-DE analysis of OA-affected samples aiming to characterize GRP 
and search for novel OA biomarkers, (ii) the characterization of fetuin-A-containing CPP-like 
entities isolated from serum and synovial fluid through gel electrophoresis and calcium 
quantifications, (iii) the analysis of differentially expressed proteins between control and 
osteoarthritic serum CPP-like entities using comparative 2-DE, and (iv) the identification of 
differentially expressed proteins in OA, associated to fetuin-A-containing CPP-like entities.  
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 5.2 Experimental procedures 
 
5.2.1 Biological material and sample processing 
 
Osteoarthritic articular cartilage and synovial fluid, and pathological and control 
clotted blood samples were obtained as described in Chapter 2, section 2.2.1. Cartilage tissues 
were immediately frozen at – 20 °C after collection, and the biological fluids centrifuged for 
15 min at 3.000 x g and room temperature (RT), before storage at – 80 °C until further use. 
 
5.2.2 Sample preparation for proteomic analysis 
 
Articular cartilage protein extraction for subsequent proteomic analysis was achieved 
using Laemmli buffer, as described in Chapter 3, section 3.2.6.  
Synovial fluid samples (1.5 mL) were depleted from high abundant proteins, such as 
albumin and immunoglobulins, using the ProteoMiner protein enrichment kit (Bio-Rad, 
Richmond, CA, USA), according to the manufacturer's protocol. The isolation of fetuin-A-
containing CPP-like entities from synovial fluid and serum samples was also performed for 
proteomic analysis, following previously described procedures [228,230]. Briefly, 1.5 mL of 
fluids were centrifuged for 2 h at 16.000 x g and 4 °C and the supernatants were discarded. 
Centrifuge tubes were rinsed twice with 150 mM NaCl to wash the obtained pellets and 
centrifuged for 10 min at 16.000 x g and 4 °C. Final supernatants were discarded. 
 
5.2.3 Total protein and calcium quantification 
 
The protein content of the final cartilage extracts and synovial fluid samples depleted 
from high abundant proteins, obtained as described in the previous section, was estimated 
based on the general reference setting that a protein solution with an extinction coefficient (E) 
of 0.1% (1 mg/ml) produces an absorbance of 1.0 at 280 nm (whit a path length of 1 cm) 
[193]. Aliquots of purified sturgeon GRP, human recombinant GRP and bovine MGP, 
obtained within the scope of parallel projects [15,16], were also quantified by absorbance at 
280 nm. 
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Calcium concentrations of the fetuin-A-containing CPP-like entities isolated from 
synovial fluid and serum as described in the previous section, were estimated after dissolving 
the pellets in 60 µl of 1 M HCl overnight at 4 ᵒC, using a commercially available colorimetric 
kit (Calcium assay CA-590, Randox, Co. Antrim, UK), following the manufacturer's protocol. 
The protein content of the samples was then estimated after adding equimolar amounts of 
NaOH containing 0.5% w/v SDS, to neutralize the remaining HCl-mineral phase. Total 
protein concentrations were measured using the micro BCA protein assay kit (Thermo 
Scientific, Waltham, MA, USA), according to the manufacturer’s protocol. For calcium 
concentrations, statistical analysis data are presented as mean (n=8) ± standard error, non-
paired t-tests were used to compare control and OA groups and statistical significance was 
defined as P≤0.05 (*), P≤0.005 (**) and P≤0.0005 (***). 
 
5.2.4 SDS-PAGE, native gel and western blot analysis  
 
Freeze-dried aliquots of purified sturgeon GRP, human recombinant GRP and bovine 
MGP, synovial fluid proteins and CPP-like entities isolated from synovial fluid and serum, 
were dissolved/diluted in lithium dodecyl sulphate (LDS) sample buffer (NuPage, Invitrogen, 
Carlsbad, CA, USA) containing reducing agent. Subsequently, samples were size-separated 
by SDS-PAGE and stained with coomassie brilliant blue (CBB), as indicated in Chapter 3, 
section 3.2.7.  
Fetuin-A-containing CPP-like entities isolated from synovial fluid were also dissolved 
in a non-denaturant and non-reducing sample buffer (10% v/v glycerol, 0.5 M Tris pH 6.7, 
0.5% w/v bromophenol blue) without boiling, for native polyacrylamide gel electrophoresis 
analysis. Samples were then size-separated on a 7.5 % w/v linear polyacrylamide gel and the 
protein profiles were revealed with CBB. 
Western blot analysis and immunodetection of total GRP was performed as described 
in Chapter 3, section 3.2.7. Fetuin-A was immunodetected using mouse monoclonal anti-
fetuin-A (1 µg/mL, Santa Cruz Biotechnology, Dallas, TX, USA). All WB analysis were 
repeated at least three times using different osteoarthritic cartilage samples and CPP-like 
entities obtained from the synovial fluid and serum of different individuals.  
 
5.2.5 Sample preparation for 2-DE  
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Freeze-dried aliquots of sturgeon GRP were treated with ReadyPrep 2-D Cleanup kit 
(Bio-Rad), to remove contaminating substances, and resuspended in a mixture of two 
rehydration/sample buffers from Bio-Rad, namely 66% v/v of ReadyPrep 2-D Starter Kit 
Rehydration/Sample buffer and 34% v/v of ReadyPrep 2-D Rehydration/Sample buffer 1. The 
previous mixture resulted in a final buffer composition (8 M urea, 1 M thiourea, 1.5% v/v 
CHAPS, 0.5% v/v ABS-14, 30 mM DTT, 15 mM Tris, 0.15% v/v Bio-Lyte 3/10 ampholyte, 
0.001% bromophenol) indicated for the solubilisation of highly insoluble proteins [231].  
Cartilage extracts and synovial fluid samples depleted from high abundant proteins 
using the ProteoMiner kit (Bio-Rad), were converted into low conductivity samples and/or 
cleaned from contaminating substances, using ReadyPrep 2-D Cleanup kit. The resulting 
pellets were dissolved in the mixture of Bio-Rad rehydration/sample buffers.  
Freeze-dried aliquots of human recombinant GRP  and bovine MGP, and serum 
isolated CPP-like entities, were directly resuspended/dissolved in the mixture of Bio-Rad 
rehydration/sample buffers.  
 
5.2.6 Two-dimensional gel electrophoresis  
 
Samples were loaded onto linear immobilized pH gradient (IPG) strips (11 cm, pH 3-
10, Bio-Rad). Rehydration proceeded passively overnight. The first dimension IEF was 
initially ran with a gradient until 150 V for 1h30, then constant 500 V for 1 h, following a 
gradient until 6000 V for 2 h and finally constant 6000 V for 3 h, with a limiting current of 50 
mA per strip. After IEF was complete, strips were sequentially equilibrated in equilibration 
buffer I (0.375 M Tris-HCl pH 8.8, 20% v/v glycerol, 2% w/v SDS, 6 M urea and 130 mM 
DTT) and equilibration buffer II (same as buffer I but DTT was replaced by 2.8% w/v 
iodoacetamide). The second dimension electrophoresis was conducted on 12 % Bis-Tris gels 
(Bio-Rad) at 180 V until the bromophenol blue reached the bottom of the gel. Proteins 
separated by analytic 2-DE were visualized with a specific CBB (G-250, Bio-Rad) compatible 
with MS analysis (34% v/v methanol, 17% w/v aluminium sulphate, 2% v/v phosphoric acid, 
1% w/v CBB). 
The first comparative 2-DE analysis performed between control and osteoarthritic 
serum-isolated fetuin-A-containing CPP-like entities was carried using 3 biological replicates 
(3 gels) of each condition. Based on the power analysis results obtained after comparative gel 
analysis, as described in section 5.2.8, a final comparative 2-DE analysis of the same samples 
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was performed using 5 biological replicates of each condition. Following the final 
comparative gel analysis and selection of differentially expressed spots to be picked, as 
indicated in section 5.2.8, two master gels were analysed by 2-DE, one containing sample 
from a control individual and other from an OA patient, and the selected spots were excised 
from both gels and stored in 0.5 mL tubes at – 20 °C, until further analysis. 
 
5.2.7 In silico protein sequence analysis 
 
Isoelectric point predictions of sturgeon and human GRP protein sequences were 
obtained using Compute pI/Mw tool available at Expasy portal, 
http://web.expasy.org/compute_pi.  
 
5.2.8 Comparative gel analysis 
 
Comparative gel analysis of fetuin-A-containing CPP-like entities isolated from 
control and osteoarthritic serum was initiated after gel scanning using a GS-800 Calibrated 
Imaging Densitometer (Bio-Rad). Progenesis SameSpots software (Nonlinear Dynamics, 
Quayside, UK) was subsequently used for spot detection, quantification, and matching. The 
intensities of the spots in each gel were compared and the differentially expressed spots 
between control and osteoarthritic conditions were highlighted. The initial comparative 2-DE 
analysis resulted in a power analysis suggesting the use of 4 biological replicates of each 
condition to obtain results with statistical significance. According to these indications, a final 
comparative gel analysis was performed and the differentially expressed spots between 
conditions, with statistical significance of P≤0.05 based on ANOVA P-value, were selected 
for spot picking.  
 
5.2.9 Protein identification by mass spectrometry and data analysis 
 
Two-dimensional electrophoresis gels of osteoarthritic cartilage extracts stained with 
CBB, obtained as described in section 5.2.2, were overlaid with corresponding 2-DE WB 
membranes of the same sample, with positive GRP immunoreactive signal. The matching 
protein strikes of the CBB gel with the WB signal were excised and sent to Instituto de 
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Tecnologia Química e Biológica (ITQB) (Mass Spectrometry Laboratory, Oeiras, Portugal) 
for protein sequencing and peptide analysis, as described in Chapter 3, section 3.2.9.  
The selected differentially expressed spots between control and osteoarthritic serum 
isolated CPP-like entities, excised from two master gels as indicated in section 5.2.6, were 
washed with water and acetonitrile, and lyophilized. Dried samples were sent to Life Sciences 
Research Institute VIB (University of Gent, Gent, Belgium) for protein sequencing by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), as described [232]. Briefly, spots 
were in gel-digested with 50 mM trypsin in 0.1 M NH4HCO3 overnight at 37 ᵒC to generate 
peptides. Peptide mixtures were transferred to MS compatible vials and analysed by LC-
MS/MS on an Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) with 
injected volumes of 6 µL. Protein identification using LC-MS/MS raw data was performed 
with Mascot Daemon software (Matrix science, Boston, MA, USA). Results of the database 
search were analysed using the Knime software program (http://www.knime.org/) and the 
main biological roles attributed to each identified protein were accessed at UniProt portal 
(http://www.uniprot.org/). 
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5.3 Results 
 
5.3.1 Proteomic analysis for the characterization of GRP in OA-
affected tissues and discovery of novel osteoarthritis biomarkers  
 
To clarify the potential of GRP as a biomarker for OA, the initial aim of this chapter 
was to evaluate the expression patterns of GRP between control and osteoarthritic conditions 
in cartilage tissues, and to identify and characterize GRP protein species present in each 
condition. Therefore, procedure optimization for the 2-DE analysis of cartilage extracts was 
conducted and among the tested protein extraction procedures (data not shown), the best 
results were obtained using Laemmli buffer. Accordingly, final osteoarthritic cartilage 
extracts for 2-DE were obtained using Laemmli buffer protein extraction followed by a clean-
up step, to lower the sample conductivity. CBB staining results evidenced low protein 
resolution and vertical striking (Fig. 5.1, CBB), probably indicative of the interference of 
collagen and proteoglycans species, in concordance with the known limitations of cartilage 2-
DE analysis [177,179]. Nevertheless, the detection of GRP by WB was performed using the 
CTerm-GRP antibody (Fig. 5.1, WB), and showed positive immunodetection in the form of 
two horizontal strikes (Fig. 5.1, WB) at acidic pI, with apparent molecular weights of 16 and 
18 kDa, similar to those observed on previous SDS-PAGE analysis (Chapter 3, section 3.3.4, 
Fig. 3.7). In addition to the poor protein resolution indicated by the CBB staining, the 
horizontal strikes of GRP immunodetection might be associated to different γ-carboxylation 
degrees of GRP protein forms present in the extract, that should represent a challenge to the 
IEF. In fact, isoelectric point predictions for human GRP using Compute pI/Mw available at 
Expasy portal indicate a pI of 5.05, however, γ-carboxylation post-translational modifications 
are not considered in prediction programs, thus, the observed pI of the strikes ranging from 3 
to 5 may indicate different γ-carboxylation degrees of GRP, that should result in different 
charged entities (Fig. 5.1, WB). Moreover, the faint signal obtained by WB in the 2-DE gels 
compared to previous WB results using SDS-PAGE (Chapter 3, section 3.3.4, Fig. 3.7) might 
indicate protein loss, suggesting poor protein solubilisation in the 2-DE buffer which also 
interferes with the IEF.  
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Fig. 5.1 – Two-dimensional gel electrophoresis (2-DE) map of human osteoarthritic articular 
cartilage extracts obtained with Laemmli buffer (CBB) and GRP immunodetection (WB). 
Articular cartilage extracts containing 175 µg of total protein were analysed by 2-DE and the 
protein profile revealed using coomassie brilliant blue (CBB) staining. Western blot (WB) 
results of the same extract in the same amounts of protein showed the immunodetection of 
GRP with CTerm-GRP antibody. Relevant molecular mass markers (kDa) and the pH 
gradient and orientation of the immobilized pH gradient (IPG) strips are indicated.  
 
In order to obtain visible spots with CBB staining in the areas matching GRP positive 
WB signals (Fig. 5.1, WB), 2-DE gels were loaded with double protein amounts, and the 
corresponding detected strikes were picked and sent to ITQB institute for protein analysis by 
LC-MS/MS. Although the analysis was focussed on GRP identification and characterization, 
LC-MS/MS results were only able to identify a vesicle transport protein and tyrosine-rich 
acidic matrix protein representing the highest score proteins for the 16 kDa and the 18 kDa 
bands, respectively, and no peptides matching with GRP were found.  
To further understand the observed constraints of GRP in the 2-DE analysis of 
cartilage extracts, aliquots of reverse phase-high performance liquid chromatography (RP-
HPLC) purified sturgeon GRP and human recombinant GRP, obtained within the scope of 
parallel projects [15] and corresponding to fully γ-carboxylated and non-carboxylated GRP 
forms, respectively, were analysed by 2-DE. Coomassie brilliant blue staining revealed a 
substantial protein loss of sturgeon GRP, when compared to half of the amount of protein 
analysed by SDS-PAGE, and poor protein focusing  with an apparent pI of 3.5-4 (Fig. 5.2, A). 
The protein loss of sturgeon GRP in the 2-DE gel in comparison with SDS-PAGE gels was 
associated to poor buffer solubilisation, most likely due to the lack of SDS in the 2-DE 
buffers, in which GRP is highly soluble. The low pI of γ-carboxylated sturgeon GRP, when 
compared to the isoelectric point predictions of 5.09 for sturgeon noncarboxylated protein 
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form, further supports the hypothesis that detected GRP strikes located at acidic pI in the 
osteoarthritic cartilage extracts (Fig. 5.1, WB), could represent carboxylated GRP forms. 
Non-carboxylated GRP was detected as a defined spot with an apparent pI of 5.5-6 (Fig. 5.2, 
B), also different from the predicted pI for human GRP, in this case associated to the 33 aa 
His-V5 tag, present in this recombinant protein [15]. The CBB staining of human 
recombinant protein, unlike sturgeon GRP, did not reveal a high protein loss (Fig. 5.2, B), 
that might be related with the lack of Gla residues. Trying to improve sturgeon GRP 2-DE 
analysis, the effect of sample clean-up was evaluated (Fig. 5.2, A), and active rehydration and 
cup-loading rehydration techniques were also tested (results not shown), yet without further 
improvements on the final results.  
To test the behaviour of another related and highly insoluble γ-carboxylated protein on 
2-DE, purified bovine MGP obtained within the scope of a parallel project [16] was analysed 
(Fig. 5.2, C). Gel results also showed a considering protein striking effect, indicative of the 
existence of multiple unfocused spots, possibly due to different MGP γ-carboxylated forms, 
and poor protein solubilisation in the 2-DE buffers.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Fig. 5.2 – Two-dimensional gel electrophoresis (2-DE) of purified sturgeon GRP (A), human 
recombinant GRP (B) and bovine MGP (C) obtained by reverse phase-high performance 
liquid chromatography (RP-HPLC) [15,16]. Left panels contain the protein profile of 5 µg of 
purified fractions of sturgeon GRP (A), human recombinant GRP (B) and bovine MGP (C) 
revealed by SDS-PAGE. Right panels show the 2-DE analysis of 10 µg of sturgeon GRP 
fractions after a clean-up step (A), and 5 µg and 10 µg, respectively, of human recombinant 
GRP fractions (B) and bovine MGP fractions (C), without a clean-up. Gels were stained with 
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coomassie brilliant blue (CBB). Relevant molecular mass markers (kDa) and the pH gradient 
and orientation of the used immobilized pH gradient (IPG) strip are indicated. 
 
The obtained 2-DE results using the available purified protein standards combined 
with previous cartilage extracts analysis further evidenced that a 2-DE approach was probably 
not adequate for GRP analysis, hampering the initial aim of analysing GRP content between 
control and osteoarthritic conditions using 2-DE. 
In addition to the analytical limitations described, the collection of an adequate 
number of control cartilage samples suitable to perform comparative 2-DE analysis was not 
achieved, as described in Chapter 2, hindering the initial goal of searching for novel OA 
biomarkers using cartilage tissue samples. To overcame this situation, attention was focused 
on biological fluids, the recipients of structural molecules and fragments derived from 
cartilage, bone and the synovial membrane [176]. Biological fluids are more easily available 
in terms of sampling and considerably more simple to analyse by 2-DE than joint tissues 
[176].   
The synovial fluid has been shown to be the most valuable biological fluid to assess 
joint tissue metabolism [179], thus the optimization of procedures for the analysis of 
osteoarthritic synovial fluid by 2-DE was performed. Final osteoarthritic synovial fluid 
samples for 2-DE analysis were obtained using an affinity kit for the depletion of high 
abundant proteins, such as albumin and immunoglobulins, followed by a clean-up step to 
eliminate kit reagents that might interfere with the IEF. Resulting 2-DE gels stained with 
CBB (Fig. 5.3) showed a good representation of lower abundant proteins, that were more 
difficult to detected before high abundant protein depletion (data not shown), and good 
protein resolution. Although the analysis of synovial fluid by 2-DE did not apparently 
implicate technical challenges, the collection of control synovial fluid samples throughout the 
project  was, once again, a severe constraint (Chapter 2), hampering the performance of 
comparative analysis using this fluid.  
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Fig. 5.3 – Two-dimensional gel electrophoresis (2-DE) map of human osteoarthritic synovial 
fluid after sample depletion of high abundant proteins. Left panel (SDS-PAGE) shows the 
SDS-PAGE protein profile of direct osteoarthritic synovial fluid samples (1 µl, SF) and 
samples depleted from high abundant proteins using the Bio-Rad ProteoMiner kit (60 µg, 
dSF). Right panel (2-DE, dSF), shows the 2-DE analysis of depleted from high abundant 
proteins osteoarthritic synovial fluid after a clean-up step (150 µg). Gels were stained with 
coomassie brilliant blue (CBB). Relevant molecular mass markers (kDa) and the pH gradient 
and orientation of the used immobilized pH gradient (IPG) strip are indicated.  
 
5.3.2 Characterization of fetuin-A-containing CPP-like entities 
isolated from serum and synovial fluid  
 
Serum samples also contain the diluted degradation products present in the synovial 
fluid and represent a more accessible biospecimen, thus differential expression patterns of 
proteins in OA are often focussed on serum proteomic analyses using 2-DE approaches 
[177,179]. Also, since the occurrence of pathological mineralization is a common feature of 
OA [48], calcification inhibitors such as fetuin-A-containing calciprotein particles (CPP) 
[57,58] may represent interesting candidates as OA biomarkers. Therefore, control and 
osteoarthritic serum preparation for subsequent 2-DE analysis was performed following 
previously described procedures for the isolation of serum CPP [228,230]. In addition, 
considering that fetuin-A-containing CPP were also described to exist in the synovial fluid 
[229], a CPP-like entity derived from osteoarthritic synovial fluid was also analysed. The 
protein profile of each sample obtained at 16.000 x g was determined by SDS-PAGE, 
revealing some similarities between the three samples, namely the three main protein bands 
detected in each protein profile, two of them located between 50 and 70 kDa of apparent 
molecular weight, and the remaining located around 25 kDa (Fig. 5.4, CBB). Since fetuin-A 
is a well described and crucial component of CPP [229,230], its presence in the isolated CPP-
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like entities was confirmed by WB, showing  positive fetuin-A immunodetection in all 
samples (Fig. 5.4, WB).  
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 5.4 – Protein profiles of fetuin-A-containing calciprotein particles (CPP)-like entities 
isolated from control and osteoarthritic serum and osteoarthritic synovial fluid, and positive 
fetuin-A immunodetection in the same samples. Left panel, shows the SDS-PAGE protein 
profiles stained with coomassie brilliant blue (CBB) of 50 µg of fetuin-A-containing CPP-like 
entities isolated from control (C) and osteoarthritic (OA) serum (S) and osteoarthritic synovial 
fluid (SF). Right panel, reveals the immunodetection of fetuin-A by western blot (WB) in the 
previous samples using the same protein amounts. Relevant molecular mass markers (kDa) 
are indicated. 
 
Fetuin-A-containing CPP-like entities isolated from osteoarthritic synovial fluid were 
further characterized using native polyacrylamide gel electrophoresis (Fig. 5.5). This 
approach allows protein separation in their native/folded conformation and could therefore be 
used to help analysing if the previous visualized entities on SDS-PAGE (Fig. 5.4, CBB) were 
part of a complex. As expected, protein solubilisation in the non-denaturant and non-reducing 
sample buffer was limited compared with the solubilisation in SDS-containing sample buffer 
(Fig. 5.5), yet a differential pattern was observed between the two gel conditions, indicative 
of the presence of complexes of proteins in the native gel (Fig. 5.5, Native).  
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Fig. 5.5 – Protein profiles of fetuin-A-containing calciprotein particles (CPP)-like entities 
isolated from osteoarthritic synovial fluid (SF) on SDS-PAGE and native gels. Left panel, 
shows the SDS-PAGE protein profile (50 µg) and right panel the native protein profile (25 
µg, corresponding to the maximum volume that could be loaded on the well) of the CPP-like 
entities stained with coomassie brilliant blue (CBB). Gradient gels of 4-12% acrylamide were 
used for the SDS-PAGE while linear gels of 7.5% acrylamide for the native gel. Relevant 
molecular mass markers (kDa) are indicated. 
 
Serum-derived fetuin-A-containing CPP-like entities were further analysed regarding 
their calcium content. Calcium quantifications were performed in a total of 16 serum samples, 
8 of each condition (subject information of the used samples is described in Chapter 2, 
sections 2.3.1 and 2.4.1, Tables 2.I,  2.II and 2.III), and revealed higher calcium levels in the 
CPP-like particles isolated from osteoarthritic samples (Fig. 5.6).  
 
 
 
 
 
 
 
 
 
Fig. 5.6 – Calcium levels of CPP-like particles isolated from serum of control (C) and   
osteoarthritic patients (OA). Pellets were obtained after centrifugation (16.000 x g) of 1.5 mL 
of original serum and calcium was quantified using a Randox colorimetric kit (Calcium assay 
CA-590). Data is presented as mean (n = 8) ± standard error. Nonpaired t-tests were used. 
Statistical significance was defined as P≤0.05 (*). 
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The combined results obtained in this section suggest the existence of fetuin-A-
containing CPP-like entities in both control and osteoarthritic serum and osteoarthritic 
synovial fluid, and unveiling the composition of the former complexes might represent a 
novel approach to study the dysregulated mineralization occurring in OA and potentially 
uncover new disease biomarkers.  
 
5.3.3 Differentially expressed proteins between control and 
osteoarthritic serum fetuin-A-containing CPP-like entities  
 
To further access the potential use of CPP-like entities as a source of OA biomarkers, 
and further explore its protein content, comparative 2-DE was performed between control and 
osteoarthritic derived samples. A preliminary comparative study was conducted using 3 
biological replicates of each condition. SameSpots software gel analysis revealed the 
existence of differentially expressed spots between control and osteoarthritic samples, and the 
obtained power analysis estimated the use of 4 biological replicates of each condition in the 
final analysis, to achieve statistical significant data. Accordingly, final comparative gel 
analysis was performed using 5 replicates of each condition (subject clinical information for 
each sample selected for this study is described in Chapter 2, sections 2.3.1 and 2.4.1, Tables 
2.I, 2.II and 2.III) and 19 differentially expressed spots between the two conditions were 
detected using the previous software (Fig. 5.7).    
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Fig. 5.7 – Differentially expressed proteins between control and osteoarthritic serum isolated 
CPP-like entities. Comparative two-dimensional gel electrophoresis (2-DE) analysis was 
performed in control and osteoarthritic samples using 130 µg of total protein. Differentially 
expressed spots attributed by SameSpots software are evidenced with numbering in a 
representative gel of a control sample, stained with coomassie brilliant blue (CBB). Relevant 
molecular mass markers (kDa) are indicated as well as the pH gradient and orientation of the 
used immobilized pH gradient (IPG) strip. 
 
After final gel analysis, two master gels were run, with the same amounts of total 
protein previously used for the comparative approach, containing a control and an 
osteoarthritic sample, respectively. The 19 differentially expressed spots between conditions 
were excised from both gels, in gel digested with trypsin and further analysed by LC-MS/MS, 
at Life Sciences Research Institute VIB (University of Gent, Gent, Belgium).  
 
5.3.4 Identification of differentially expressed proteins in 
osteoarthritis associated to CPP-like entities  
 
All the 19 excised spots from the two master gels analysed by LC-MS/MS, resulted in 
positive protein identification (Table 5.I). The majority of the identified proteins was found 
upregulated in control conditions, and only two, cytosol aminopeptidase (AMPL) and 
immunoglobulin γ 1 chain C region (IGHG1) were found upregulated associated to OA 
(Table 5.I). 
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Table 5.I – Identification of differentially expressed proteins between control and osteoarthritic serum 
isolated fetuin-A-containing CPP-like entities 
 
The identified proteins were classified into six groups based on their known biological 
functions (Fig. 5.8). Most of the entities were involved in enzyme catalysis, cell adhesion, 
defence or cell motility processes; the remaining entities were associated to transport and 
signal transducing functions (Fig. 5.8).  
 
 
 
 
 
 
 
 
 
Spot 
 
ANOV
A (P) 
 
Fold 
 
Accession 
Number 
 
Protein 
Average Normalized 
volume 
  Control OA 
1657 0,005 9,4 P08514 Integrin α-IIb (ITA2B)    71109 7603 
198 0,006 2,7 P14923 Cytosol aminopeptidase (AMPL)  10740 29250 
1656 0,006 5,8 P05155 Inter-α-trypsin inhibitor heavy chain H4 
(ITIH4) 
67720 11670 
1652 0,006 5,4 Q9Y490 Vinculin (VINC) 119900 22320 
1653 0,008 6,0 Q9NZT1 Serotransferrin (TRFE) 148600 24940 
426 0,011 3,1 P61626 Talin 1 (TLN1) 39730 12750 
1666 0,014 5,6 P00738 Actin cytoplasmic 1 (ACTB) 1144000 203700 
1109 0,015 5,1 P63104 Tropomyosin α 4 chain (TPM4) 117500 23010 
147 0,015 2,0 P06280 von Willebrand factor D and EGF 
domain-containing protein (VWDE) 
41930 20700 
704 0,017 2,8 P01871 Immunoglobulin mu chain C region 
(IGHM) 
58090 20960 
998 0,025 3,3 P60709 Leukocyte elastase inhibitor (ILEU) 25950 7980 
1680 0,030 3,0 P23528 Cofilin 1 (COF1) 122800 40790 
397 0,033 3,7 P07355 Plakophilin 1 (PKP1) 236400 62360 
1685 0,033 2,0 O75083 WD repeat-containing protein 1 
(WDR1) 
63510 31670 
1134 0,036 4,1 P31946 Cathepsin D (CATD) 193400 47180 
914 0,036 2,5 Q8N4S0 α-galactosidase A (AGAL) 26820 10870 
624 0,044 1,9 P15924 Junction plakoglobin (PLAK) 26810 13940 
1669 0,049 3,6 P06727 Apolipoprotein A-IV (APOA4) 188600 52980 
733 0,049 4,0 Q86YZ3 Immunoglobulin γ 1 chain C region 
(IGHG1) 
58720 237400 
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Fig. 5.8 – Differentially expressed proteins identified between control and osteoarthritic 
serum samples using second-dimension gel electrophoresis (2-DE) were distributed according 
to known associated functions. ITA2B, VINC, TLN1, PKP1, PLAK and VWDE are related to 
cell adhesion; WDR1 to signal transduction; IGHM, IGHG1 to immune defense; ITIH4, 
AMPL, ILEU, CATD, AGAL to enzyme catalysis; TRFE, APOA4 to transport and ACTB, 
TPM4, COF1 to cell motility. 
 
Among the identified differentially expressed proteins, inter-α-trypsin inhibitor heavy 
chain H4 (ITIH4), serotransferrin (TRFE), actin cytoplasmic 1/β-actin (ACTB) and 
apolipoprotein A-IV (APOA4), had been previously associated to serum fetuin-A-containing 
CPP [228,229], obtained using similar procedures such as those used in this chapter. 
Moreover, APOA4 [233], leukocyte elastase inhibitor/serpin B1 (ILEU) [234] and cathepsin 
D (CATD) [235], had already been associated to OA, although the last two not associated to 
CPP, further supporting their suitability as OA biomarkers.  
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5.4 Discussion 
 
The main aim of this chapter was the identification of novel candidate OA biomarkers 
using 2-DE for a potential use in diagnose and monitoring of OA treatments, with a particular 
focus on GRP. The 2-DE analysis of osteoarthritic cartilage extracts and purified protein 
standards revealed that the study of GRP using this approach would be a highly challenging 
task, yet a set of promising candidate biomarkers for OA was identified.  
Cartilage tissues can provide a direct insight into the pathogenesis of OA, representing 
the best biospecimen for early biomarkers discovery [81]. Therefore, to clarify the potential of 
GRP as a biomarker for OA, a 2-DE approach was used to evaluate the differential expression 
pattern of GRP between control and osteoarthritic cartilage tissues. The 2-DE analysis was 
also aimed at favouring GRP protein identification compared to previous performed SDS-
PAGE (Chapter 3), allowing GRP separation from other entities by molecular weight and pI. 
This approach could represent an alternative to further obtain molecular data for GRP 
identification and characterization of GRP forms existing between control and osteoarthritic 
conditions. However, GRP 2-DE analysis revealed to be limited by protein loss and 
ineffective IEF. Optimal protein solubilisation is crucial for 2-DE and in fact, the analysis of 
insoluble proteins, such as membrane proteins, in common 2-DE buffers, represents a major 
technical challenge for this approach [236]. To increase protein solubility, detergents with a 
linear alkyl tail such as the zwitterionic ASB-14 are recommended together with the 
combination of the nonionic chaotropes urea and thiourea, which ease the solubilisation 
process by altering the ionic bonds strength and facilitating protein unfolding [231]. However, 
the use of such buffer composition was not efficient for the 2-DE analysis of the highly 
insoluble native GRP and MGP proteins. Also, the analysed cartilage osteoarthritic extract 
was known to contain both carboxylated and undercarboxylated GRP forms (Chapter 3, 
section 3.3.4, Fig. 3.7) and the presence of several GRP protein forms differing on their γ-
carboxylation status, representing entities with similar molecular weights and pIs, may have 
difficult the IEF. Considering the encountered limitations it was not possible to explore GRP 
potential as a biomarker for OA using 2-DE and it was not surprising that no peptides 
matching GRP were found when attempting protein identification from the 2-DE gels. 
Moreover, limitations on GRP protein identification might not only be associated to low 
protein recovery in the 2-DE gels, but also related to the generation of peptides suitable for 
fragmentation and known difficulties on the identification of Gla residues [200]. Vitamin K-
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dependent proteins may undergo neutral loss of CO2 from the γ-carboxyl carbon during 
ionization by matrix-assisted laser desorption/ionization (MALDI) or following collision-
induced dissociation tandem MS/MS which may difficult the identification of Gla residues 
[200]. To further understand GRP limitations on MS analysis, digestion experiments using 
carboxylated and undercarboxylated GRP purified standards were performed in the laboratory 
(unpublished results), strongly indicating a very low digestion efficiency of both protein 
forms with different proteases, including trypsin. This problem was highly aggravated in the 
case of carboxylated GRP. In fact, the recent identification of GRP by LC-MS/MS was 
achieved from SDS-PAGE gels but only after using a double trypsin digestion protocol [16].  
Subsequent studies focused on the identification of other possible biomarkers for OA 
using 2-DE. The ideal biospecimens to use for such purpose would be articular cartilage 
tissue or synovial fluid samples, which best reflect the molecular processes occurring in OA 
[177,179]. However, an adequate number of control samples to perform a comparative 
analysis was not achieved for any of the former biospecimens during the time course of this 
project. Therefore, serum samples containing the diluted degradation products present in the 
synovial fluid [179] and easily obtained from both control individuals and OA patients, were 
used to search for candidate OA biomarkers. Fetuin-A-containing CPP are believed to be 
formed in situations where bone formation and resorption are imbalanced [59] and 
hypothesised to be associated with ectopic calcification situations [58,229], two features of 
OA [48,121]. In this line, serum fetuin-A-containing CPP-like entities were used for a 
comparative analysis to investigate novel associations between these entities and OA.  
Nineteen differentially expressed proteins in OA were identified associated to serum 
CPP-like entities, which were classified into six groups. Most attention was given to proteins 
grouped within categories previously associated to other fetuin-A-containing serum CPP 
entities, namely immune defence, enzyme catalysis and transport [229]. Opsonins presence in 
CPP have been proposed to indicate the complexes propensity to be rapidly phagocytised by 
the reticuloendothelial system, only accumulating in the fluids in particular situations, such as 
pathological conditions [229]. Accordingly, the identified immunoglobulins in this study, as 
opsonins, may be associated with phagocytosis enhancing. In the enzyme catalysis group 
ILEU, CATD, AMPL and ITIH4, all except AMPL downregulated in osteoarthritic pellets, 
were highlighted. ILEU and CATD had been previously associated to OA although not 
related to CPP [234,235]. Osteoarthritic serum low levels of CATD were related to decreased 
chondrocyte numbers in OA [235], while ILEU decreased urine concentrations suggested as 
biomarker for OA [234]. Serine proteases are described to contribute for cartilage destruction 
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[237], thus, the lack of protease inhibitors such as ILEU [238] or ITIH4, previously associated 
to serum derived-CPP [229], may contribute for OA progression. Interestingly, AMPL 
upregulation in serum has been associated to high lymphocyte infiltration situations [239], 
which frequently occurs in osteoarthritic synovial membranes [87]. The identification of the 
transporters TRFE and APOA4, downregulated in osteoarthritic pellets, was also interesting 
since they had been previously associated to serum derived-CPP [229]. The iron transporter 
TRFE may be associated with the induction of iron-dependent processes such as the 
activation of immune cells [240]. Also, TRFE was previously described to be less 
accumulated in cases of inflammatory responses [240]. The observation that CPP entities can 
interact with apolipoproteins suggests that these complexes may influence lipid transport 
pathways [229]. Notably, impairments in lipid transport resulting in altered levels of 
adipokines contribute to OA development by inducing the expression of proinflammatory 
factors as well as degradative enzymes [241], and in fact, low serum levels of APOA4 have 
been related to OA [233].  
The identification of immune regulators, protease inhibitors, and lipid/molecule 
carriers, some of which previously associated to OA, and the immunodetection of the 
calcification inhibitor fetuin-A in the CPP-like entities, suggests a possible association of 
these complexes with osteoarthritic features, namely pathological calcification and 
inflammatory processes. The higher levels of mineral associated to the osteoarthritic entities, 
like observed in CKD patients in comparison with control samples [228], also might indicate 
an association with OA regarding extraosseous calcification stress, as suggested for CKD 
patients. Yet, no reports were identified associating higher levels of calcium or mineral to 
osteoarthritic serum, although the presence of calcium crystals is well known in osteoarthritic 
synovial fluid [112,140]. Nevertheless, it should be referred that although the presented 
results strongly indicate the existence of a CPP entity that can be differentially associated to 
OA, additional characterization of the analysed samples is necessary. Cellular components 
such as platelets and/or microparticles may co-sediment at the low centrifugation speed used 
for CPP isolation [228], contributing to a final heterogeneous mixture. Indeed, the cellular 
component ACTB identified in the present study and previously associated to CPP [228,229], 
was suggested to sediment at this centrifugal force but not to be part of the complex [228]. 
Also, extracellular vesicles (EVs), capable of efficiently nucleate mineral and known  key 
players in the initiation of physiological and pathological calcification [242,243], may also 
sediment in serum at such centrifugation speed [244].  
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Overall, this study contributed for the identification of candidate OA biomarkers that 
should now be further validated and tested in earlier stages of the disease, to verify their 
potential as early disease markers. The protein and mineral content associated to the CPP-like 
entities suggests possible relations of the complex with OA, regarding ectopic calcification 
and inflammatory processes, thus further work should be performed to elucidate these 
possible associations.  
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6. General conclusions and future perspectives  
 
 During the present work new data was collected associating for the first time Gla-rich 
protein (GRP), the latest discovered vitamin K-dependent protein (VKDP), with the prevalent 
form of degenerative joint disorders, osteoarthritis (OA). Osteoarthritis is believed to onset 
after articular cartilage damage, accompanied by tissue inflammation, abnormal bone 
formation and extracellular matrix (ECM) mineralization [96,99,100]. Also, OA may be a 
silent disorder for many years before current diagnostic criteria can detect it, allowing 
irreversible articular cartilage damage to occur, for which there are no effective disease 
modifying drugs available [81,96]. This multifactorial disease is still poorly understood and 
additional knowledge is necessary to further uncover pathophysiological mechanisms 
triggering OA development, as well as the molecular factors and pathways involved in the 
complexity of pathological processes leading to OA progression [96,101]. Additionally, it is 
commonly accepted that the discovery of reliable molecular targets and biomarkers benefiting 
OA management are needed. Gla-rich protein was previously shown to accumulate in mouse 
and sturgeon cartilage [54,74,75], and at sites of skin and vascular calcification in human 
[14,15]. Moreover, GRP was proposed as a negative regulator of osteogenesis [74,75]. In this 
line, the main objective of this project was to investigate the possible involvement of GRP 
with OA development. Also, we aimed to identify potential OA biomarkers, especially 
focusing in GRP analysis.  
 To achieve our aims, a well characterized human biobank was collected during the 
project to study OA. This biobank comprised samples of knee articular cartilage, subchondral 
bone, synovial membrane, synovial fluid, and blood, from knee OA patients and individuals 
with no history of joint disorders. The number and amounts of biospecimens collected from 
OA patients is now considerable, representing an important achievement; however, the 
collection of control samples was not equally effective. Yet, the availability of this biobank 
was crucial for the studies performed in this project, which allowed the association of GRP 
with the pathological mineralization and inflammation occurring in OA, and the identification 
of candidate OA biomarkers. A chondrocyte and synoviocyte cell system was also developed 
within the scope of this project to study GRP association with mineralization and 
inflammatory mechanisms, complementing the information retrieved from experiments using 
in vivo samples from the biobank. Both the biobank and in vitro system are presently 
available for future studies aiming at further investigating OA-associated molecular features. 
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GRP association with OA was initially studied at gene expression level using 
cartilage, synovial membrane and bone tissue samples. Four alternatively spliced transcripts 
of GRP gene, GRP-F1, F2, F3, and F4, were previously identified in mice and zebrafish 
[72,73,76]. Here, two novel GRP splice variants were unveiled in human, GRP-F5 and F6, 
characterized by the loss of carboxylation and secretion motifs, whereas GRP-F2, F3 and F4 
were not detected. GRP-F1, corresponding to the full length protein, was shown to be the 
most relevant variant expressed in cartilage and synovial membrane tissues, suggesting that 
associations existing between GRP and OA should mainly reflect the contribution of this 
transcript. GRP-F1 was also found upregulated in osteoarthritic cartilage comparing to control 
tissues. In concordance, comparative analysis of GRP patterning at transcriptional level using 
the developed chondrocyte and synoviocyte cell system revealed GRP upregulation in OA-
derived cells. GRP association with OA was further explored at translational level using tissue 
and body fluid samples and conformation-specific antibodies against carboxylated (cGRP) 
and undercarboxylated (ucGRP) GRP. Although both protein forms were immunodetected in 
all analysed samples and accumulated at sites of ectopic calcification, ucGRP was shown to 
be the prevalent form accumulated in osteoarthritic cartilage and synovial membrane. 
Similarly, matrix Gla protein undercarboxylated form (ucMGP) was found primarily 
accumulated in osteoarthritic cartilage. Interestingly, comparative gene expression studies 
using the developed in vitro cell system pointed for a reduced γ-carboxylation capacity of 
OA-derived cells, with decreased expression of genes known to be involved in the γ-
carboxylation machinery. Altogether, our results suggest that the impairment of VKDPs γ-
carboxylation may be associated with OA. This hypothesis is in agreement with a previous 
study where the absence of carboxylated matrix Gla protein (MGP) in osteoarthritic 
chondrocytes and chondrocyte-derived matrix vesicles was suggested to be an important 
mechanism for the increased mineralization observed in osteoarthritic cartilage [92]. The 
same study also reported the association of a reduced γ-carboxylase activity in osteoarthritic 
chondrocytes. Interestingly, our immunohistochemistry results revealed that GRP 
accumulation was not restricted to sites of ectopic calcification in osteoarthritic synovial 
membranes, being also accumulated in the lining layer of these tissues and suggesting a role 
in other cell mediated processes. Moreover, GRP was co-localized with sites of abnormal 
infiltration of inflammatory cells in consecutive tissue sections of osteoarthritic synovial 
membranes. The involvement of GRP with OA mineralization and possible association with 
inflammatory events was further studied using the developed in vitro cell system. GRP was 
shown to be upregulated during induced mineralization and inflammation, associated to cell 
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differentiation towards ECM mineralization and inflammatory responses, in both 
chondrocytes and synoviocytes. Importantly, GRP biological functions in OA were 
highlighted through the inhibition of ECM mineralization and decreased inflammatory 
response, following GRP supplementation. While γ-carboxylation was required for GRP anti-
mineralization function, like previously shown in the cardiovascular system [16], GRP or 
GRP-coated basic calcium phosphate (BCP) crystals-mediated anti-inflammatory effect was 
independent of protein γ-carboxylation status, suggesting additional functions for ucGRP. The 
mechanism behind cGRP calcification inhibition capacity is believed to be related with its 
ability to alter calcium availability in the local environment or its capacity to change the 
dynamics of crystal growth [16]. However, the mechanisms behind GRP-mediated anti-
inflammatory effect are currently unclear. In the case of GRP-coated BCP crystals, it is 
possible that GRP binding may interfere with crystal-cell membrane interactions, modulating 
the production of proinflammatory mediators. In fact, BCP-mediated inflammation is believed 
to rely on direct physical contact [140], and it is postulated that proteins and other entities 
bound to these crystals affect their ability to initiate inflammation [100]. Thus, GRP binding 
to crystals may not only be related with its ability to inhibit ectopic calcification events, but 
also to crystal-induced inflammatory responses. Interestingly, fetuin-A-containing 
calciprotein particles (CPP), known for their role in the prevention of pathological 
mineralization, were reported to decrease cytokine production in macrophages compared with 
naked hydroxyapatite crystals [58]. Also, serum-derived CPP have been shown to produce a 
higher protective effect than synthetic CPP in macrophage activation [58]. This protective 
effect most possibly reflects the inhibitory activity of other serum components, such as GRP. 
Notably, calcification inhibitors other than fetuin-A have been associated to CPP, including 
MGP [226,229], indicating that GRP might also be part of such complex. In fact, an 
association between GRP, MGP and fetuin-A was recently shown at sites of aortic valves 
calcification and GRP calcification inhibitory function was proposed to occur constitutively 
via this potent inhibitory system [16]. CPP could function as a chaperone to carry the highly 
insoluble GRP through circulation and GRP association to CPP might be related with this 
complex suggested roles as a pathological calcification and inflammatory inhibitor [58]. 
Accordingly, GRP possible association with these complexes should be further investigated. 
Our preliminary results also point for an association between MGP and inflammatory 
processes in OA. In concordance, a previous study suggested that ucMGP was a potential 
joint inflammatory marker in arthritis patients [95]. Overall, our data suggests that the 
increased expression of VKDPs, like GRP and MGP, in the context of OA where cell 
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hypertrophic differentiation and ECM calcification occur, might function to counteract 
calcification. Yet, system overload may lead to impaired γ-carboxylation capacity resulting in 
increased levels of ucGRP and ucMGP. Undercarboxylated GRP might contribute to control 
the levels of inflammatory mediators through still unknown mechanisms, thereby protecting 
articular joints from damage. 
The final part of this project focused on the investigation of candidate OA biomarkers, 
for a potential use in diagnose and monitoring of disease treatments, with a particular interest 
on GRP. Since classical two-dimension gel electrophoresis (2-DE) proteomic analysis 
revealed to be inadequate for the study of GRP, alternative OA biomarkers were searched 
within CPP-like entities derived from serum samples. The performed 2-DE comparative 
analysis identified 19 differentially expressed proteins between control and osteoarthritic 
conditions. Some of these entities had been previously associated to OA, representing the 
most relevant candidate biomarkers. Moreover, the identification of immune regulators, 
protease inhibitors and lipid/molecule carriers, and the immunodetection of fetuin-A in the 
CPP-like entities, strengthens the hypothesis of a possible association of CPP with 
osteoarthritic pathological calcification and inflammation.  
Further characterization of GRP anti-mineralization and putative anti-inflammatory 
activity, the molecular pathways involved, and correlation with its γ-carboxylation status, is 
now fundamental to better understand osteoarthritic pathological calcification and 
inflammatory processes. One of our future perspectives is to further study VKDPs γ-
carboxylation impairments associated with OA. Such feature may be originated by vitamin 
K1 and K2 deficiencies, which in fact have been related with OA. Subclinical vitamin K 
levels were associated with increased risk of knee OA development [82-84] and vitamin K2 
was hypothesized to affect bone turnover [85]. Also, vitamin K has been proposed to exert a 
protective effect against inflammatory events and oxidative stress [24-26,28,29]. Accordingly, 
vitamin K should be considered a potential therapeutic/prophylactic agent for OA, and its 
nutraceutical value should be further evaluated. Studies aiming to relate vitamin K1/K2 
supplementation with GRP and MGP γ-carboxylation status and OA, can be conducted using 
the available cell model and conformation-specific antibodies, although we are aware that in 
vitro cell systems may have limited γ-carboxylation capacity [200], and results should be 
carefully interpreted. The availability of a system for the immunodetection of GRP in serum 
should open novel perspectives to establish a relationship between levels of circulating 
c/ucGRP and the degree of ectopic calcification and inflammatory processes in OA. For that, 
the development of a specific GRP enzyme-linked immunosorbent assay (ELISA), able to 
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distinguish different degrees of γ-carboxylation, is currently under development. 
Macrophages are one of the most abundant cellular type infiltrating the synovial membrane 
upon OA, generating a broad spectrum of cytokines and immune factors with roles in OA 
development and progression [130]. To further explore GRP association with the 
inflammatory processes occurring in OA we can study the effect of GRP supplementation in 
co-cultures of macrophages with control chondrocytes or synoviocytes, accounting with a 
macrophage-derived THP-1 cell line available at the laboratory. Nevertheless, we may be 
limited by the short time-frames in which differentiated monocytic cells can survive in 
cultures [245], thus an alternative approach is the stimulation of the currently available cell 
system with conditioned media from the macrophage-derived THP-1 cell line. To collect new 
knowledge relating GRP with both mineralization and inflammatory events occurring in OA, 
a three-dimensional (3D) model, where cells can secret and build typical in vivo components 
[156,157], comprising co-cultures of control synoviocytes and monocytic cells over healthy 
cartilage explants, could be developed. Such system may dynamically mimic OA processes of 
calcification and cartilage degradation, and respective analysis under control and mineralizing 
conditions should allow the collection of new data relating GRP with two of the most relevant 
pathological features associated to OA. To explore the possible association of GRP with CPP, 
we intend to additionally characterize the serum-derived CPP-like entities obtained in this 
work, focusing on GRP, MGP and fetuin-A identification. Following, to access new data 
relative to CPP association with calcification and inflammatory mechanisms in OA, the 
characterized complexes may be added to the available in vitro cell system conditioned media 
under mineralizing or inflammatory conditions. Regarding the identified candidate 
biomarkers from the serum-derived CPP-like entities, these should now be validated using 
western blot or ELISA approaches and subsequently, their expression in earlier stages of the 
disease should be analysed to verify if they are suitable as early OA markers. The origin of 
the identified proteins should also be further clarified since although most of them are likely 
to be components of CPP, the analysed samples may represent an heterogeneous mixture 
[228,244]. Further morphological characterization can be accomplished in the isolated 
samples using scanning and transmission electron microscopy. Our efforts to clarify the 
potential of GRP as a biomarker for OA using comparative proteomic approaches and serum 
samples will continue, accounting with the recent knowledge acquired from GRP positive 
identification from calcified aortic valves extracts [16]. We intend to use SDS-PAGE gels 
instead of 2-DE to improve GRP solubilisation, use a double trypsin digestion for better 
peptide fragmentation, and mass spectrometry by MALDI-time-of-flight (TOF/TOF), 
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followed by MS/MS data acquisition, which already proved to be effective for GRP positive 
identification [16]. Ultimately, the study of extracellular vesicles (EVs) association with OA 
may be one of our future approaches, since we strongly believe that these entities might be 
related with the calcification and inflammatory processes described in OA. EVs are 
considered an emerging area in clinical diagnosis and therapeutics [243], they have a known 
role on mineralization [41,46] and were shown to be released from synoviocytes and 
macrophages, with increasing levels upon calcification or inflammatory stimuli [246,247]. 
Moreover, GRP, MGP and fetuin-A were recently detected inside EVs isolated from the 
media of cultured aortic segments, and GRP downregulation throughout time in EVs released 
after a calcifying stimulus suggested that it might act as a blocker of mineral growth and 
nucleation in EVs in healthy situations [16]. GRP was also recently detected inside EVs 
derived from chondrocytes and macrophages culture media (laboratory unpublished data). To 
study a possible association between GRP and EVs in OA we may account with our available 
cell system, which will enable the study of EVs released from chondrocytes and synoviocytes 
at structural and compositional levels, during induced mineralization and inflammation 
processes mimicking OA features.  
Overall, this study collected novel and important data associating, for the first time, 
GRP with molecular features of osteoarthritis. Our new data supports the proposal of GRP as 
an inhibitor of pathological calcification in this pathology and unravelled an unprecedented 
association between GRP and inflammatory processes in OA. This work has therefore 
contributed for new knowledge regarding the pathological calcification and inflammatory 
processes occurring in OA, evidencing GRP as a new player acting in these mechanisms.  
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Scope: Gla-rich protein (GRP) is a vitamin K dependent protein, characterized by a high density
of -carboxylated Glu residues, shown to accumulate in mouse and sturgeon cartilage and at
sites of skin and vascular calcification in humans. Therefore, we investigated the involvement
of GRP in pathological calcification in osteoarthritis (OA).
Methods and results: Comparative analysis of GRP patterning at transcriptional and transla-
tional levels was performed between controls and OA patients. Using a RT-PCR strategy we
unveiled two novel splice variants in human—GRP-F5 and F6—potentially characterized by
the loss of full -carboxylation and secretion functional motifs. GRP-F1 is shown to be the
predominant splice variant expressed in mouse and human adult tissues, particularly in OA
cartilage, while an overexpressing human cell model points it as the major -carboxylated iso-
form. Using validated conformational antibodies detecting carboxylated or undercarboxylated
GRP (c/uc GRP), we have demonstrated cGRP accumulation in controls, whereas ucGRP was
the predominant form in OA-affected tissues, colocalizing at sites of ectopic calcification.
Conclusion: Overall, our results indicate the predominance of GRP-F1, and a clear association
of ucGRP with OA cartilage and synovial membrane. Levels of vitamin K should be further
assessed in these patients to determine its potential therapeutic use as a supplement in OA
treatment.
Keywords:
Alternative splicing / -Carboxylation / Gla-rich protein / Osteoarthritis / Vitamin K
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
1 Introduction
Gla-rich protein, or GRP, is the newest vitamin K-dependent
protein (VKDP), first identified in sturgeon calcified cartilage;
the mature protein exhibits an extensive -carboxyglutamic
Correspondence: Dr. Dina C. Simes, CCMAR, University of Al-
garve, Campus de Gambelas, 8005-139 Faro, Portugal
E-mail: dsimes@ualg.pt
Fax: +351-289800069
Abbreviations: c/uc, carboxylated/undercarboxylated; COMP,
cartilage oligomeric matrix protein; ECM, extracellular matrix;
GRP, Gla-rich protein;MGP, matrix Gla protein;OA, osteoarthritis;
OC, osteocalcin; VKDP, vitamin K-dependent protein
acid (Gla) domain—16 Gla residues in this species—
suggesting a strong calcium-binding capacity [1]. The associ-
ation of GRP to pathological calcification in human skin and
vascular tissues was shown by detection of protein accumula-
tion at sites of mineral deposition in cases of dermatomyosi-
tis, pseudoxanthoma elasticum, and chronic kidney disease,
further supporting the notion that GRP strongly binds to cal-
cium mineral deposits [2].
Osteoarthritis (OA) is a common degenerative joint dis-
ease characterized by progressive loss of articular cartilage,
accompanied by tissue inflammation, causing pain and dis-
ability [3]. Current treatments of OA pathology have limited
efficacy and various side effects, urging the need to iden-
tify novel therapeutic and prophylactic agents for treatment
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and prevention. Vitamin K represents an interesting candi-
date due to its determinant role in skeletal metabolism, either
through bone and cartilage VKDPs, osteocalcin (OC), andma-
trix Gla-protein (MGP) or, more recently, GRP [4–6]. In fact,
several studies have now evidenced that subclinical vitamin
K levels are associated with an increased risk of developing
knee OA [7–9]. At cellular level, OA results from the failure
of chondrocytes to maintain the appropriate balance between
synthesis and degradation of extracellularmatrix (ECM) com-
ponents, followed by the occurrence of ectopic calcification
[3]. In later stages, this results in the formation of bony out-
growths at the joint margin (osteophytes), altered subchon-
dral bone architecture and synovial membrane inflammation
[3, 10]. Osteoarthritis has been reported to be directly associ-
ated with basic calcium phosphate crystals deposition either
in the articular cartilage, synovial fluid, or synovial mem-
brane [11–15]. The regulation of calcium availability and sub-
sequent deposition in the ECM is also reported to be deter-
minant for disease progression, which prompted us to inves-
tigate the relation between calcium mineral deposition and
GRP expression and accumulation. Furthermore, GRP, also
named Ucma (upper zone of growth plate and cartilage ma-
trix associated protein), was reported as a specific cartilage-
associated protein and suggested to be a negative regulator
of osteogenic differentiation in mice [16]. Four alternatively
spliced transcripts of the Ucma/GRP gene were reported in
mouse chondrocytes and shown to be associated with the
early stages of chondrogenesis [17]. Recently, an Ucma/GRP-
deficient mousemodel was produced and no association with
calcification mechanisms was found during skeletal develop-
ment, although it should be noted that ageing or pathological
conditions were not yet described in this model [18].
Here, we report for the first time the identification of two
novel alternatively splice variants of human GRP and a new
alternative transcript in mouse. Using an overexpressing hu-
man cellmodel, wewere able to demonstrate that although all
human isoforms could be secreted, GRP-F1 (corresponding
to the full length protein) is the predominant -carboxylated
protein isoform. We also demonstrate the prevalence of the
GRP-F1 splice variant, both in mouse and human adult tis-
sues, in particular in OA cartilage where results point to a
higher expression. Comparative analysis of -carboxylation
status reveals the prevalence of cGRP in healthy control sam-
ples, both in cartilage and synovial membrane; this is in con-
trast to OA-affected tissues that produce significantly more
ucGRP, suggesting that GRP may become an additional vita-
min K target to beneficially affect OA pathology.
2 Materials and methods
2.1 Biological material and sample processing
Knee articular cartilage and synovialmembrane sampleswere
obtained from osteoarthritic patients who had undergone to-
tal knee replacement surgery; control samples (cartilage, syn-
ovial membrane, and all adult human tissues analyzed) were
obtained either from subjects with no history of joint disease
following autopsy at AlgarveMedical Centre or by arthroscopy
(cartilage and synovial membrane samples). Fetal samples
were collected from 37 to 40 gestational weeks’ stillbirths at
HPP Cascais Hospital. Samples were immediately collected
into RNAlater (Sigma-Aldrich, St. Louis, MO, USA) or sterile
4% w/v PFA solution for RNA extraction or histological anal-
ysis, respectively. For histological preparation, samples were
embedded either in paraffin or glycol methacrylate as de-
scribed [19,20]. Mineral deposits were detected using the von
Kossa method counterstained with hematoxylin. This study
was approved by the ethical committees of Algarve Medi-
cal Centre and HPP Cascais Hospital. Mouse tissue samples
were collected from 9 weeks old male black 6 mice, washed
in PBS followed by immediate RNA extraction.
2.2 RNA extraction
Total RNA was extracted from human and mouse tissues as
described by Chomczynski and Sacchi [21], RNA concentra-
tion determined by spectrophotometry at 260 nm and quality
evaluated by agarose-denaturating gel electrophoresis.
2.3 Human and mouse GRP cDNA amplification
One microgram of total RNA was treated with DNase I
(Promega,Madison,WI,USA), and reverse-transcribed using
Moloney-murine leukemia virus reverse transcriptase, RNase
Out (both from Invitrogen, Carlsbad, CA, USA), and an
oligo(dT) adapter (5′-ACGCGTCGACCTCGAGATCGATG
(T)13–3′), according tomanufacturer’s recommendations.Hu-
man and mouse GRP-coding sequences were amplified by
nested PCR starting with 250 ng of reverse-transcribed RNA
and Taq DNA polymerase (Invitrogen) using primers listed
in Supporting Information Table 1. All nested PCR products
were size-separated onto a 2% w/v agarose gel and selected
fragments were purified using the GFX Gel Band Purifica-
tion kit (GE Healthcare, Waukesha, WI, USA), cloned into
pCRII-TOPO vector (Invitrogen) and sequenced (CCMAR,
Faro, Portugal).
2.4 Expression profile
To determine the presence of GRP alternative transcripts in
a broad number of tissues both from human and mouse,
primers were designed in order to specifically amplify each
of the splice variants, while human ribosomal 18S andmouse
GAPDHwere used as loading controls (Supporting Informa-
tion Table I). RT-PCR amplification was achieved using 25 ng
cDNA and SsoFast Eva Green supermix (Bio-Rad, Richmond,
CA, USA) in reactions of 50 cycles.
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2.5 Sequence analysis
Human and mouse genomic sequences (GenBank accession
numbers NC_000010 and NC_000068), respectively, were
used to confirm transcripts structure using Spidey mRNA-to-
genomic alignment tool at NCBI. Prediction of signal peptide,
protein targeting, and phosphorylation sites was performed
using SignalP, TargetP, and NetPhos 2.0, respectively, avail-
able at http://www.cbs.dtu.dk/services.
2.6 Protein expression in HEK293T cells
The complete coding sequence of human GRP alternative
transcripts was cloned into the pmkate2-N vector (Evrogen,
Moscow, Russia), producing a fusion protein where the GRP
C-terminus is fused to the mkate2 N-terminus (primers used
for directional cloning are listed in Supporting Information
Table 1); mkate is a far-red fluorescent protein usually used
to tag and solubilize proteins of interest [22]. Transfections
of HEK293T cells, cultured in DMEM (Invitrogen) supple-
mented with 10% v/v fetal bovine serum (Sigma-Aldrich)
were performed using the calcium/phosphate method, and
conditioned media were collected after 48 or 72 h. Total cell
extracts were obtained using RIPA buffer and protein content
was determined using a micro BCA kit (Thermo Scientific,
Waltham, MA, USA).
2.7 Protein size-separation and Western blot
Aliquots of total protein extracts were size-separated on a 4–
12%w/v gradient polyacrylamide precast gel containing 0.1%
w/v SDS (NuPage, Invitrogen) and transferred onto a nitro-
cellulose membrane as previously described [23]. Detection
of -carboxylated proteins was performed using 5 g/mL of
M3B antibody (American Diagnostica Inc., Stamford, CT,
USA); mkate2/GRP fusion proteins were detected using
0.2 g/mL tRFP (Evrogen) and GRP using 5 g/mL of
CTerm-GRP (GenoGlaDiagnostics, Faro, Portugal) produced
against the C-terminus of rat GRP peptide following a
previously described procedure [2]. Immunodetection was
achieved using species-specific secondary horseradish per-
oxidase conjugated antibodies (Sigma-Aldrich) and Western
Lightning Plus-ECL (PerkinElmer Inc., Waltham,MA, USA).
2.8 Immunolocalization
Immunohistochemistry was performed in paraffin or glycol
methacrylate tissue sections to detect antigens in soft
and calcified tissues, respectively [24]. Antigen retrieval
of cartilage and synovial membrane tissue sections was
performed by incubation with 2 mg/mL hyaluronidase
(Sigma-Aldrich) and by boiling in 0.2% v/v citric acid pH 6.0,
respectively. After peroxidase and nonspecific antibody block-
ings, incubations with the primary antibodies polyclonal
rabbit CTerm-GRP [2], and chicken cGRP (5 and 1 g/mL,
respectively (GenoGla Diagnostics); mouse monoclonals
ucGRP (7.3 g/mL, Vitak BV, Maastricht, the Netherlands),
cMGP and ucMGP (both at 10 g/mL, IDS, Boldon, UK) and
cartilage oligomeric matrix protein (COMP; 4 g/mL, Santa
Cruz) were performed O/N at RT. Conformational-specific
carboxylated/undercarboxylated (c/uc) GRP antibodies
were produced against the following peptides: QRNEFEN-
FVEEQND (E residues are -carboxylated) and NEFEN-
FVEEQNDEQEERSREAVEQ, respectively (Viegas et al., in
press). Peroxidase activity was detected using the respective
peroxidase-conjugated secondary antibodies (Sigma-Aldrich)
and ImmPACT NovaRED substrate kit (Vector laboratories
Ltd, Peterborough, UK). Negative controls consisted of
the substitution of the primary antibody with TBST. Final
counterstaining was achieved using hematoxylin.
3 Results
3.1 Identification of novel GRP splice variants in
human and mouse
The presence of GRP splice variants was investigated through
a nested RT-PCR strategy using human osteoarthritic carti-
lage and bone and cartilage from wild type murine femurs;
primers designed in exons 1 and 5 were used to amplify
the complete or partial GRP complete coding sequence, re-
spectively (Supporting Information Fig. 1 and Supporting
Information Table 1). For both human and mouse GRP we
have identified different fragments (Fig. 1A), corresponding
to novel splice variants. The longest human cDNA fragment
is 504-bp long and contains the complete open reading frame
for full-length GRP (GRP-F1, GenBank accession number
JX169863), while after sequencing two cDNA fragments of
408- and 342–bp (Fig. 1A) were confirmed to be coding for
two hitherto undiscovered GRP protein isoforms. The new
splice variants were named GRP-F5 and F6 (GenBank acces-
sion numbers JX169864 and JX169865, respectively; Fig. 1B)
following previous nomenclature adopted for mouse and ze-
brafish [6,17,25].Wehave then performed an extensive search
of GRP splice variants in other cartilage and synovial mem-
brane samples, both from control and OA patients, and no
other GRP alternative transcript was further identified. In ad-
dition, the same set of splice variants was also amplified from
several other human tissues (heart and skin, among others,
results not shown) further suggesting that these novel GRP
splice variants might be species-specific.
Regarding mouse GRP splice variants, we were able to
detect the GRP-F1, F2, F3 and F4 transcripts previously de-
scribed [17], and a new one of 178-bp corresponding to GRP-
F7 (Fig. 1A andB, Supporting Information Fig. 1B). Although
we have sequenced approximately 40 clones from different
tissues, no GRP-F5 and F6 have been identified in mice, re-
inforcing the notion of a possible species-specificity.
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Figure 1. Identification of novel GRP alternative splice variants in human and mouse. (A) RT-PCR from RNA isolated from OA human
articular cartilage and bone and cartilage (femur) of wild-type black-6 mice. For both mouse and human, several PCR products were
amplified, cloned, and sequenced, respectively, and further identified as different GRP splice variants. Transcript sizes (bp) are indicated
on the right side of the panel. (B) Schematic representation of GRP-splice variants, including an overview of our results (human F5 and F6
and mouse F7) and previously published data for mouse and zebrafish [6, 17, 25]. Arrow head indicates putative signal peptide cleavage
site; arrow is furin-like cleavage site; SP indicates signal peptide; Pro, propeptide; MP, mature protein, and GGCX, -glutamyl carboxylase
putative recognition site. (C) Alignment of humanGRP-splice variants deduced proteins. Triangles indicate intron insertion sites; underlined
sequence indicates -glutamyl carboxylase (GGCX) putative recognition site; a rectangle shows the furin-like proteolytic site (RGKR); black
dots sign putative -carboxylated Glu residues; circles indicate predicted tyrosine and serine phosphorylated residues; signal peptide is
shown in dark gray, while propeptide in light gray. First residue of mature protein in F1 isoform is assigned as number 1 and signal peptide,
propeptide, and mature protein are indicated accordingly.
3.2 In silico characterization of human GRP protein
isoforms
For each detected transcript (Fig. 1A), splicing sites and
coding regions were predicted using the Spidey mRNA to
genomic alignment tool at NCBI (Fig. 1B and Supporting
Information 1A). Considering nonprocessed protein iso-
forms, full length GRP-F1 encodes 138-aa, whereas the two
novel transcripts encode putative proteins of 106 (GRP-F5)
and 84 amino acids (GRP-F6), respectively (Fig. 1B and C,
and Supporting Information Fig. 1A). Both GRP-F5 and F6
variants lack exon 3, an exon skipping that has never been de-
scribed in previously analyzed species (mouse and zebrafish,
[6, 17, 25], Fig. 1B), resulting in the loss of the -glutamyl
carboxylase recognition site (GGCX) and the furin-like cleav-
age site for propeptide processing (RGKR, Fig. 1B and C).
Conversely, F6 lacks both exons 2 and 3 which, in addition
to the modifications produced in GRP-F5, will also be trans-
lated with a shorter signal peptide (Fig. 1B–C, and Support-
ing Information 1A). Although the probability of this shorter
signal peptide functionality is lower than for GRP-F1/F5 (cal-
culated D-score for F1/F5 is 0.731 and for F6 0.634, both
above SignalP algorithm cutoff [26]), the prediction shows
that targeting to the secretory pathway is still a possible
event. Overall, and considering signal peptide processing for
both variants, GRP-F5 and F6 will be 80- and 67-aa long,
that is, comparable to the 74-aa F1 mature isoform in terms
of protein size (Fig. 1C). Although no N- or O-glycosylation
post-translational modifications were in silico predicted, two
(GRP-F1) and three (GRP-F5 and F6) serine and tyrosine
residues exhibit high probability of phosphorylation (Fig. 1C).
3.3 Production and characterization of GRP isoforms
in HEK293T cells
To determine mature protein processing and evaluate
-carboxylation of Glu residues, we have performed transient
transfections of HEK293T cells with GRP-mkate2 fusion pro-
teins of theoretical molecular weights of approximately 43, 39
and 37 kDa for GRP-F1, F5, and F6, respectively. Our results
indicate that 48h after transfection, the three fusion proteins
are translated and can be detected in total cell extracts, but
only the GRP-F1 and F5 isoforms are secreted, while GRP-
F6 remains intracellularly (Fig. 2A); identification of secreted
GRP-F1 isoform was further confirmed by LC-MS/MS (data
not shown). Nevertheless, 72 h after transfection, GRP-F6
is also found in conditioned media (Fig. 2A), confirming
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Figure 2. Analysis of secretion and -carboxylation potential of human GRP protein isoforms. GRP-mkate2 fusion proteins were expressed
in HEK293T cells and intracellular extracts (In) and/or conditioned media (Ex) were analyzed by SDS-PAGE followed by Western blot. (A)
mkate2 detectionwas achievedwith specific antibody (tRFP) at 48 or 72 h after transient transfection. (B) Immunodetection of -carboxylated
and GRP protein in conditioned media, 72 h after transfection, using M3B and CTerm-GRP antibodies, respectively. Relevant molecular
weights in kDa are indicated on the left side of panels.
theoretical predictions indicating a lower secretory potential
due to an incomplete signal peptide and a time-dependent
secretion of GRP isoforms. -carboxylation status of secreted
GRP isoforms was then investigated using a Gla-specific
antibody (monoclonal M3B antibody) and the CTerm-GRP,
which reacts with both carboxylated or undercarboxylated
GRP forms with results evidencing GRP-F1 as the major
-carboxylated isoform produced in this human cell system
(Fig. 2B).
3.4 Expression pattern of human and mouse GRP
transcripts
Primers were strategically designed to specifically amplify
individual transcripts (Supporting Information Table 1 and
Supporting InformationFig. 2) and confirmed to amplify only
the target sequence for each of the splice variants except for
murine GRP-F3. In this case, several sets of primers were
tested but all exhibited unspecific amplification.
For human samples, our results show GRP-F1 transcript
as predominant and almost ubiquitously expressed (Fig. 3A),
both in fetal and adult tissues.On the other hand,GRP-F5 and
F6 are barely or not detectable inmost adult tissues, although
in the fetal tissues analyzed their expression is clearly detected
in cartilage, heart, and skin (Fig. 3A).
For murine samples, both GRP-F1 and F7 were found
mainly expressed in calcified tissues formed by bone and/or
cartilage (ear, femur, foot, tail, tibia) and also in heart, testis
and thymus (Fig. 3B), while F2 and F4 splice variants were
not detected in any of the tissues analyzed. The GRP-F3 ex-
pression pattern was not determined since we were not able
to develop a specific set of primers (Supporting Information
Fig. 2B).
3.5 Gene expression analysis of GRP transcripts in
human control and osteoarthritic tissues
Due to the number of samples available (Supporting Infor-
mation Table 2) we have only analyzed GRP gene expression
levels under saturating PCR conditions (50 cycles) in the two
major OA affected tissues. The results indicate higher expres-
sion of GRP-F1 in cartilage of OA patients (Fig. 4A) when
compared to controls, while no association could be deter-
mined in synovial membrane samples (Fig. 4B). GRP-F5 was
clearly less represented (Fig. 4) than F1 in both tissues, while
GRP-F6 could not be detected in any of the cartilage sam-
ples analyzed, in control or OA, but it was found in certain
synovial membrane samples (Fig. 4), suggesting a restricted
pattern of expression.
3.6 Differential accumulation pattern of c/ucGRP in
control and osteoarthritic tissues
While no calcification was observed in control samples
(Fig. 5A and C), ectopic calcifications were detected in the
tangential layer of osteoarthritic cartilage (Fig. 5B and D).
The presence of GRP was then investigated by IHC and
both cGRP and ucGRP co-localized at sites of cartilage calci-
fication (Fig. 5I and N); these observations were confirmed
with CTerm-GRP antibody (Fig. 5O–S). The two protein
forms were found accumulated in control and osteoarthritic
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Figure 3. GRP-F1 is the predominant splice variant in human tissues. The qualitative expression profile of knownGRP alternative transcripts
was investigated by RT-PCR in fetal and adult human (A) and adult mouse (B) tissues. 18S andmouse GAPDHwere used as loading controls
for sample integrity.
chondrocytes (Fig. 5E–H and J–M), although ucGRP was
more evident than cGRP in osteoarthritic cartilage matrix
(Fig. 5J–M; and 5E, H, respectively). In contrast to GRP,
control chondrocytes exhibited cMGP accumulation while
pathological counterparts exhibited ucMGP only (Supporting
Information Fig. 3A–D and F–I), both MGP protein forms
were co-localized with sites of ectopic calcifications (Sup-
porting Information Fig. 3E and J). Moreover, ucMGP accu-
mulation was shown to be more predominant in the ECM of
osteoarthritic cartilage than in that of controls (Supporting In-
formation Fig. 3F, G, H, and I). Immunohistochemical anal-
ysis of COMP, a well-established marker of OA [27], showed
protein accumulation only in pathological chondrocytes ECM
and ectopic calcification sites (Supporting Information Fig.
3K–O). Altogether, our results show that the tangential layer
of cartilage is the most affected tissue area, where not only
COMP, but also ucGRP and ucMGP accumulate to consider-
able higher levels than in the corresponding healthy tissue.
Synovial membranes showed substantial histological dif-
ferences between controls and OA patients (Fig. 6A–C). OA
samples exhibited a higher number and altered pattern of
lining cells, accompanied by the presence of ectopic calcifi-
cations (Fig. 6B–C). Immunodetection of total GRP, using
CTerm-GRP antibody, showed protein accumulation within
synovial membrane lining cells both in control and OA
samples (Fig. 6D and E). Using conformational antibodies,
ucGRP accumulation was detected in the OA tissues lining
layer, whereas only cGRP was detected in the lining layer
of control tissues (Fig. 6D, E, G, H, J, and K). In addition,
both cGRP and ucGRP were detected at sites of ectopic cal-
cifications (Fig. 6F, I, and L), a result also confirmed with
CTerm-GRP antibody (Fig. 6F). While no MGP was detected
in control and OA synovial membrane lining cells (Support-
ing Information Fig. 4A–D), carboxylated and ucMGP were
both found co-localized with ectopic calcifications (Support-
ing Information Fig. 3B and D).
Figure 4. Osteoarthritic cartilage evidences higher GRP-F1 expression over controls. The presence of the three human GRP splice variants
was investigated in cartilage (A) and synovial membranes (B) of controls and osteoarthritic patients; 18S was used as a loading control.
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Figure 5. UndercarboxylatedGRP (ucGRP) is predominant in osteoarthritic cartilage. The presence of ectopic calcificationswas investigated
by von Kossa staining in osteoarthritic (B and D) and control (A and C) cartilage samples. Specific antibodies for cGRP, and ucGRP (N–J)
and CTerm-GRP (O–S) were used to immunodetect carboxylated (cGRP), undercarboxylated GRP (ucGRP) and total (t-GRP) protein forms.
Tg, tangential layer. Scale bars represent 50 m.
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Figure 6. Undercarboxylated GRP is highly accumulated in osteoarthritic synovial membrane lining cells. Hematoxylin eosin (HE) staining
shows severe histological changes between control (A) and osteoarthritic (B) synovial membrane lining cells and evidences ectopic
calcifications within OA samples (C). Total GRP (D–F), carboxylated (G–I), and undercarboxylated (J–L) accumulation was detected using
respective CTerm-GRP, cGRP, and ucGRP antibodies. Scale bars represent 50 m.
4 Discussion
GRP is the newest member of VKD family of proteins and
exhibits the highest density of Gla residues ever described,
suggesting a strong affinity for calcium [1]. The protein, first
named Ucma for ‘unique cartilage matrix associated protein’
[28], was identified as a VKDP protein [1] and demonstrated
to have a wide tissue expression in rat [1] and zebrafish [25].
GRP/UCMA was also shown to be highly accumulated in
mouse, rat, and Adriatic sturgeon cartilage [1, 28]. This work
is a follow-up study on the previously reported association
of GRP with calcinosis in skin and vascular diseases [2] by
further investigating a possible relationship between GRP
andOA due to the reported association of ectopic calcification
and this pathology [15].
Gene expression studies performed in OA-associated tis-
sues confirmed the consistent presence of the transcript cod-
ing for full-length GRP protein (GRP-F1), and unveiled two
novel GRP alternative transcripts [6, 17, 25]. Furthermore,
our extensive efforts to detect splice variants F2, F3 and F4
in human samples were unsuccessful, while GRP-F5 and
F6 were only detected in humans; the possibility that other
variants might exist cannot be completely ruled out, but our
data strongly indicate the prevalence of these three GRP tran-
scripts. Our gene expression data demonstrate that GRP-F1
is themost abundant transcript in almost all adult human tis-
sues analyzed, while GRP-F5 and F6 were mostly restricted
to fetal development emphasizing that the biological func-
tion of GRP splice variants in humans should be further
evaluated throughout development. In addition to F3 and F4
transcripts, suggested to be involved in early chondrogenesis
[17], a new alternative transcript was also identified in mice
(GRP-F7), although we did not find murine homologs of hu-
man GRP-F5 and F6. The identification of a novel murine
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transcript might be, as previously suggested [17], related to
a time-dependent expression of GRP variants. It is still note-
worthy that all described splice variants (human, mouse or
zebrafish) preserve theGRP-coding frame and that amodular
alteration of the protein product has been proposed to be an
evidence of protein product functionality [29]. Also, phospho-
rylation of serine and tyrosine residues are in silico predicted
for all human putative GRP isoforms and their occurrence
should be further investigated. This is of particular interest,
since three phosphorylated serine residues of human MGP
were previously demonstrated to be determinant for its func-
tion as a inhibitor of calcification in vascular smooth muscle
cells [30].
Recent functional studies on GRP showed contradictory
results: while GRP-deficient mice did not exhibit a clear phe-
notype in bone and cartilage [18], zebrafish functional data
suggested an essential role of GRP in skeletal development
and calcification [6]. Our results reinforce the notion that the
GRP-deficient mouse has shortcomings since the data ob-
tained from this model cannot be directly translated to the
human situation [18].
In this respect, and since variants F5 and F6 appear to
be human-specific and are characterized by the loss of es-
sential domains that may alter GRP function, we have fur-
ther explored their secretory and -carboxylation potentials
as well as for F1. All protein isoforms were translated and
detected intracellularly; however, F6 secretion occurs later
than F1 and F5 isoforms, indicating a lower efficiency dur-
ing the secretory process as predicted by the 9-aa loss of the
signal peptide C-terminus. Detection of Gla residues in the
secreted GRP-protein isoforms, using the M3B Gla-specific
antibody, showed clear specific immunoreactivity with the
F1 isoform, suggesting that this is a -carboxylated protein.
However, since in vitro cell systems are usually not able to
fully -carboxylate overexpressed VKDPs, the presence of Gla
residues in GRP-F5 and F6 cannot be completely ruled out.
Further studies should be performed to determine the Gla
content in the three GRP isoforms, since our functional
in vitro cell model has been described to possess a limited
-carboxylation potential [31], while comparative studies
on mineral binding capacity of different GRP isoforms
might also bring new insights into the relevance of protein
three dimensional structure and carboxylation status for its
functionality.
The selective expression of GRP-F1 transcript supports
the use of our antibodies, either the total GRP CTerm-GRP or
conformational c/ucGRP antibodies, and IHC results should
reflect the accumulation of the GRP-F1 isoform-only. Al-
though, the conformational anti-GRP antibodies monospeci-
ficity against native GRP species is still under investigation in
our laboratory—as we cannot as yet discard the possibility of
residual overlapping detection of c/ucGRP protein forms—
these antibodies were found to have high specificity towards
the respective synthetic GRP-related peptides used as anti-
gens (Viegas et al., in press).
Our comparative data clearly shows the colocalization of
undercarboxylated GRP at sites of ectopic calcification of both
cartilage and synovial membrane in OA. Moreover, control
subjects, showing no signs of mineral deposition in both
tissues, exhibit only -carboxylated protein in their ECM
and lining cells. Altogether, these results suggest that GRP
-carboxylation should be crucial for calcium mineral forma-
tion inhibition. Furthermore, MGP immunodetection also
supports the relevance of -carboxylation for pathology de-
velopment, since OA mineralized cartilage showed signifi-
cantly higher amounts of ucMGP. Previous studies, both in
mice and human, have shown that MGP-deficient chondro-
cytes are hypertrophic, exhibiting an abnormal maturation,
and organization that can lead to endochondral ossification
[5, 32, 33]. Specific -carboxylase activity has been further
found to be higher in cultured control chondrocytes when
compared to the ones derived from osteoarthritic tissue [34];
the same study evidences that matrix vesicles isolated from
OA human articular cartilage also contained significantly less
cMGP when compared to those isolated from control tissue
[34]. Undercarboxylated MGP was also proposed to be used
as an inflammatorymarker of arthritis through the combined
analysis of serum and local synovial fluid ucMGP [35], further
pointing to the relevance of carboxylation levels of VKDPs
in OA. Overall these data reinforce the notion that lower
levels of functional VKDPs might result from a decreased
-carboxylase activity in OA, possibly accompanied by a loss
of vitamin K function that might be intimately related with
its subclinical levels [9]. In fact, all extra-hepatic Gla-proteins
analyzed thus far were found to be undercarboxylated in non-
vitamin K-supplemented healthy individuals [36].
The combined study of local and serum levels of carboxy-
lated and undercarboxylated GRP with vitamin K1 and K2
serum levels in OA patients will definitely strengthen our
present findings, since vitamin K is known to act either as a
substrate for the vitamin K epoxide reductase, an essential co-
factor for -carboxylation, or as a protective agent associated
to the production of certain inflammatory cytokines affect-
ing articular cartilage and subchondral bone through differ-
ent molecular mechanisms [37]. Insufficient vitamin K levels
have been proposed to cause impaired functions not only of
MGP but also OC and associated to abnormalities observed in
OA [4, 5]. GRP biosynthesis is also most possibly affected by
vitamin K availability and consequently related to OA patho-
physiological features, such as cartilage mineralization and
synovial membrane inflammation. Accordingly, recent stud-
ies have demonstrated a clear association between knee OA
and subclinical vitamin K insufficiency [7–9], but none of
them has considered GRP as a target protein. Our results
showing a relation between GRP and MGP -carboxylation
deficiency andOA are also in agreement with recent findings,
suggesting that vitaminKmetabolismmay be associated with
synovitis in OA patients, and that serum undercarboxylated
OC could be a biomarker for OA [38]. The novel associa-
tion of both phylloquinone (vitamin K1) and menaquinone
C© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
10 M. S. Rafael et al. Mol. Nutr. Food Res. 2014, 00, 1–11
(vitamin K2) deficiency with the disease further suggests the
use of vitamin K as a potential therapeutic/prophylactic agent
for OA [39]. We are currently collecting a representative num-
ber of OA patients and controls sera samples to determine
and compare levels of (i) vitamin K1 and K2 and (ii) c/uc GRP
protein forms, for which we are developing an ELISA detec-
tion kit (industrial application reported in the international
patent request PCT/PT2009000046). We strongly believe that
the integrated study of these parameters together with clinical
and biochemical characterizations will unravel new insights
into OA pathology progression and severity.
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Abstract Osteoarthritis (OA) is a whole-joint disease
characterized by articular cartilage loss, tissue inflamma-
tion, abnormal bone formation and extracellular matrix
(ECM) mineralization. Disease-modifying treatments are
not yet available and a better understanding of
osteoarthritis pathophysiology should lead to the discovery
of more effective treatments. Gla-rich protein (GRP) has
been proposed to act as a mineralization inhibitor and was
recently shown to be associated with OA in vivo. Here, we
further investigated the association of GRP with OA min-
eralization–inflammation processes. Using a synoviocyte
and chondrocyte OA cell system, we showed that GRP
expression was up-regulated following cell differentiation
throughout ECM calcification, and that inflammatory
stimulation with IL-1b results in an increased expression of
COX2 and MMP13 and up-regulation of GRP. Impor-
tantly, while treatment of articular cells with c-
carboxylated GRP inhibited ECM calcification, treatment
with either GRP or GRP-coated basic calcium phosphate
(BCP) crystals resulted in the down-regulation of inflam-
matory cytokines and mediators of inflammation,
independently of its c-carboxylation status. Our results
strengthen the calcification inhibitory function of GRP and
strongly suggest GRP as a novel anti-inflammatory agent,
with potential beneficial effects on the main processes
responsible for osteoarthritis progression. In conclusion,
GRP is a strong candidate target to develop new thera-
peutic approaches.
Keywords Osteoarthritis  Gla-rich protein 
ECM mineralization  Gamma-carboxylated GRP 
Inflammation
Introduction
Osteoarthritis (OA) is the leading form of degenerative
joint diseases [1] characterized by progressive loss of
articular cartilage, abnormal bone formation, tissue
inflammation and synovial proliferation, culminating in
pain, loss of joint function and disability [2, 3]. At the
cellular level, OA results from abnormal chondrocyte dif-
ferentiation into a hypertrophic phenotype and impairment
of the homeostatic balance between synthesis and degra-
dation of their extracellular matrix (ECM). This phenotype
is commonly associated with ECM mineralization that can
result from basic calcium phosphate (BCP) crystals depo-
sition [4] contributing to disease progression [5]. Crystal
deposition in OA is not unique for cartilage and has also
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been reported in the synovial fluid and membrane, where it
modulates inflammatory responses [6, 7]. The prevailing
theory is that proinflammatory and catabolic mediators,
such as nitric oxide, cytokines, prostaglandins and matrix
metalloproteinases (MMPs) [5, 7, 8], are released from
cartilage into the synovial space, and that the presence of
calcium crystals amplifies the production of such media-
tors, contributing to joint inflammation and cartilage
degradation [5, 7].
Osteoarthritis prevention and treatment are still limited
impelling the need to identify novel targets and biomarkers
for prevention, therapeutics and prophylactic treatment [9].
An interesting candidate is vitamin K, which is critical for
preventing soft tissue mineralization [10, 11]. Moreover,
vitamin K was also suggested as a protective agent against
inflammation [12]. Vitamin K is an essential cofactor for
the post-translational modification of vitamin K-dependent
proteins (VKDPs), where specific glutamic acid (Glu)
residues can be modified to calcium binding c-carboxyg-
lutamic acid (Gla) residues [13]. While subclinical vitamin
K levels have been associated with an increased risk of OA
development [14, 15], several VKDPs, such as matrix Gla
protein (MGP), osteocalcin (OC), and recently Gla-rich
protein (GRP), have been associated with the disease.
Moreover, the presence of undercarboxylated OC in serum,
resultant of vitamin K insufficiency, is considered as a risk
marker for OA [16]. Importantly, impaired c-carboxylation
of MGP has been associated with increased mineralization
of osteoarthritic cartilage [15], whereas also levels of
undercarboxylated MGP in synovial fluid and serum were
recently suggested as a potential inflammatory marker of
arthritis [17].
GRP is the newest member of the VKDP family. It was
first identified in sturgeon calcified cartilage and charac-
terized by the presence of 15 putative Gla residues in man
[18], but its function and molecular mechanisms of action
remain to be further clarified. GRP has been suggested to
act as a modulator of calcium availability in the ECM [19,
20], and an inhibitor of calcification in the cardiovascular
system [21]. However, conflicting data, particularly asso-
ciated to its function in mouse skeletal tissues, reinforce the
need for additional characterization of GRP potential
association to human pathological conditions such as OA.
While GRP-deficient mice did not reveal evident pheno-
typic alterations in bone and cartilage [22], zebrafish
knockdown studies highlighted the essential role of GRP in
skeletal development and calcification [23]. Although GRP
has been shown to function as a negative regulator of
osteogenic differentiation [24, 25] and to be down-regu-
lated by bone morphogenetic protein 2 (BMP-2) in
chondrogenic cells [24], recent data suggested that GRP is
up-regulated by both runt-related transcription factor 2
(Runx2) and osterix (Osx) stimulating osteoblast
differentiation and nodule formation [26]. Our previous
studies revealed a differential pattern of GRP gene
expression and protein accumulation between control and
osteoarthritic human articular cartilage and synovial
membrane tissues. Furthermore, we verified that GRP
accumulation was not restricted to sites of ectopic calcifi-
cation [27], suggesting the involvement of this VKDP in
cell-mediated processes other than ECM calcification in
OA.
In this context, and to further understand the relevance
of GRP for OA etiology, we used an in vitro cell system to
study the relationship between GRP and the mineralization
and inflammatory processes involved in OA development
and progression. Our results demonstrate the involvement
of GRP in calcification processes associated to OA-affected
tissues, supporting a previously proposed role for GRP as a
novel biomarker for calcification-related diseases. More-
over, we describe, for the first time, a new role for GRP in
inflammatory events, and propose this VKDP as a novel
factor linking the two main pathological processes
responsible for OA development and progression.
Materials and methods
Biological material and sample processing
Knee articular cartilage and synovial membrane samples
were obtained from osteoarthritic patients who had
undergone arthroplasty surgeries. Tissues were collected in
Dulbecco’s Modified Eagle’s Medium (DMEM, Invitro-
gen, Carlsbad, CA, USA) for cell culture preparation and in
formalin for histological processing, followed by paraffin
embedding as described [28]. This study was approved by
the ethics committees of the hospitals involved, and written
informed consent was obtained from all the participants.
Cell culture development and maintenance
Tissues, both articular cartilage and synovial membrane,
were digested overnight with 2 mg/mL collagenase in
DMEM at room temperature (RT). Fragments were washed
three times with DMEM, placed in 24-well plates, and
cultured in the same medium supplemented with 1 % (v/v)
penicillin–streptomycin, 1 mM L-glutamine and 10 % (v/
v) fetal bovine serum (FBS), at 37 C in a humidified
atmosphere with 5 % CO2. OA-derived chondrocytes (OA-
HAC, osteoarthritic human articular chondrocytes) and
synoviocytes (OA-HFLS, osteoarthritic human fibroblast-
like synoviocytes) were allowed to migrate from fragments
and adhere to wells for approximately 2 weeks, then col-
lected using trypsin solution (Invitrogen) for cell passage,
and placed into new plate dishes with fresh media. Cultures
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were routinely sub-cultured (1:2) at early confluence by
trypsinization. Cellular proliferation measurements indi-
cated higher growth performance using advanced DMEM
(Invitrogen) supplemented with 1 % (v/v) penicillin–
streptomycin, 1 mM L-glutamine and 10 % (v/v) FBS
when compared with DMEM. Therefore, advanced DMEM
was used throughout the study, in all cell lines. Cells used
in the experiments were between passages 4 and 14.
Control primary chondrocytes (NHAC, Lonza, Visp,
Switzerland) and synoviocytes (HFLS, ECACC, Sigma-
Aldrich, St. Louis, MO, USA) were commercially
obtained. A second set of OA and control-derived primary
chondrocytes cultures (OAC and NC, respectively) and
primary synoviocytes cultures (SOAR and SNR, respec-
tively) were obtained using well-defined methodology [29,
30], and used to confirm the results obtained with of the
first set of cells.
Cellular proliferation measurement
Cells were seeded in 96-well plates at 2 9 104 cells/well
and cultured in DMEM and advanced DMEM supple-
mented with 1 % (v/v) penicillin–streptomycin, 1 mM L-
glutamine and 10 % (v/v) FBS and both culture conditions
were analyzed for cell viability at appropriate times using
the CellTiter 96 cell proliferation assay (Promega, Madi-
son, WI, USA), following manufacturer’s instructions. Cell
viability of cultures supplemented with 5.4 mM CaCl2,
500 ng/mL of sturgeon cGRP or human recombinant
ucGRP [20], 5 ng/mL of interleukin 1b (IL-1b) or 100 lg/
mL of BCP crystals (prepared as described below) was also
determined using the same procedure.
RNA extraction, cDNA amplification
and quantitative real-time PCR (qPCR)
Total RNA was isolated from cell cultures as described by
Chomczynski and Sacchi [31]. RNA concentration was
determined by spectrophotometry at 260 nm and quality
evaluated by agarose-denaturing gel electrophoresis. Five
hundred ng of total RNA was treated with DNase RQ-I
(Promega) and reverse transcribed using Moloney-murine
leukemia virus reverse transcriptase (MMLV-RT, Invitro-
gen), RNase Out (Invitrogen), and an oligo(dT) adapter
(ACGCGTCGACCTCGAGATCGATG(T)13), according
to manufacturer’s recommendations.
Quantitative real-time PCR reactions were performed
using the StepOne system (Life Technologies, Carlsbad,
CA, USA), SsoFast Eva Green Supermix (Bio-Rad, Rich-
mond, CA, USA), 300 nM of forward and reverse gene-
specific primers (final concentration) for genes of interest
(Online Resource 1) and a 1:5 dilution of reverse-tran-
scribed RNA reaction mixture. The following PCR
conditions were used: initial denaturation/enzyme activa-
tion step at 95 C for 5 min, 50 cycles of amplification
(one cycle is 30 s at 95 C and 15 s at 66 C); 18S was
used as a housekeeping gene to normalize expression.
Immunofluorescence and immunohistochemistry
Immunofluorescence (IF) was performed in sub-confluent
cultures, seeded the previous day. Cells were washed with
PBS and fixed for 10 min in 4 % (v/v) paraformaldehyde.
Fixed cells were incubated at RT for 1 h with CTerm-GRP
(10 lg/mL, GenoGla Diagnostics, Faro, Portugal), mouse
monoclonal cGRP (10 lg/mL, GenoGla Diagnostics) or
mouse monoclonal ucGRP [20] (7.3 lg/mL, VitaK BV,
Maastricht, The Netherlands) primary antibodies, followed
by incubation for 1 h, at RT with Alexa488 or Alexa594
labeled secondary antibodies (Invitrogen), respectively.
Fluorescence images were obtained using an Axio Imager
Z2 microscope (Zeiss, Jena, Germany) equipped with a
digital camera and AxioVision imaging software. Final
images were processed using Image J Version 1.41 m.
Immunohistochemistry (IHC) was performed in paraffin
tissue sections of osteoarthritic synovial membrane as
described [32]. Antigen retrieval was performed by boiling
tissue sections in 0.2 % (v/v) citric acid pH 6.0, followed
by endogenous peroxidase and nonspecific antibody
blocking and incubations with CTerm-GRP (5 lg/mL) or
mouse monoclonal cluster of differentiation 45 (CD45,
2 lg/mL, Santa Cruz Biotechnology) primary antibodies.
Peroxidase activity was detected using the respective per-
oxidase-conjugated secondary antibodies (Sigma-Aldrich)
and ImmPACT NovaRED substrate kit (Vector laborato-
ries Ltd., Peterborough, UK). Sections were counterstained
with hematoxylin.
ECM mineralization assay
To induce mineralization of the ECM, confluent cultures
grown in advanced DMEM were supplemented with CaCl2
to a final calcium concentration of 5.4 mM. The experi-
ment was performed during 3 weeks with media changes
twice a week and each week set as an experimental time
point (T0–T3). Mineral content was detected by von Kossa
staining as described [33]. Formation of mineralized nod-
ules in the ECM was observed under a Motic AE 31
inverted light microscope.
To analyze the effect of GRP on mineralization, con-
fluent chondrocytes and synoviocytes were grown for
3 weeks in advanced DMEM under mineralizing condi-
tions supplemented with 500 ng/mL of cGRP or ucGRP
and compared with respective controls. At appropriate
times, calcium/protein ratios were determined, as described
below.
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Calcium and total protein quantification
At appropriate times, cell cultures grown in control or
mineralizing conditions were washed twice with PBS and
mineral was dissolved overnight with 1 M HCl, at 4 C.
ECM calcium concentration was then determined using a
commercially available kit (Calcium assay CA-590, Ran-
dox, Co. Antrim, UK). Equimolar amounts of NaOH
containing 5 % (w/v) SDS were then used to neutralize the
remaining HCl-mineral phase and determine total protein
concentration using the micro BCA protein assay kit
(Thermo Scientific, Waltham, MA, USA). Results are thus
presented as calcium/protein ratios.
Inflammation assay
Confluent chondrocytes and synoviocytes were cultured in
advanced DMEM or supplemented with 500 ng/mL of
cGRP, 500 ng/mL of ucGRP or 2 lM dexamethasone
(DXM) during 24 h. Cells were washed twice with PBS
and media were changed for advanced DMEM supple-
mented with 5 ng/mL of IL-1b for 72 h. At appropriate
times, cell media were collected for prostaglandin E2
(PGE2) quantification and cells washed twice with PBS for
RNA extraction. PGE2 measurement was achieved using
an available ELISA kit (Thermo Scientific) following
manufacture’s protocol.
Protein mineral complex (PMC) assay
BCP crystals were produced based on a previously
described procedure, and the resulting crystals were
washed three times with Milli-Q water and reduce to fine
particles by sonication (Vibra-cell apparatus, Sonics &
Materials, Inc., Newtown, MA, USA) [21, 34]. PMCs were
prepared by incubating BCP crystals (100 lg) in Milli-Q
water for 30 min at 37 C with approximately 500 ng of
cGRP or ucGRP [21]. Pellets containing PMCs or BCP
crystals were added to confluent chondrocytes and syn-
oviocytes and assayed for 72 h (controls consist of culture
medium only). At appropriate times, cells were washed
twice with PBS prior to RNA extraction and cell media
were collected for PGE2 measurement as previously
described.
Statistical analysis
Data are presented as mean (n[ 2) ± standard error.
Ordinary one-way ANOVA was used for comparisons
within the same group. Multiple t tests were used for
comparison between two groups. For two groups submitted
to a variable, significance was determined using two-way
ANOVA and multiple comparisons were achieved with the
Tukey’s test. Statistical significance was defined as
P B 0.05 (*), P B 0.005 (**) and P B 0.0005 (***).
Results
GRP and genes involved in the c-carboxylation
machinery are associated with osteoarthritis
The association of GRP with OA was analyzed on chon-
drocyte and synoviocyte primary cell cultures, the two
main cell types involved in OA pathology. Human articular
chondrocytes and fibroblast-like synoviocytes, either con-
trol (NHAC and HFLS, respectively) or derived from OA
patients (OA-HAC and OA-HFLS, respectively), were
characterized by gene expression profiling of differentia-
tion and known OA-related markers, and correlated with
the expression of GRP, MGP, and genes related to c-car-
boxylation processing. The obtained results showed higher
levels of OC, cartilage oligomeric matrix protein (COMP)
and collagen type X (Col10a1), and lower levels of colla-
gen type II (Col2a1) in OA-HAC cells (Fig. 1a),
confirming an osteoarthritic chondrocyte phenotype. Also,
OA-HFLS cells, exhibited higher levels of the OA-asso-
ciated gene markers OC, MMP13 and CD68, and lower
vimentin expression (Fig. 1a).
GRP and MGP were found to be up-regulated in both
OA-derived cultures, OA-HAC and OA-HFLS, while c-
carboxylase (GGCX) and vitamin K epoxide reductase
(VKOR) were shown to be expressed at lower levels than
in control-derived cells (Fig. 1b), suggesting an increased
production of VKDPs, but an impaired c-carboxylation
capacity in OA-derived cells. To access GRP c-carboxy-
lation status, the protein accumulation pattern was
analyzed in OA and control cells by IF using the confor-
mation-specific monoclonal antibodies cGRP and ucGRP,
and the polyclonal CTerm-GRP recognizing total GRP
(Fig. 2). In concordance with previously reported data from
osteoarthritic cartilage and synovial membrane tissue
samples [27], both cGRP and ucGRP were detected in
pathological and control chondrocyte cells, while only
ucGRP was found associated with the OA-HFLS cells.
Overall, the results indicate that OA-derived cells
showing osteoarthritic gene expression patterns have GRP
up-regulation and indications of a reduced c-carboxylation
capacity.
Calcification and cell differentiation in OA are
correlated with GRP expression
The calcification capacity of both NHAC/OA-HAC and
HFLS/OA-HFLS cells was assessed by von Kossa staining
(Fig. 3a) and by calcium quantification of the mineral
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deposited in the ECM (Fig. 3b). The results showed that all
cell cultures were able to mineralize their ECM, although
after the 3 weeks of treatment higher calcium levels and
mineral deposition were found in chondrocyte-derived
cultures when compared to synoviocytes (Fig. 3a, b, T3).
Significant differences in calcium quantification between
OA and control chondrocytes were evident at week 1 (T1),
although during subsequent weeks the differences gradu-
ally disappeared.
The expression patterns of gene markers for cell dif-
ferentiation and mineralization were simultaneously
investigated, in control and OA-derived primary cells to
determine their correlation with calcification. After the first
week of treatment (T1), OA-HAC cells showed higher
expression levels of GRP, MGP, OC, Osx and Col10a1,
and lower levels of Col2a1, compared to control NHAC
cells (Fig. 4a). The progressive down-regulation of Col2a1
in parallel with the up-regulation of Col10a1, Osx and OC
throughout the treatment in both cultures is consistent with
differentiation occurring in chondrocytes towards a
hypertrophic phenotype and ECM calcification.
The most significant differences between control and
OA-derived cells were observed at T1, suggesting that,
under calcification stimulating conditions the already
altered phenotype of primary OA-derived cells induces a
faster response. However, at T3 most of the gene markers
were found similarly expressed, in concordance with the
similar levels of calcification obtained for both cultures
(Fig. 3b). Notably, levels and patterns of GRP and Osx
gene expression were found similarly up-regulated in OA-
derived chondrocytes, throughout mineralization treatment,
with higher levels in OA-derived cells at all-time points. In
synoviocytes, vimentin down-regulation and CD68 up-
regulation were observed during induced calcification, in
both OA-derived and control cells; this is suggestive for a
phenotypic change from fibroblast-like synoviocytes
towards a macrophage lineage, while GRP, MGP, OC and
osteopontin (OPN) were gradually up-regulated throughout
mineralization, with only minor differences observed
between OA-derived and control cells (Fig. 4b).
Carboxylated GRP is able to reduce mineral
deposition in articular cells ECM
To determine the direct effect of GRP in ECM mineral-
ization of chondrocytes and synoviocytes, and further
unveil the relevance of its c-carboxylation status, cells
cultured under control and mineralizing conditions were
supplemented with ucGRP or cGRP. Cell proliferation
assays were performed for both GRP protein forms to
Fig. 1 Characterization of control and osteoarthritic-derived (OA)
chondrocyte and synoviocyte cell cultures through gene expression
patterns determined by qPCR. a Expression of OA (OC, COMP and
MMP13) and differentiation (Cola2a1, Cola10a1, CD68 and vimen-
tin) gene markers in control (NHAC and HFLS) and OA-derived
(OA-HAC and OA-HFLS) chondrocytes and synoviocytes.
b Expression of VKDP-related genes (GRP, MGP, GGCX and
VKOR) in control and OA-derived chondrocytes and synoviocytes.
Values are relative to a reference sample (control cell culture) set to 1.
All experiments were repeated at least three times. Multiple t tests
were performed. Statistical significance was defined as P B 0.05 (*),
P B 0.005 (**) and P B 0.0005 (***)
Gla-rich protein is involved in the cross-talk between calcification and inflammation in…
123
confirm that the treatment was not cytotoxic (data not
shown). The results showed that the addition of cGRP
significantly decreased mineral deposition after 3 weeks of
treatment, in both control (Fig. 5) or OA-derived (results
not shown) chondrocytes and synoviocytes, while no effect
was observed with ucGRP treatment.
GRP is associated with inflammatory events in OA
To study the interplay between mineralization and inflam-
matory events in OA, the inflammatory response of
chondrocytes and synoviocytes under mineralization condi-
tions was determined by analyzing the expression patterns of
inflammation markers. Increased expression of COX2 and
MMP13, throughout the time course indicated that a min-
eralization stimulus is able to trigger the inflammatory
response in both cells systems (Fig. 6a). Since in this model,
GRP was also found to be up-regulated with mineralization
treatment (Fig. 4), we have further studied the possible
relation between GRP and inflammation by inducing chon-
drocytes and synoviocytes with an inflammatory stimulus
and evaluating GRP expression pattern. A sharp rise in GRP
gene expression concomitant with an increase in COX2 and
MMP13 expression was obtained at 3 h after IL-1b
treatment (Fig. 6b). From 6 to 72 h of stimulation, the
expression of GRP and inflammatory gene markers had
progressively decreased until control levels. To evaluate the
association of GRP with inflammation in vivo, the presence
of GRP in osteoarthritic synovial membrane was determined
by IHC and the results showed co-localization of GRP with
CD45 positive cells, indicative of leucocytes (Fig. 6c–f).
GRP is a novel factor in the cross-talk
between calcification and inflammation processes
Since BCP crystals deposition has been associated with
inflammatory responses in OA, and GRP binding capacity
to calcium crystals has been previously reported [21],
chondrocytes and synoviocytes were treated with BCP
crystals and BCP crystals coated with either cGRP/ucGRP
(PMCs), during 72 h, to evaluate the inflammatory
response. Up-regulation of COX2 and MMP13 expression
in BCP-treated cells confirmed the inflammatory response
mediated by BCP crystals, both in synoviocytes and
chondrocytes cell systems, while treatment of cells with
non-cytotoxic doses of PMCs, containing either cGRP or
ucGRP, resulted in decreased COX2 and MMP13 expres-
sion (Fig. 7a). A corresponding significant reduction of
Fig. 2 Accumulation patterns of GRP protein forms in both control
(NHAC and HFLS) and OA (OA-HAC and OA-HFLS)-derived
chondrocytes and synoviocytes. Immunofluorescence imaging was
obtained for total GRP (CTerm-GRP), c-carboxylated (cGRP) and
undercarboxylated GRP (ucGRP) protein forms using specific anti-
bodies. Cell nuclei were stained with DAPI; scale bar represents
100 lm. All experiments were repeated at least twice
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PGE2 accumulation in cell media was detected after 72 h
of treatment with PMCs, when compared with cells treated
with BCP crystals (Fig. 7b). Altogether, our results showed
that GRP coating significantly diminished the inflamma-
tory reaction associated with BCPs, and point GRP as a
new mediator factor linking mineralization and inflamma-
tory processes.
GRP acts as an anti-inflammatory agent
in osteoarthritis
To determine if GRP had a direct effect on inflammatory
processes and if this response was dependent of its c-car-
boxylated state, chondrocytes and synoviocytes, stimulated
with IL-1b, were pre-treated with ucGRP/cGRP or DXM,
the latter used as a control anti-inflammatory agent. In both
cell systems stimulated with IL-1b, the treatment with
either ucGRP/cGRP, resulted in significant lower levels of
COX2 and MMP13 expression relative to non-treated cells
(Fig. 8a), indicating an anti-inflammatory effect of GRP.
To further confirm these results, PGE2 accumulation in cell
media after 24 h of pre-treatment with cGRP and ucGRP
(Fig. 8b) was measured, and the results showed lower
levels of PGE2 in media of cells pre-treated with both
protein forms relative to non-treated cells. Moreover, a
similar anti-inflammatory effect was observed in OA-HAC
and OA-HFLS cells. Notably, the ucGRP/cGRP effects on
COX2 and MMP13 expression were comparable with
levels obtained after 3 h of IL-1b stimulation in cells pre-
treated with DXM, particularly in chondrocytes (Online
Resource 2). The 3-h stimulation period corresponds with
the inflammatory peak response. These results strongly
suggest that GRP might be a powerful anti-inflammatory
agent in OA that can exert its function independent of its c-
carboxylation status.
Discussion
In this study, we demonstrate for the first time the
involvement of GRP, the most recently discovered VKDP,
in the two major molecular processes affecting
Fig. 3 In vitro ECM mineralization of control and OA-derived
chondrocytes and synoviocytes (NHAC and OA-HAC, and HFLS and
OA-HFLS, respectively). a Representative von Kossa staining at
week 3 (T3) in control or induced mineralizing conditions with
5.4 mM CaCl2 (Ca). Scale bar represents 100 lm. b Mineralization
rate was determined every week (T0–T3) through calcium quantifi-
cation normalized to protein levels. Data are representative of three
independent experiments. Two-way Anova and multiple comparisons
were achieved with the Tukey’s test. Statistical significance was
defined as P B 0.05 (*) and P B 0.005 (**)
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osteoarthritis: mineralization and inflammation of articular
tissue. GRP appears to be functioning as an ECM miner-
alization inhibitor and as an anti-inflammatory agent, both
on chondrocytes and synoviocytes, the two main articular
cell types. Moreover, while GRP c-carboxylation was
shown to be essential for its calcification inhibitor effect, it
Fig. 4 Association of GRP with calcification and cell differentiation
in osteoarthritis. a Gene expression patterns of GRP, mineralization
(MGP, OC and Osx) and differentiation (Col2a1 and Col10a1)
markers during induced mineralization of chondrocytes (NHAC and
OA-HAC). b Gene expression patterns of GRP, mineralization (MGP,
OC and OPN) and differentiation (vimentin and CD68) markers
during induced mineralization of synoviocytes (HFLS and OA-
HFLS). Gene expression was determined every week during 3 weeks
(T0–T3). Gene expression values are relative to the reference sample
(control cell culture) and set to 1. Data are representative of three
independent experiments. Two-way Anova and multiple comparisons
were achieved with the Tukey’s test. Statistical significance was
defined as P B 0.05 (*) and P B 0.005 (**)
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was apparently irrelevant for its anti-inflammatory action,
pointing to differential roles for undercarboxylated and
carboxylated GRP.
GRP gene expression was found to be up-regulated in
OA-derived chondrocytes and synoviocytes, and was
associated with higher levels of the calcification inhibitor
MGP and OA-related gene markers such as OC, COMP
and Col10a1. The results here obtained are in concordance
with our previous studies with biological samples, where
we showed an increase in GRP expression associated with
OA [27], and also with the higher demand of calcification
inhibitors, required to balance increased cell differentiation
and ECM calcification occurring in OA [4]. Moreover, c-
carboxylated GRP was shown to decrease calcification in
both chondrocytes and synoviocytes, and the increase in
GRP expression accompanied cell differentiation towards
ECM mineralization, in both cell systems. The up-regula-
tion of GRP during osteochondrogenic differentiation,
characterized by a decrease in Col2a1 and concomitant
increase in Col10a1, was recently shown during osteogenic
differentiation of MC3T3 cells, supporting the suggested
up-regulation of GRP gene by Osx [26]. Nevertheless,
previous studies have shown that GRP is repressed by
BMP2, a protein known to be responsible for Osx up-
regulation during osteogenesis [24]. These controversial
data emphasize that the molecular mechanism of GRP
action requires further clarification. Moreover, while GRP
was suggested to act as a stimulating factor in osteoblast
differentiation and nodule formation [26], previous data
have shown an impairment of osteogenic differentiation by
GRP [24, 25]. None of these studies have taken into con-
sideration the fact that GRP is a c-carboxylated protein,
and we have shown that although both forms, cGRP and
ucGRP, have mineral-binding capacity, only cGRP is able
to inhibit ECM calcification in the vascular system [21]. In
concordance, GRP knockdown in zebrafish resulted in
severe growth retardation and perturbance of skeletal
development, while warfarin treatment mimicked the GRP
knockdown phenotype, suggesting an essential role of c-
carboxylation for GRP function [23]. Our new data, using
GRP media supplementation in chondrocyte and synovio-
cyte cell cultures, strengthen the proposed calcification
inhibitory function of GRP and reinforce the importance of
its c-carboxylation status, probably acting by decreasing
calcium availability in the local environment, or changing
the dynamics of crystal growth [21]. Increased extracellular
calcium levels have been shown to drive chondrocyte dif-
ferentiation towards a mineralizing phenotype, while
calcium depletion from culture media maintains a stable
cellular phenotype [35]. GGCX and VKOR are two crucial
enzymes involved in c-carboxylation [13]. Remarkably,
the increase of GRP and MGP expression in OA-derived
cells was associated with a down-regulation of GGCX and
VKOR genes, suggesting a reduced capacity of OA cells,
and consequently a decrease in the c-carboxylation of
target proteins such as GRP and MGP. In fact, we have
previously shown a predominance of ucGRP and ucMGP
in biological OA samples [27]. Moreover, reduced vitamin
K-dependent c-carboxylase activity has been reported in
OA chondrocytes and correlated with (1) decreased c-
carboxylation of MGP and (2) increased matrix mineral-
ization [36]. Although the triggers for articular cartilage
calcification associated with OA are still not completely
understood, dysregulation of mineral metabolism such as
calcium and phosphate and an imbalance in the production
of mineralization inhibitors are crucial factors favoring
cartilage calcification and deposition of calcium-containing
crystals, such as BCPs. It should be noted that these factors
that trigger articular calcification are important to avoid
chondrocyte phenotype alterations such as hypertrophic
differentiation, apoptosis, as well as altered responses to
inflammatory cytokines and mediators of inflammation
Fig. 5 Effect of GRP in ECM mineral deposition in chondrocytes
and synoviocytes. Mineralization rate was determined by calcium
measurement (normalized to protein levels) after 3 weeks of NHAC
and HFLS cells treatment with 5.4 mM CaCl2 (Ca), or supplemented
with 500 ng/mL of ucGRP (Ca?ucGRP) or cGRP (Ca?cGRP).
Control corresponds to cells cultured in non-supplemented media.
Data are representative of three independent experiments. Ordinary
one-way ANOVA was performed. Statistical significance was defined
as P B 0.05 (*)
Gla-rich protein is involved in the cross-talk between calcification and inflammation in…
123
[37]. Interestingly, we also showed that synoviocytes were
able to produce a mineralized ECM with up-regulation of
OC and OPN, and down-regulation of vimentin, suggesting
a possible contribution of synoviocytes to the production of
BCPs in OA articular joint. BCPs have been shown to play
an important role in the onset and progression of OA [5],
and are considered to be early phenomena affecting the
whole joint, occurring even before any evidence of
cartilage breakdown [4]. BCPs have been found in the
synovial fluid, synovial membrane and cartilage from OA
patients [4, 6, 7], and are currently considered a damage-
associated molecular pattern (DAMP). The underlying
mechanism is thought to be the signaling to the immune
system a state of stress [8], and potentially contributing to
OA-associated inflammation through stimulation of artic-
ular cells [6, 7]. Besides their effect on synoviocyte
Fig. 6 In vitro and in vivo studies of GRP association with
inflammatory events in osteoarthritis. a Gene expression of COX2
and MMP13 over 3 weeks of mineralizing treatment (5.4 mM
calcium) in NHAC and HFLS (each week a set point, T0–T3).
Values of gene expression are relative to the reference sample (T0)
and set to 1. Data are representative of three independent experiments.
Two-way Anova and multiple comparisons were achieved with the
Tukey’s test. Statistical significance was defined as P B 0.05 (*) and
P B 0.005 (**). b Gene expression levels of COX2, MMP13 and
GRP in NHAC and HFLS cells, after 72-h inflammatory stimulation
with 5 ng/mL IL-1b. Values are relative to the reference sample (0 h).
Data are representative of three independent experiments. Two-way
Anova and multiple comparisons were achieved with the Tukey’s test.
Statistical significance was defined as P B 0.05 (*). c–f Immunode-
tection of CD45, showing leucocyte infiltration sites (c and d) and
total GRP (e and f, CTerm-GRP antibody) in consecutive sections of
osteoarthritic synovial membrane samples. Counterstaining with HE;
sale bar represents 100 lm
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proliferation, along with production of inflammatory
cytokines, MMPs and prostaglandins, BCP crystals also
induce articular chondrocytes to produce prodegradative
soluble factors such as nitric oxide and to undergo apop-
tosis [5, 7, 8]. Production of MMPs and chondrocyte
apoptosis contributes to cartilage destruction, while
Fig. 7 Effect of GRP in the inflammatory process promoted by the
addition of BCP crystals to articular cells. a Gene expression of
COX2 and MMP13 in NHAC and HFLS cells supplemented for 72 h
with BCP crystals (BCP) or BCPs coated with ucGRP
(BCP ? ucGRP) or cGRP (BCP ? cGRP). Values are relative to
the reference sample (untreated cells 0 h). Data are representative of
three independent experiments. Two-way Anova and multiple
comparisons were achieved with the Tukey’s test. Statistical signif-
icance was defined as P B 0.05 (*), P B 0.005 (**) and P B 0.0005
(***). b PGE2 accumulation in NHAC and HFLS conditioned media
of cells treated for 72 h as described in a. Control corresponds to
culture media of non-treated cells. Ordinary one-way ANOVA was
performed. Statistical significance was defined as P B 0.05 (*),
P B 0.005 (**) and P B 0.0005 (***)
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Fig. 8 Effect of GRP in chondrocytes and synoviocytes under
in vitro inflammatory conditions mimicking osteoarthritis. a Gene
expression of COX2 and MMP13 in NHAC and HFLS cells pre-
treated with 500 ng/mL of ucGRP or cGRP or 2 lM dexamethasone
(DXM) followed by IL-1b stimulation (5 ng/mL) during 72 h. Cells
untreated with GRP or DMX were also analyzed (IL-1b). Control
corresponds to cells grown in advanced DMEM only. Values are
relative to the reference sample (0 h). Data are representative of three
independent experiments. Two-way Anova and multiple comparisons
were achieved with the Tukey’s test. Statistical significance was
defined as P B 0.05 (*), P B 0.005 (**) and P B 0.0005 (***).
b PGE2 accumulation in cell media of NHAC and HFLS treated for
24 h as described in (a). Control corresponds to culture media of non-
treated cells. Ordinary one-way ANOVA was performed. Statistical
significance was defined as P B 0.05 (*), P B 0.005 (**) and
P B 0.0005 (***)
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cartilage degradation products drive inflammatory events
in a pathological mineralization–inflammation tissue
degradation cycle [5, 7]. To unveil the role of GRP in the
mineralization–inflammation processes associated with
OA, we decided to investigate the effect of GRP-induced
modulation of inflammatory conditions triggered by a
mineralization stimulus. COX2 and MMP13 up-regulation
was observed during mineralization in chondrocytes and
synoviocytes and confirmed that calcification can stimulate
proinflammatory signaling that parallels cell differentia-
tion, whereas calcification is also accompanied by an up-
regulation of GRP expression. These results reinforce the
concept that also other cells of the joint, including fibrob-
last-like synoviocytes and chondrocytes, directly contribute
to the innate immune activation and cytokine production in
OA [8]. Moreover, the concomitant increase in GRP
expression with inflammation, triggered by mineralization
conditions, indicates a calcium-mediated role for GRP in
the inflammatory processes. However, our experiments
also showed increased GRP expression after inducing
inflammation with IL-1b, with a highly similar pattern to
the inflammatory markers COX2 and MMP13. These
results suggest that the involvement of GRP in inflamma-
tory-mediated processes might not be exclusively mediated
by mineralization events, opening new perspectives for
GRP as a novel cross-talk factor linking calcification and
inflammation processes occurring in articular cells that
should become highly relevant for the study of OA
development and progression.
As previously reported, GRP is able to bind BCP crys-
tals in vitro and the calcification inhibitory function of GRP
might be through modulation of crystal formation and/or
growth [21]. Moreover, BCPs have been suggested to have
a direct pathogenic role in OA, driving synovial inflam-
mation and cartilage degradation [5]. Based on these facts,
we decided to further investigate the potential role of GRP
in the inflammatory response mediated by BCPs in the
articular cell system. Our results clearly demonstrate that
coating BCP crystals with GRP reduces its proinflamma-
tory effect, protecting cells from the increased expression
of MMP13 and PGE2 production. It has been proposed that
calcium-containing crystals may activate articular cells by
either leading to an increase in intracellular calcium levels
after crystal endocytosis or phagocytosis, with consequent
intralysosomal crystal dissolution, through direct crystal-
cell membrane interaction, that may occur via electrostatic
bonds with the naked crystal surface, or by membrane
receptor stimulation with naked or protein-coated crystals
[37]. Although the mechanisms behind a GRP-BCP
mediated anti-inflammatory effect in articular cells are
currently unknown, we speculate that GRP binding to BCP
will probably interfere with crystal–cell membrane inter-
action, thus modulating the production of proinflammatory
mediators. It is interesting to note that, compared with
naked hydroxyapatite crystals, fetuin-A-containing cal-
ciprotein particles (CPP), well known for their role in the
prevention of uncontrolled mineralization, were recently
reported to decrease cytokine production in macrophages
[38]. Moreover, serum-derived CPP have been shown to
produce a higher protective effect than synthetic CPP in
macrophage activation [38], probably reflecting the inhi-
bitory activity of other serum components, such as GRP.
We have recently shown an association between GRP,
fetuin-A and MGP at sites of aortic valves calcification,
and proposed that the calcification inhibitory function of
GRP may occur constitutively via this potent inhibitory
system formed by proteins with strong calcium phosphate
binding capacity [21]. Furthermore, pre-treatment of
chondrocytes and synoviocytes with GRP followed by IL-
1b stimulation mirrored the anti-inflammatory effect
observed with GRP-coated BCPs. This is consistent with
an anti-inflammatory role by down-regulation of cytokines
and MMPs production, in some cases at levels comparable
to DXM. Interestingly, the anti-inflammatory-mediated
effect of GRP was apparently independent of its c-car-
boxylation status, suggesting additional functions for
undercarboxylated GRP. Although undercarboxylated
VKDPs are generally regarded as non-functional and
related to pathological states [32, 39], decreased c-car-
boxylation of OC has been implicated in the regulation of
energy metabolism, with novel metabolic roles [40]. This
area is still under debate, however, and whether carboxy-
lated or uncarboxylated osteocalcin acts as the active
hormone in energy metabolism remains to be clarified.
Moreover, in the past decade, vitamin K biological func-
tions other than acting as a coenzyme of GGCX have been
proposed, namely the anti-inflammatory effect of vitamin
K2 through suppression of the NF-kB pathway with a dual
pro-anabolic and anti-catabolic activity in bone [41]. In
fact, inappropriate regulation of anti-catabolic activity in
bone has been shown as one of the major causes of setting
an inflammatory state in both OA and rheumatoid arthritis
[42]. Although we have shown in this work that GRP is
associated to inflammation in osteoarthritic synovial
membrane undergoing synovitis, a process characterized
by lymphocytes and plasma cells infiltration [43], its
involvement in immune cells inflammatory responses is
presently unclear. Also, additional characterization of the
anti-inflammatory activity of GRP and correlation with c-
carboxylation status is necessary to further unveil the
molecular pathways involved.
Overall, we propose that in a context of OA with
induced cell differentiation and ECM calcification, the
increased expression of VKDPs such as GRP and MGP
might function to counteract calcification. However, sys-
tem overload could lead to hampered c-carboxylation
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capacity resulting in increased levels of undercarboxylated
GRP, which might contribute to control the levels of
inflammatory mediators through still unknown mecha-
nisms, and thereby protecting the joint structures from
damage. Moreover, our results have shown that the effects
of GRP in both calcification and inflammation processes
were similar in control and OA-derived cell cultures,
indicating that GRP can exert its function as calcification
inhibitor and mediator of inflammation at different OA
stages. Therefore, it is a potential candidate for therapeutics
in OA, acting at both calcification and inflammation
processes.
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